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Abstract 
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder 
characterized by widespread loss of lower motor neurons from the spinal cord. 
Lower motor neuron degeneration leads to a progressive decline in motor 
development, manifesting as muscle atrophy and weakness. It is now well 
characterised that ubiquitin homeostasis is altered in SMA and that reduction of the 
ubiquitin-like modifier-activating enzyme 1 (UBA1) is central to this disruption. 
UBA1 is responsible for activating ubiquitin as the first step in the ubiquitin 
conjugation process, marking unwanted proteins for degradation by the proteasome. 
While it is known that therapies targeting UBA1 rescue neuromuscular phenotypes in 
SMA models, the mechanism by which UBA1 mediates neurodegeneration is 
unclear. In fact, very little is known about the function of UBA1 beyond its canonical 
role in the ubiquitin proteasome system. To better understand the role of UBA1 in 
motor neuron degeneration, a robust set of antibodies for both in vivo and in vitro 
work to study UBA1 have been identified. This enabled a novel characterisation of 
UBA1 distribution throughout disease progression in SMA spinal motor neurons to 
be performed, revealing that UBA1 reduction is an important pre-symptomatic 
molecular feature of SMA. To identify downstream targets of UBA1 critical for 
UBA1-mediated degeneration in SMA, label-free proteomics was performed on 
HEK293 cells after overexpression or knockdown of UBA1. The proteomics data 
was analysed across multiple platforms, including Biolayout, IPA and DAVID to 
identify UBA1-dependent pathways and demonstrated that modulation of UBA1 
levels lead to disruption of key cellular pathways including translation elongation, 
nuclear transport, and tRNA synthetases. Validation of target proteins from these 
UBA1-dependent pathways identified that the tRNA synthetease GARS behaves in a 
UBA1-dependent manner across a range of model systems in vitro and in vivo. It was 
then identified that GARS expression is significantly dysregulated across a range of 
neuronal tissues in a mouse model of SMA. Interestingly, mutations in GARS cause 
Charcot-Marie-Tooth disease type 2D (CMT2D), an axonal neuropathy, in which a 
disruption to sensory neuron fate in dorsal root ganglia has recently been identified. 
In a mouse model of SMA we identified a phenotype consistent with that in the 
CMT2D mouse model and showed that disruption to sensory neuron fate is 
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reversible and dependent on changes in UBA1 and GARS expression in SMA. In 
conclusion, modulation of UBA1 levels leads to disruption of key cellular pathways, 
with dysregulation of tRNA synthetases a prominent feature that is likely to play a 
role in the pathogenesis of SMA.  
   vii 
Lay Summary 
The most common inherited form of death during childhood is a motor neuron 
disease called spinal muscular atrophy (SMA). In SMA, motor nerves in the spinal 
cord degenerate and die meaning that they can no longer pass signals from the brain 
to the muscle. This means that the child has weak muscles and does not develop 
normal motor skills. One of the molecular pathways that is changed in SMA is the 
system responsible for recycling unwanted proteins by breaking them down so that 
the building blocks of the proteins can be used elsewhere. In SMA, the key 
disruption to this protein recycling pathway is a reduction in the levels of a particular 
protein, called ubiquitin-like modifier-activating enzyme 1 (UBA1). Therapies that 
increase UBA1 protein levels reverse muscle weakness and motor nerve 
degeneration in mice that have SMA. However, it is still unknown how low levels of 
UBA1 causes motor nerve degeneration in SMA. To try and understand how UBA1 
is involved in degeneration, tools and techniques to study UBA1 in cells and mice 
were developed. This meant that a study to look at the amount of UBA1 protein 
through disease progression could be performed. In this study, I found that reduction 
of UBA1 levels occurs very early on in the disease, before motor nerves die and 
before muscle become weak. This suggests that low levels of UBA1 has a key role in 
causing motor nerve degeneration in SMA. To see how UBA1 might be causing or 
contributing to motor nerve degeneration in SMA, a study was performed to identify 
proteins that are changed due to the reduction in UBA1 levels. This showed that 
changes in UBA1 levels leads to changes in key pathways within cells, including a 
disruption of transport within the cell, and disruption to the process of making 
proteins. One of the proteins identified in this study that is involved in making other 
proteins is called GARS. We found that there are changes in the levels of GARS in 
mice that have SMA. Genetic changes in GARS causes another hereditary disease 
called Charcot-Marie-Tooth disease type 2D (CMT2D). This disease is similar to 
SMA as it also causes motor nerve death and muscle weakness. CMT2D patients 
also have degeneration of sensory nerves. Mice that have CMT2D have different 
amounts of the types of sensory nerves. To see if GARS could be causing 
degeneration in SMA, we looked at types of sensory nerves present in SMA mice. 
The SMA mice have the same disruption to sensory nerves that occurs in mouse 
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models of CMT2D. This disruption to sensory nerves is caused by changes in protein 
levels of GARS and UBA1. By increasing UBA1 protein levels, GARS protein 
levels were restored and the change to sensory nerve types was reversed. In 
conclusion, changes to UBA1 levels disrupts important pathways within cells, which 
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Chapter 1 Introduction 
1.1 Spinal muscular atrophy 
Spinal muscular atrophy (SMA) is a hereditary form of motor neuron disease, 
characterized by degeneration of motor neurons in the anterior horn of the spinal 
cord (Kolb and Kissel, 2011). This leads to progressive proximal muscle weakness 
and atrophy and, in severe cases, paralysis and death. The prevalence of SMA is 
approximately 1-2 per 100,000 persons, and with an incidence of 1 in ~10,000 live 
births this autosomal recessive disease is the most common genetic cause of infant 
mortality (Lunn and Wang, 2008; Sugarman et al., 2012; Verhaart et al., 2017). The 
monogenetic cause of SMA has been long known (Lefebvre et al., 1995) and as such 
there has been considerable drive within the research community to understand SMA 
and develop promising therapeutic strategies to treat this lethal disease. This section 
(1.1) of the introduction contains text adapted from my published review (Shorrock 
and Gillingwater, 2016). 
1.1.1 The history of SMA 
Spinal muscular atrophy was first described by Guido Werdnig in 1891 where he 
presented the case of two infant brothers with proximal muscle weakness and 
atrophy (Dubowitz, 2009; Werdnig, 1891). This was supplemented by seven 
additional cases from three separate families described by Johan Hoffmann from 
1893 to 1900 (Dubowitz, 2009; Hoffmann, 1893, 1897, 1900). Interestingly, the first 
description of what is now known as severe SMA was not until 1903 when Beevor 
described the fourth affected child in one family; the previous three cases had died 
by 6 months, and this case showed degeneration of anterior horn cells of the spinal 
cord (Beevor, 1902; Dubowitz, 2009). During the 1950s a milder form of SMA was 
described by Kugelberg and Welander. The report described patients who were 
ambulant and presented with muscular dystrophy; however, the disease was shown to 
be neurogenic based on electromyography (Dubowitz, 2009; Kugelberg and 
Welander, 1956). Similarly, in the 1960s an intermediate form of SMA was 
described in a review of 12 cases by Victor Dubowitz (Dubowitz, 1964). During 
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characterisation of the wide range of cases of SMA, anterior horn cell degeneration 
and proximal weakness were identified along with weakness affecting axial, 
intercostal and bulbar musculature; it therefore became understood that these are the 
hallmarks of SMA. Throughout the rest of the 20th century the variability in severity 
of SMA was further characterised and defined (Dubowitz, 2009). 
1.1.2 Clinical manifestations 
The degeneration of lower motor neurons that occurs in SMA leads to a progressive 
decline in motor development, manifesting as muscle atrophy and weakness, 
primarily affecting proximal muscle groups (Harding et al., 2015). The profile of 
disease progression can vary substantially between patients with some phases of 
plateau in the decline of motor development (Mercuri et al., 2016). Based on the age 
of onset, motor function achieved, and typical age of death, SMA can be classified 
into as many as five distinct clinical subgroups with varying severity (Mercuri et al., 
2012).  
Type 0 SMA is the most severe form of the disease, with onset occurring in 
utero with reduced fetal movements. Life does not normally extend beyond the first 
few weeks after birth and patients present with joint contractures and a failure to 
swallow and breathe (Kolb and Kissel, 2011). Type 1 SMA, otherwise known as 
Werdnig-Hoffman disease, is the most common type of SMA (Hoffmann, 1893; 
Mercuri et al., 2012; Werdnig, 1891). Disease onset occurs by six months and 
patients are unable to sit without support and cannot control head movement (Lunn 
and Wang, 2008). Patients with SMA type 1 show generalized muscle weakness with 
severe hypotonia and often a bell-shape-like conformation of the thorax due to 
impaired ribcage expansion. Poor bulbar function and weak intercostal muscles lead 
to difficulties feeding and breathing, resulting in death within the first two years of 
life in the absence of palliative care (Faravelli et al., 2015). 
Patients with type 2 SMA (Dubowitz disease) have an intermediate 
phenotype and are able to maintain a sitting position unaided; some patients may be 
able to stand but do not develop the ability to walk independently (Dubowitz, 1964; 
Faravelli et al., 2015). Onset occurs between 7 and 18 months of age where the 
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patients show a delay in the development of gross motor skills; death frequently 
occurs during adolescence due to respiratory problems (Dubowitz, 2009; Lunn and 
Wang, 2008). Type 3 SMA (Kugelbery-Welander disease) shows marked symptom 
heterogeneity: some patients are able to walk independently and have some muscle 
weakness, while others begin to walk but require wheelchair assistance in childhood. 
Patients show wasting of proximal muscle groups and varying degrees of muscle 
hypotonia while bulbar involvement is less frequent than in the more-severe forms of 
SMA (Dubowitz, 2009; Kugelberg and Welander, 1956; Lunn and Wang, 2008). 
Type 4 SMA disease onset typically occurs in the second or third decade of life, with 
patients suffering from muscular weakness, atrophy and fasciculations without 
respiratory problems (Faravelli et al., 2015). The disease course is usually stable and 
mild. For both SMA type 3 and type 4, life expectancy is often comparable to that of 
the general population (Mercuri et al., 2012). In all subtypes, molecular genetic 
analysis is now the gold standard for diagnosis. Several rare forms of SMA also 
exist, including X-linked SMA, SMA with respiratory distress, and spinal and bulbar 
muscular atrophy (Kennedy’s disease) (Faravelli et al., 2015). 
1.1.3 Genetics of SMA 
By performing linkage analysis, several groups identified that the disease-causing 
gene for SMA resided on the long arm of chromosome 5, location 5q11.2 – 13.3 
(Brzustowicz et al., 1990; Lefebvre et al., 1995; Melki et al., 1990) (Figure 1-1A). 
Lefebvre et al. (1995) identified that this genomic region contains a large inverted 
duplication and narrowed the critical region to a 140kb segment within the telomeric 
section of this duplication. They were then able to identify that the survival motor 
neuron 1 (SMN1) gene was either absent or interrupted in 226 of 229 SMA patients 
investigated. The three remaining patients had either a point mutation or a short 
deletion at consensus splice sites of introns 6 and 7 (Lefebvre et al., 1995). 
It is now understood that in ~95% of cases SMA is caused by homozygous 
deletion or mutation of SMN1 (Lefebvre et al., 1995). A mutation for which 1 in ~50 
people are carriers (Lunn and Wang, 2008; Sugarman et al., 2012). SMN1 is a 20kb 
gene comprised of 9 exons interrupted by 8 introns, encoding the survival motor 
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neuron protein (SMN), which is comprised of 294 amino acids (Figure 1-1B). 
Humans are unique as they have two SMN genes, a telomeric SMN1 copy and an 
almost identical, centromeric SMN2 copy (Lefebvre et al., 1995) (Figure 1-1A). The 
SMN2 gene has a C to T substitution that leads to alternative splicing, resulting in the 
exclusion of exon 7 from mRNA which therefore encodes an unstable, truncated 
protein product (Lorson et al., 1999; Monani et al., 1999). This unstable protein 
product is then rapidly degraded (Han et al., 2012; Lefebvre et al., 1995) (Figure 
1-1B). However, exclusion of exon 7 is incomplete and a small amount of SMN2 pre-
mRNA transcripts retain exon 7 during splicing. This results in the production of full 
length SMN protein; it is estimated that approximately 10-15% of the protein 
produced from SMN2 is full length SMN (Lefebvre et al., 1997; Monani et al., 1999) 
(Figure 1-1B). As complete loss of SMN protein is embryonic lethal (Monani et al., 
2000), SMA patients are dependent on SMN protein produced by the SMN2 gene 
(Hamilton and Gillingwater, 2013). 
SMN1 and SMN2 are located in an unstable genomic region, meaning that 
there is variability in the number of copies of SMN2 between individuals (Schmutz et 
al., 2004). These differences in SMN2 copy number cause variability in the SMA 
phenotype: individuals with a higher SMN2 copy number have a less severe disease 
phenotype (Harding et al., 2015). Thus, SMN2 copy number represents the primary 
determinant of disease severity in SMA (Kolb and Kissel, 2011). Interestingly, 
however, SMN protein levels do not always correlate with SMN2 copy number 
(Crawford et al., 2012; Wadman et al., 2016) and the number of SMN2 copies does 
not always correlate directly with disease severity in patients (Wadman et al., 2017). 
Indeed, twins with the same SMN1 genotype and SMN2 copy number have been 
shown to present with different severities of SMA; in one instance one twin was 
diagnosed with SMA type 1 while the other had SMA type 2 (Pane et al., 2017). 
Characterisation of discordant families such as this lead to the identification of other 
genetic modifiers, such as PLS3 and NCALD, that influence the clinical phenotype of 
SMA (Hosseinibarkooie et al., 2016; Oprea et al., 2008; Riessland et al., 2017). 
Following the identification of the disease-causing gene, it has become 
possible to model SMA in various animal systems (McWhorter et al., 2003; Sleigh et 
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al., 2011). Animal models of SMA focus on reducing the amount of full length SMN 
protein and exist for Caenorhabditis elegans, Drosophila melanogaster, Danio rerio 
(zebrafish) and Mus musculus (mouse) (Jablonka and Sendtner, 2017; Sleigh et al., 
2011). There is also now a large animal model of SMA in pigs (Duque et al., 2015). 
Of these, mouse and zebrafish models are the most widely used with several mouse 
models of SMA being available, most of which are based on deleting the endogenous 
mouse Smn gene and inserting an SMN2-like transgene. Studies in these animal 
models have led to an increased understanding of the molecular pathogenesis of 
SMA (Jablonka and Sendtner, 2017; Sleigh et al., 2011). 
 
Figure 1-1 Genetics of SMA 
A Overview of the human chromosome 5q13 locus containing the telomeric SMN1 and the 
centromeric SMN2 genes. B Structure, splicing and protein production from SMN1 and 
SMN2. Full length SMN protein contains multiple functional domains: tudor domain (Tudor) 
which regulates the interaction with Sm proteins and other RGG-domain containing proteins; 
a proline-rich region (Pro) which is known to regulate the interaction of SMN and profilin; and 
a YG-box domain (YG) which regulates the self-oligomerization SMN. Adapted from (Groen 
et al., in preparation). 
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1.1.4 The survival motor neuron protein 
In order to successfully target the survival motor neuron protein (SMN) as a 
therapeutic approach for SMA, it is necessary to understand the functions of the 
SMN protein, the downstream effects of the reduction in SMN and the widespread 
cellular and molecular pathways subsequently disrupted in this disease. 
1.1.4.a Biogenesis of snRNPs 
Survival motor neuron protein is a ubiquitously expressed, multifunctional protein 
that forms a macromolecular complex essential for the splicing of pre-mRNAs 
(Fischer et al., 1997; Liu et al., 1997; Massenet et al., 2002). SMN associates with 
Gemins 2-8 and unrip to form a complex that then facilitates the formation, transport 
and maturation of small nuclear ribonuclear proteins (snRNPs). snRNPs consist of 7 
Sm core proteins and uridine-rich small nuclear RNAs (Fischer et al., 1997; Liu et 
al., 1997; Pellizzoni et al., 2002). Once formed the partially mature snRNPs are 
imported into the nucleus where they mature in Cajal bodies. The snRNPs then 
localise to nuclear speckles from where they can be recruited to active spliceosomes 
in the nucleus when required (Jady et al., 2003; Sleeman and Lamond, 1999; Spector 
and Lamond, 2011). 
During pre-mRNA splicing, snRNPs are essential for the excision of introns 
from mRNA precursors in the nucleus (Massenet et al., 2002). Reduced SMN levels 
lead to a tissue specific decrease in snRNP assembly that correlates with phenotypic 
severity in mouse models of SMA (Gabanella et al., 2007). Interestingly, SMN 
depletion increases the mobility of snRNPs as a direct effect of the impaired snRNP 
maturation, meaning that the snRNPs spend relatively less time within the 
spliceosome and more time in nuclear speckles (Clelland et al., 2012). Moreover, 
widespread splicing defects have been found in SMA tissues with a wide diversity of 
genes being affected (Zhang et al., 2008), including genes encoding splicing 
regulators and proteins required for motor circuit function (Huo et al., 2014; Lotti et 
al., 2012). However, it has also been suggested that splicing defects may represent a 
late feature of SMA indicating that alternative splicing events could represent a 
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consequence of disease progression in SMA, rather than the primary cause (Baumer 
et al., 2009). 
Further studies have suggested a broader role of SMN in RNP formation. It 
has been identified that SMN is involved in the formation, regulation and function of 
snoRNPs (small nucleolar RNPs), involved in post-translational modification of 
noncoding RNAs (Pellizzoni et al., 2001), and signal recognition particles, required 
to transport newly synthesized proteins, amongst other RNP complexes (Piazzon et 
al., 2013; Tisdale and Pellizzoni, 2015). Furthermore, SMN has been shown to 
influence a range of other RNA-related processes such as directly influencing pre-
mRNA splicing, along with roles in the transport and translation of mRNAs (Fallini 
et al., 2012; Makarov et al., 2012; Prescott et al., 2014; Rossoll et al., 2003); 
functions that lead to clear phenotypes in SMA model systems (see 1.1.4.b). 
1.1.4.b Axonal and synaptic functions of SMN 
Aside from its housekeeping function in snRNP assembly, SMN has been shown to 
have additional roles that may contribute to disease pathogenesis in SMA. For 
example, during axonogenesis and axonal sprouting there is a progressive shift of 
SMN towards an axonal localisation in human spinal cord, suggesting an axonal 
function of SMN (Giavazzi et al., 2006). Indeed, SMN is essential for RNA transport 
within the axonal compartment and is also involved in axonal elongation, with loss 
of SMN leading to defects in axon outgrowth (Groen et al., 2013; McWhorter et al., 
2003; Rossoll et al., 2003). 
SMN localises to granules associated with cytoskeletal micro- and macro-
filament systems in neurons along which the SMN granules show rapid bidirectional 
movement (Bechade et al., 1999; Pagliardini et al., 2000; Zhang et al., 2003). These 
SMN granules are involved in axonal transport to deliver mRNAs to the synapse, 
where local translation can occur (Fallini et al., 2012). For example, through 
interaction with mRNA binding proteins, SMN is involved in the localisation of beta-
actin and beta-actin mRNA to growth cones of developing motor neurons, which 
leads to axonal elongation and growth cone size regulation (Rossoll et al., 2003). 
Interestingly, while SMN deficient motor neurons have reduced growth cone size 
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(Groen et al., 2013; Rossoll et al., 2003), mice that lack beta-actin in motor neurons 
do not (Cheever et al., 2011), indicating that other pathways contribute to the 
defective axonal elongation phenotype in SMA. Indeed, in SMA decreased 
interaction of SMN and profilin has been shown to lead to an increase in the 
formation of profilin/ROCK complexes which in turn activates Rho A. As a negative 
regulator of axon outgrowth, this inappropriate activation of Rho A has been shown 
to lead to defects in neuritogenesis in SMA (Bowerman et al., 2009; Nolle et al., 
2011). Moreover, it has been demonstrated that Insulin like growth factor 1 (IGF-1) 
is essential for enhancing axonal outgrowth of motor neurons. Intriguingly, 
circulating IGF-1 levels are also reduced as a consequence of the SMN reduction in 
SMA (Hua et al., 2011; Tsai et al., 2014).  
Furthermore, defects in endocytosis have also been implicated in SMA 
pathogenesis. Endocytosis is essential for synaptic function and signal transduction at 
the neuromuscular junction (NMJ), one of the primary sites of pathology in SMA 
(Hosseinibarkooie et al., 2017). In SMA both misregulation of calcium dynamics and 
alterations to F-actin dynamics cause defects in endocytosis (Hosseinibarkooie et al., 
2016; Riessland et al., 2017). Overexpression of one of the primary genetic modifiers 
of SMA, Plastin 3 (PLS3), rescues defects in endocytosis in several models of SMA. 
This likely occurs through the interaction of PLS3 with coronin 1C which then 
restores the amount of F-actin in SMA (Hosseinibarkooie et al., 2016). Moreover, 
another genetic modifier of SMA, neurocalcin delta (NCALD), is a neuronal calcium 
sensor protein that regulates the activity of clathrin (a calcium-sensitive regulator of 
endocytosis) in a calcium dependent manner (Hosseinibarkooie et al., 2017). 
Reduction in the amount of NCALD increases the presynaptic function of clathrin 
which reverses the reduction of the pool of synaptic vesicles that occurs in SMA 
(Riessland et al., 2017). Together these insights suggest that reduction of SMN leads 
to multiple defects in the growth, development and maintenance of synaptic and 
axonal functions that are more widespread than the specific role of SMN in RNA 
related processes. 
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1.1.4.c The ubiquitin proteasome system and energy homeostasis in 
SMA 
Several other cellular and molecular pathways are also dysregulated in SMA due to 
reduced SMN levels. For example, ubiquitin homeostasis is altered in SMA whereby 
SMN depletion in mouse models of SMA leads to down-regulation of ubiquitin-like 
modifier-activating enzyme 1 (UBA1) and accumulation of its downstream targets, 
including beta-catenin (CTNNB1) (Fuller et al., 2015; Wishart et al., 2014). Indeed, 
in zebrafish, knockdown of UBA1 is sufficient to induce an SMA-like phenotype 
(Wishart et al., 2014). The proteasome is also of interest for SMA as SMN 
degradation is mediated by the ubiquitin proteasome system (UPS) (Chang et al., 
2004) and inhibiting proteasome function has been shown to increase SMN levels, 
rendering this a potential therapeutic target (Kwon et al., 2011). Furthermore, the 
deubiquitylase Usp9x associates with and stabilises the SMN complex through 
interaction with SMN, which it deubiquitylates. Usp9x does not, however, 
deubiquitylate and stabilise the truncated SMN protein produced by SMN2, which is 
therefore rapidly degraded (Han et al., 2012).  
Disrupted energy homeostasis and alterations of mitochondrial function have 
also been implicated in SMA. For example, SMN reduction in NSC34 cells and 
motor neurons leads to depletion of ATP levels (Acsadi et al., 2009; Miller et al., 
2016). Mitochondrial trafficking and morphology are also altered in iPSC-derived 
motor neurons from SMA patient fibroblasts (Xu et al., 2016). Importantly, impaired 
mitochondrial biogenesis has also been seen in skeletal muscle biopsies from SMA 
patients (Ripolone et al., 2015). Moreover, motor neuron vulnerability in SMA 
correlates with the bioenergetic profile of the motor neurons. More vulnerable motor 
neuron pools have reduced transcript levels of Pgk1 which encodes the glycolytic 
enzyme phosphoglycerate kinase 1 (PGK1). Interestingly, knockdown of pgk1 is 
sufficient to mimic the SMA phenotype in wild-type zebrafish (Boyd et al., 2017). 
Overall, this indicates that reduced SMN leads to disruption of multiple cellular 
pathways beyond RNP formation and RNA processing. 
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The identification of these novel cellular and molecular functions of SMN 
indicates the broad role for SMN in the pathogenesis of SMA and in motor neuron 
biology. Clearly, these studies show that the cellular and molecular pathways 
disrupted on SMN depletion extend beyond the canonical role of SMN in snRNP 
formation. These insights also open-up the possibility of developing SMN-
independent therapies for the treatment of SMA. 
1.1.5 SMA is a multisystem disorder 
Regardless of whether therapies being developed for SMA are SMN-dependent or 
SMN-independent, one key element of any successful therapy is the ability to deliver 
it to the cells, tissues and organs that are most affected in the disease. In the case of 
SMA, the main pathological target is alpha motor neurons (Powis and Gillingwater, 
2015): ~25-30% of lower motor neuron cell bodies are lost from the spinal cord of 
late symptomatic SMA mice (Monani et al., 2000). This selective loss of lower 
motor neurons is present in all human patients (Dubowitz, 2009). However, 
neuromuscular pathology is apparent before the overt loss of motor neuron cell 
bodies occurs in SMA models (McWhorter et al., 2003; Murray et al., 2008) and 
importantly, NMJ defects are present in SMA patients (Hamilton and Gillingwater, 
2013; Wadman et al., 2012). The neuromuscular system appears to develop relatively 
normally in SMA mice, but early in the disease, structural and functional defects are 
seen in both nerve and muscle (McGovern et al., 2008; Murray et al., 2010). These 
include early pathological changes at the NMJ, such as nerve terminal loss, synaptic 
accumulation of neurofilament proteins, and defective maturation of acetylcholine 
receptor clusters (Cifuentes-Diaz et al., 2002; McGovern et al., 2008; Murray et al., 
2010). Alongside these early changes in distal extremities of motor neurons, intrinsic 
defects have been reported in skeletal muscle, including smaller myotubes as well as 
reduced proliferation, fusion defects of myoblasts and increased cell death (Martinez-
Hernandez et al., 2009; Shafey et al., 2005). These pathological changes in muscle 
occur independently of neuron degeneration and correlate with SMN reduction in 
model systems (Boyer et al., 2013; Martinez-Hernandez et al., 2009; Murray et al., 
2008; Shafey et al., 2005). 
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Aside from lower motor neurons, low SMN levels also affect other cell types 
that reside within the nervous system. For example, a defective myelination 
phenotype has been observed in the peripheral nervous system where the maturation 
of axo-glial interactions at paranodes was disrupted in SMA mice; the myelin sheaths 
were also thinner and there was an increase in the number of large diameter 
unmyelinated axons. These phenotypes were due to intrinsic defects in Schwann 
cells in mouse models of SMA (Aghamaleky Sarvestany et al., 2014; Hunter et al., 
2014; Hunter et al., 2016). Altered function of astrocytes has also been implicated in 
SMA pathogenesis whereby defects in contact interactions between motor neurons 
and astrocytes leads to impaired synaptogenesis (Rindt et al., 2015; Zhou et al., 
2016). SMA astrocytes also showed increased production and secretion of 
microRNAs (Sison et al., 2017) suggesting that the defects in astrocytes, like those in 
Schwann cells, are cell autonomous and not a result of motor neuron pathology in 
SMA. Furthermore, pathological changes have been reported in the thalamus, 
cerebral cortex, brainstem and dorsal root ganglia in severe cases of SMA (Harding 
et al., 2015). In severe mouse models of SMA, the low levels of SMN have also been 
shown to impair neurogenesis and disrupt cell proliferation leading to abnormal 
hippocampal development (Wishart et al., 2010). 
Alongside pathological changes in the nervous system and skeletal muscle, 
defects in peripheral tissues and organs including the heart, pancreas and blood 
vessels have also been reported in SMA patients (Hamilton and Gillingwater, 2013; 
Harding et al., 2015; Sintusek et al., 2016; Somers et al., 2015). For example, in 
SMA type 1 patients, septal defects and structural abnormalities of the cardiac 
outflow tract are relatively common, while cardiac rhythm disorders are more 
common in patients with milder SMA (Wijngaarde et al., 2017). Vascular defects 
have also been reported in severe SMA patients including distal digital necrosis and 
vascular depletion in skeletal muscle (Hamilton and Gillingwater, 2013; Somers et 
al., 2015). Interestingly, the extent of vasculature in mid-symptomatic SMA mice 
was reduced by 50% compared to control mice leading to significant functional 
hypoxia of the spinal cord in SMA (Somers et al., 2015). 
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There have also been several recent studies implicating defects of the immune 
system in SMA. These phenotypes include impaired T-cell development in the 
thymus and an almost complete absence of B-cells in the spleen; both organs also 
show structural differences and increased cell death in mouse models of SMA 
(Deguise and Kothary, 2017; Thomson et al., 2017). Studying mouse models of 
SMA has also revealed developmental failure of the liver in SMA mice (Szunyogova 
et al., 2016). Along with the reported defects in bone and the identification of clot-
like accumulations in hearts from SMA mice (Hamilton and Gillingwater, 2013; 
Szunyogova et al., 2016), this suggests that disruption to normal hematopoiesis may 
also occur in SMA. Abnormalities in the intestine and lungs have also been reported 
in mouse models of SMA (Hamilton and Gillingwater, 2013). Taken together these 
findings demonstrate that low levels of SMN in SMA lead to multisystem 
phenotypes with organ systems, tissues and specific cell types showing a broad 
spectrum of vulnerability. 
One working hypothesis to explain the presence of extra-neuronal pathology 
in SMA is the ‘threshold hypothesis’ where differential thresholds for low SMN 
levels exist in different cell types, with motor neurons being most vulnerable in SMA 
due to their exceptional sensitivity to low levels of SMN (Hamilton and Gillingwater, 
2013; Sleigh et al., 2011). Although extra-neural phenotypes may often manifest at 
the subclinical level in SMA patients, they are becoming of increasing importance as 
therapies prolonging a patient’s survival run the risk of unmasking disorders of other 
organ systems. Moreover, several studies have shown that restoring SMN in motor 
neurons or skeletal muscle alone is insufficient to correct disease pathology in SMA 
mice and that peripheral SMN restoration is likely to be essential for long-term 
rescue of SMA (Hua et al., 2015; Hua et al., 2011). Overall, these findings suggest 
that any successful therapy for SMA will need to target not only motor neurons and 
skeletal muscle, but also more widespread, systemic pathology. 
1.1.6 Therapeutic advances for SMA 
Due to the clear monogenic cause of ~95% of cases of SMA and the robust animal 
models available to study the disease, therapy development has been at the forefront 
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of SMA research. Until recently, palliative care options to assist with management of 
symptoms and prevention of complications were the only option for patients with 
SMA. Excitingly, however, the first therapy for SMA has recently been approved. 
There are also several other therapies at advanced stages of clinical trials and in pre-
clinical development. Given the central role that SMN plays in the disease, it is not 
surprising that the most clinically advanced therapies for SMA are targeted at 
increasing SMN protein levels. However, there are also SMN-independent therapies 
currently in clinical trials - mainly neuroprotective factors or muscle strength-
enhancing compounds - and several therapies currently in development in animal 
models of SMA targeting pathways affected downstream of SMN. 
1.1.6.a SMN-targeted therapies 
The recently approved treatment for SMA, Spinraza, is an antisense oligonucleotide 
(ASO). Several ASOs have been developed that are directed against sequences that 
inhibit the inclusion of SMN2 exon 7 (Singh et al., 2017). The binding of ASOs to 
this regulatory motif prevents the binding of repressor factors which in turn promotes 
the inclusion of exon 7, thereby increasing the amount of full-length SMN protein 
produced by SMN2 (Keil et al., 2014; Singh et al., 2006). Spinraza is at the forefront 
of these ASO-based therapies and has been approved for treatment of all types of 
SMA in Europe and the USA. A subgroup of type 1 SMA patients show substantial 
improvements in motor function following treatment with Spinraza; however not all 
patients respond in the same manner with more modest effects reported for other type 
1 SMA patients (Chiriboga et al., 2016; Finkel et al., 2016). Currently, treatment 
with Spinraza requires repeated administration via intrathecal injection which is 
expensive and adds considerable burden for patients. A second generation of ASOs 
for treatment of SMA are currently under development which might overcome the 
current disadvantages by allowing less invasive delivery routes and improving 
efficacy (Hammond et al., 2016). 
There are other strategies, several of which are currently in clinical trials, 
aimed at increasing SMN protein levels. One of these is based around small 
molecules that modify SMN2 splicing and increase SMN levels. After promising 
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results from screens in rodent and cell models of SMA, studies taking this more 
traditional pharmacological approach (including RG7916 and branaplam [formerly 
LMI070]) are currently in clinical trials (Naryshkin et al., 2014), with initial reports 
suggesting some benefit (Chamas., 2017; Mercuri, 2017). Other small molecule 
strategies to increase the levels of SMN protein include the use of histone-
deacetylase inhibitors such as Valporic acid, however, clinical trials for this approach 
have been disappointing (Kissel et al., 2014; Krosschell et al., 2017). 
Another strategy aimed at increasing SMN protein levels currently in clinical 
trials, is gene therapy to replace the faulty SMN1 gene. Promising pre-clinical data 
from animal models showed that adeno-associated virus (AAV) mediated Smn gene 
replacement resulted in widespread expression of SMN in the spinal cord and 
significantly increased survival of SMA model mice (Dominguez et al., 2011; Foust 
et al., 2010; Passini et al., 2010; Valori et al., 2010). In the ongoing phase 1 gene 
therapy clinical trial, SMN1 within a self-complimentary adeno-associated virus 
serotype 9 (scAAV9) vector is being delivered intravenously to type 1 SMA patients. 
This initial clinical trial is evaluating both the safety and efficacy of the treatment in 
the small group of infants enrolled in the study (Mendell, 2017). Although a detailed 
report of this study has yet to be released, initial results from this trial are so far very 
promising (Mendell, 2017). The one dose administration method for this therapy also 
makes it an attractive therapeutic approach, however, as viral gene therapy is not 
commonly used in clinical practice there are logistical problems to overcome if the 
therapy were to become widely available and there would need to be long-term 
health monitoring to check the safety of the treatment. 
Regardless of the technological approach used to increase SMN levels, the 
‘therapeutic time-window’ within which therapy must be delivered to have a 
maximal effect needs to be considered. Several studies have indicated that SMN is 
required at early stages of development and that sufficient SMN levels are essential 
for NMJ maturation during the early post-natal period (Chang et al., 2015; Iyer et al., 
2015; Kariya et al., 2014). It has also been demonstrated that late stage Smn gene 
replacement using scAAV9 failed to ameliorate NMJ defects, while pre-symptomatic 
delivery of scAAV9-Smn resulted in near complete rescue of the SMA phenotype in 
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mouse models (Robbins et al., 2014). Together, these studies indicate that treatment 
using SMN-enhancing therapies will need to occur before overt symptoms are 
apparent for a full restoration of the SMA phenotype. 
Indeed, there is now a move towards pre-symptomatic diagnosis of SMA by 
inclusion of real-time PCR genotyping assay for SMN1 on routine newborn screening 
panels of dried blood spot. By confirming this initial assay with a multiplex ligation-
dependent probe amplification (MPLA) assay, a study identified 7 asymptomatic 
SMA patients over a two-year period (Chien et al., 2017). Thus, this strategy would 
enable genetic diagnosis of SMA and therapy administration before the onset of 
overt symptoms, when the treatment is most likely to give the greatest benefit to the 
patient. 
1.1.6.b SMN-independent therapies 
While the first-generation of SMN-dependent therapies progress through the clinical 
trial process there are several second-generation SMN-independent therapies 
currently in pre-clinical and clinical development. The most clinically-advanced of 
these are centred around administering neuroprotective factors, or enhancing muscle 
strength. Olesoxime is one potential neuroprotective factor which exerts its 
neuroprotective effects by binding to components of the mitochondrial permeability 
pore (Sunyach et al., 2012). Phase 2 clinical trials for type 2 and non-ambulatory 
type 3 SMA patients indicated that olesoxime is safe and leads to a maintenance of 
motor function (Bertini et al., 2017). 
Several drugs in trials to improve muscle strength in SMA have previously 
been approved for other disorders involving weakness of the neuromuscular system. 
These include pyridostigmine which is in clinical trials for SMA types 2, 3 and 4, 
and 4-Aminopyridine, in trials in ambulatory SMA patients. Both these therapies are 
being assessed for their endurance-enhancing properties and their effect on reducing 
fatigability in SMA patients. Novel compounds to treat neuromuscular dysfunction, 
muscular weakness and muscle fatigue are also in development for SMA. For 
example, CK-2127107, a fast skeletal muscle troponin complex activator, is currently 
in Phase 2 clinical trials following safe pharmacokinetic and pharmacodynamics 
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findings in Phase 1 trials (Hwee et al., 2015). Similarly, SRK-015 is an inhibitor of 
myostatin that has been shown to improve muscle function in SMA mice and is due 
to enter clinical trials for SMA in 2018 (ScholarRock, 2017). 
1.1.6.c Targeting pathways affected in SMA 
Other SMN-independent therapies at early stages of development follow on from 
recent advances in the understanding of cellular and molecular pathways 
dysregulated downstream of SMN reduction in SMA (see 1.1.4.b and 1.1.4.c) and 
aim to target these pathways. For example, members of the Rho-kinase (ROCK) 
pathway have become attractive therapeutic targets due to their known potential to 
modulate axon outgrowth and growth cone motility. Although targeting downstream 
effectors of ROCK did not rescue phenotypes in mouse models of SMA (Bowerman 
et al., 2009), inhibiting ROCK did lead to positive outcomes (Bowerman et al., 2010; 
Bowerman et al., 2012). Both Fasudil and Y-27632 inhibit ROCK and resulted in an 
increase in the survival of SMA mice and improved NMJ maturation and muscle 
fibre size (Bowerman et al., 2010; Bowerman et al., 2012). Although toxicity was 
associated with Fausidil at high doses and motor neuron cell death was not reduced, 
the increase in survival points towards the importance of targeting muscle in SMA 
treatment strategies (Bowerman et al., 2010; Bowerman et al., 2012). 
The ubiquitin-proteasome system has also been highlighted as a potentially 
attractive therapeutic target for SMA. For example, inhibiting the chymotrypsin-like 
activity of the 26S proteasome using bortezomib increased SMN levels in peripheral 
tissues of SMA mice, improved motor function and increased survival (Kwon et al., 
2011). When SMA mice were treated with a combinatorial therapy of bortezomib 
and trichostatin A, a histone deacetylase inhibitor that increases SMN protein levels, 
the improvements observed across all aspects of the SMA phenotype were greater 
than when mice were treated with only one therapy (Kwon et al., 2011). This study 
therefore provides a proof-of-principle that combinatorial therapies targeting SMN 
and SMN-independent pathways in SMA may represent a viable therapeutic 
approach. However, due to toxicity issues associated with using available 
proteasome inhibitors, including bortezomib, specifically targeting the ubiquitylation 
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of SMN may be a more suitable therapeutic approach and may lead to a reduction in 
the non-specific effects associated with targeting the proteasome (Groen and 
Gillingwater, 2015). Indeed, it has recently been identified that the compound 
ML372 selectively inhibits the ubiquitylation of SMN and has no effect on the 20S 
catalytic activity of the proteasome. Administration of this compound to SMA mice 
increased SMN protein levels in muscle, brain and spinal cord, and improved motor 
function and survival of SMA mice (Abera et al., 2016). 
Alongside evidence suggesting that targeting SMN protein stability via the 
UPS may be an attractive therapeutic approach for SMA, recent experiments have 
demonstrated that UBA1, a key E1 ubiquitin-activating enzyme required for UPS 
function, is a major downstream target of SMN (Fuller et al., 2015; Wishart et al., 
2014). SMN-induced reduction of UBA1 levels in SMA leads to disruption of 
UBA1-dependent targets, such as an accumulation of beta-catenin (Wishart et al., 
2014). Experiments in SMA animal models targeting these UBA1-dependent 
pathways have demonstrated improvements in neuromuscular phenotypes, 
suggesting that these pathways are amenable to therapeutic intervention (Powis et al., 
2016; Wishart et al., 2014). 
1.1.6.d Combinatorial therapies 
It is possible that combinatorial therapies - treating SMA patients with more than one 
therapy, each from different strategies - will have the greatest potential to ameliorate 
the full spectrum of SMA disease phenotypes. Combining SMN enhancement 
therapies with muscle strength enhancing drugs or neuroprotective factors may help 
to preserve and strengthen the connections between neurons and muscles. This 
approach may result in effective treatment of SMA symptoms beyond the therapeutic 
time-window in which SMN-dependent therapies alone will be effective. It is likely 
that the first combinatorial therapies to enter the clinic for SMA will be a 
combination of SMN-dependent therapies and muscle strength enhancing 
compounds. Indeed, Scholar Rock has announced that they intend to develop SRK-
015 in combination with therapies targeting the genetic cause of SMA for clinical 
trials in SMA patients (ScholarRock, 2017). 
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While combinatorial therapies may appear attractive from both clinical and 
scientific perspectives, it may become necessary from a logistical aspect of therapy 
development for clinical trials to be combinatorial. As more patients are being treated 
with Spinraza, or are enrolled on clinical trials for other SMN-targeted therapies, the 
pool of SMA patients with no prior treatment for enrolment on clinical trials will 
become reduced; thus, rendering combinatorial approaches for second generation 
therapies necessary at the clinical trial level, at least for more severe forms of SMA. 
Alternative combinatorial therapeutic approaches include combining 
therapies to enhance SMN gene transcription with treatments to reduce SMN 
degradation (see 1.1.6.c). Or alternatively, combining therapies that target genetic 
modifiers or downstream pathways in SMA with SMN-dependent therapies. These 
approaches have the benefit of a possible dose reduction of the SMN enhancing 
agent, which may help to reduce toxicity and increase efficacy (Kwon et al., 2011). 
To study such combinations of therapies, intermediate mouse models of SMA have 
been generated by administering suboptimal doses of SMN-targeted ASOs, thereby 
recapitulating the situation in SMA patients for which SMN-targeted therapies do not 
completely rescue their symptoms (Zhou et al., 2015). Early pre-clinical, 
combinatorial therapy experiments using such mouse models have shown promising 
results. For example, by increasing PLS3 expression there was a significant 
improvement in survival and improvement of motor function compared to treatment 
with the SMN-targeted ASO alone (Hosseinibarkooie et al., 2016; Kaifer et al., 
2017). Interestingly, this therapy also restored defects in endocytosis seen in SMA 
(Hosseinibarkooie et al., 2016). Similarly, combination of suboptimal SMN-targeted 
ASOs and down-regulation of NCALD improved a range of neuromuscular 
phenotypes in the SMA mice (Riessland et al., 2017). 
Importantly, the studies described here provide a proof-of-concept that 
combinatorial therapies are a promising therapeutic approach for the next generation 
of SMA therapies. While it is likely that the first clinical combinatorial therapies will 
be a combination of SMN-targeted therapies and muscle strength enhancing drugs, 
due to the multisystem defects in SMA and the range of pathways disrupted in this 
disease, it may prove more beneficial to target SMN and correct downstream 
  Understanding the role of UBA1 in SMA 
Introduction 19 
pathways that are disrupted in SMA. This may be of particular importance in severe 
SMA patients and may be especially beneficial when targeting pathways known to 
be disrupted pre-symptomatically in SMA models and patients. One such candidate 
that would merit being tested in a combinatorial approach is UBA1. While it is 
known that UBA1 is a key downstream target of SMN and that therapies targeting 
UBA1 rescue neuromuscular phenotypes across a range of SMA models (Powis et 
al., 2016; Wishart et al., 2014), the mechanism by which UBA1 mediates 
degeneration in SMA is unknown.  
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1.2 Ubiquitin-like modifier activating enzyme 1 
The ubiquitin-like modifier activating enzyme 1 (UBA1) is a promising therapeutic 
target for combinatorial therapy of SMA. UBA1 is the ubiquitin activating enzyme at 
the apex of the ubiquitin conjugation process and its role in this process is well 
characterised. Interestingly, UBA1 has also been shown to be important for neuronal 
homeostasis and has been implicated in a wide range of neurodegenerative 
conditions. 
1.2.1 UBA1 and the ubiquitin proteasome system 
As previously mentioned, UBA1 is responsible for activating ubiquitin in the 
ubiquitin proteasome system (UPS). In this process, the active adenylation domain of 
UBA1 binds Mg2+ and ATP to catalyse the binding with ubiquitin (Figure 1-2). This 
complex is then stabilised by the inactive adenylation domain of UBA1 (for domain 
organisation of UBA1 see Figure 1-3) (Lee and Schindelin, 2008). AMP is then 
released allowing the formation of a high-energy thioester bond between the 
carboxyl terminus of ubiquitin and the reactive cysteine (C632) of UBA1 (Figure 
1-2). In another Mg2+ and ATP dependent reaction a ternary complex is formed, 
consisting of the UBA1-ubiquitin thioester with another molecule of ubiquitin-AMP 
bound (Bedford et al., 2011; Haas et al., 1982). This favourable conformation of the 
UBA1-ubiquitin complex enables a transthiolation reaction to occur, resulting in the 
thioester bound ubiquitin being transferred to an E2 conjugating enzyme, again 
forming a thioester bond (Schulman and Harper, 2009). UBA1 then forms a thioester 
bond with the second ubiquitin, again releasing AMP, thus activating this ubiquitin 
molecule (Figure 1-2). Formation of a ternary complex again allows the transfer of 
the activated ubiquitin to an E2 enzyme and in this manner the ubiquitin activation 
cycle continues (Bedford et al., 2011). 
Once the activated ubiquitin is bound to an E2 conjugating enzyme, the E2 
can then bind an E3 ligase enzyme which is typically already bound to a protein 
substrate; therefore, allowing the transfer of ubiquitin to an acceptor lysine residue 
on the substrate (Figure 1-2) (Bedford et al., 2011). This process may continue 
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leading to the formation of polyubiquitin chains on the protein substrate (Ye and 
Rape, 2009). In some situations, an E4 enzyme may also be involved in the 
elongation of ubiquitin chains (Ciechanover and Brundin, 2003). If the polyubiquitin 
chain is formed by linking ubiquitin molecules at K48, on release from the E3 ligase 
enzyme the proteasome recognises the substrate for degradation. If the substrate is 
monoubiquitylated or polyubiquitylated using different ubiquitin lysine sites, on 
release from the E3 ligase the ubiquitylation on the protein substrate will signal for 
different functions of the substrate such as enzyme activation, signalling and protein 
trafficking (Figure 1-2) (Kulathu and Komander, 2012; Ye and Rape, 2009). Finally, 
deubiquitylating enzymes remove ubiquitin moieties from protein substrates (Figure 
1-2) (Ciechanover and Brundin, 2003) and so may alter the function of the substrate 
or prevent its degradation by regulation of the ubiquitin modifications. Therefore, 
through activation of ubiquitin at the outset of this conjugation process, UBA1 can 
influence a range of downstream pathways through its canonical function. 
 
Figure 1-2 The ubiquitin conjugation pathway 
Overview of the ubiquitin conjugation pathway leading to protein degradation or altered 
function of the substrate protein. Ub: ubiquitin; UBA1: Ubiquitin-like modifier activating 
enzyme 1; E2: E2 ubiquitin conjugating enzymes; E3: E3 ubiquitin ligase enzymes; DUB: 
deubiquitylating enzymes. E2, E3 and DUB enzymes have different specificities for the 
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enzymes in the pathway and the protein substrates. Solid lines represent thioester bonds, 
dashed lines represent ubiquitin-AMP bound to UBA1. 
1.2.2 UBA1 and neuronal homeostasis 
Neurons are very specialised cells with specific needs for local translation and 
degradation to maintain cellular homeostasis and normal functioning. With the UPS 
having key roles in these processes, it is unsurprising that the UPS is required for 
many different aspects of pre-and postsynaptic development and function 
(Deglincerti et al., 2015; Jiang et al., 2010). For example, inhibition of the 
proteasome prevents a reduction in the number of readily releasable vesicles at active 
synapses. This in turn prevents the induction of persistent presynaptic silencing and 
so inhibition of the proteasome interferes with adaptive plasticity of hippocampal 
neurons (Jiang et al., 2010). The UPS was also shown to be important for the 
response of growth cones to axonal guidance cues. RhoA is one example of a 
transcript that is locally translated in response to axon guidance cues. In growth 
cones there are high levels of ubiquitylation of RhoA which lead to its degradation 
(Deglincerti et al., 2015). Similarly, the main targets of ubiquitylation in the growth 
cone are newly synthesised, locally translated proteins, suggesting that UPS activity 
is required for efficient responses to both attractive and repulsive axon guidance cues 
during neuronal development (Deglincerti et al., 2015). 
Not surprisingly, as UBA1 is a key component of the UPS, specific 
requirement of UBA1 itself has been shown to be necessary for development and 
maintenance of neuronal function. For instance, inhibition of UBA1 causes an 
increase in miniature and spontaneous synaptic currents in cultured hippocampal 
neurons. This occurs at both excitatory and inhibitory synapses indicating that UBA1 
may be necessary to regulate the activity state of presynaptic proteins (Rinetti and 
Schweizer, 2010). Similarly, loss of UBA1 blocks axon pruning during development 
in Drosophila, a process that is mediated by local degeneration (Watts et al., 2003), 
suggesting that UBA1 is required for normal axonal pruning. Furthermore, UBA1 
has also been implicated in the slow Wallerian degeneration (Wlds) phenotype, a 
mouse model in which axons and synapses are protected from degeneration. One of 
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the pathways through which this neuroprotection is thought to occur is increased 
levels of UBA1 with specific changes in the synaptic expression of UBA1 (Wishart 
et al., 2007; Wishart et al., 2008). Together, these findings reveal an important role 
for the UPS and, more specifically, for UBA1 in the regulation of a range of cellular 
and molecular pathways necessary for the maintenance and function of neurons. 
1.2.3 Protein homeostasis and UBA1 in neurodegeneration 
Given the importance of UBA1 and the UPS in neuron development and function it 
is not surprising that disruption to protein homeostasis and UBA1 have been 
identified in a range of neurodegenerative conditions. Many neurodegenerative 
diseases display a common molecular signature of disruption to protein homeostasis 
through accumulation of ubiquitylated proteins in aggregates (Rubinsztein, 2006). In 
several diseases, such as Parkinson’s disease (PD), Alzheimer’s disease (AD), 
Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), there is evidence 
that these protein aggregates contribute to disease pathogenesis (Arrasate and 
Finkbeiner, 2012; Blokhuis et al., 2013; Ittner and Gotz, 2011; Lashuel et al., 2013). 
Disruption of protein homeostasis has also been evidenced in neurodegenerative 
diseases in the absence of ubiquitylated protein aggregates, for example in SMA 
(Fuller et al., 2015; Wishart et al., 2014). 
Interestingly, mutations in components of the UPS machinery lead to several 
of these conditions. Mutations in the E3 ligase PARKIN, the E3 ligase component 
FBXO7 and the deubiquitylating enzyme UCHL1 are associated with PD (Leroy et 
al., 1998; Lohmann et al., 2015; Ryan et al., 2015). Similarly, mutations in UBQLN2 
which encodes a protein that targets polyubiquitylated proteins to the proteasome, 
cause ALS (Deng et al., 2011). Interestingly, motor neuron specific knockout of the 
proteasome subunit Rpt3 lead to ALS like phenotypes in mice, including aggregation 
of proteins (Tashiro et al., 2012). It has also been shown that mutations in 
Drosophila Uba1 lead to reduced survival and motor impairment, implicating 
specific dysfunction of UBA1 in neurodegeneration (Liu and Pfleger, 2013). 
Indeed, disruption of UBA1 has been observed in several neurodegenerative 
diseases. For example, UBA1 is an important modifier of polyglutamine protein 
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toxicity in a HD mouse model, whereby reduction in nuclear UBA1 expression 
correlates with mutant huntingtin accumulation in Huntington’s disease (Wade et al., 
2014). Similarly, UBA1 modifies toxicity of a Tau mutant in Drosophila (Blard et 
al., 2007) and the activity and expression of UBA1 is reduced in cytosolic fraction of 
AD patient brain samples (Lopez Salon et al., 2000). Furthermore, UBA1 
preferentially binds to ALS-causing mutant fused in sarcoma (FUS) protein but not 
to wild-type FUS, again suggesting a modifying effect of UBA1 on disease 
pathogenesis (Wang et al., 2015). Finally, UBA1 has been implicated in the 
pathogenesis of idiopathic PD as exposure of rodent models to pesticides increased 
expression of a-synuclein, caused damage to dopaminergic neurons and motor 
dysfunction; changes that were specifically due to inhibition of UBA1 (Chou et al., 
2008; Viquez et al., 2012). Taken together, these studies provide evidence linking 
altered UBA1 activity or expression with pathogenic events in a range of 
neurodegenerative diseases. Interestingly, however, spinal muscular atrophy is the 
neurodegenerative disease with the most evidence implicating UBA1 as a causative 
factor in disease pathogenesis. 
1.2.4 UBA1 in spinal muscular atrophy 
UBA1 is implicated in SMA on a number of levels, not least because mutations in 
UBA1 cause a rare form of SMA (X-linked SMA) but also because widespread 
disruption to UBA1 expression has been identified in various models of SMA. 
Furthermore, as previously mentioned, therapeutically targeting UBA1 or its 
downstream targets rescues neuromuscular phenotypes in SMA. 
1.2.4.a X-linked SMA 
Mutations in UBA1 cause a rare form of SMA known as X-linked SMA (XL-SMA). 
XL-SMA is clinically similar to SMA and is characterised by loss of lower motor 
neurons in the anterior horn of the spinal cord, muscle weakness, hypotonia and a 
lack of reflexes. In addition to these features shared with SMA, congenital 
contractures and fractures are also commonly associated with XL-SMA (Dlamini et 
al., 2013; Jedrzejowska et al., 2015; Ramser et al., 2008). Other pathologies seen in 
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XL-SMA patients include widespread involvement of the sensory neuron system, 
and developmental and degenerative cerebellar abnormalities (Dlamini et al., 2013). 
Interestingly, all the mutations identified in UBA1 that cause XL-SMA cluster in 
exon 15 of the gene (Figure 1-3) (Dlamini et al., 2013; Jedrzejowska et al., 2015; 
Ramser et al., 2008). It is possible that these mutations lead to altered methylation 
patterns of exon 15 with potential implications for blocking transcription enhancers 
and reducing UBA1 expression (Ramser et al., 2008). However, it so far seems 
unlikely that mutations in UBA1 cause disruption to either the adenylation activity of 
UBA1 or its ability to form thioester bonds with ubiquitin. 
 
Figure 1-3 Domains of UBA1 and mutations identified in XL-SMA 
UBA1 has a methionine residue at position 40 that provides an alternative translation start 
site leading to the generation of the UBA1b isoform. The full-length transcript produces the 
UBA1a isoform which contains a nuclear localisation sequence (NLS) and several serine 
residues which can be phosphorylated (P-residues). Mutations in UBA1 shown to cause XL-
SMA cluster in exon 15 of the protein. When UBA1 is folded into its 3D structure, the first 
catalytic cysteine half-domain and the second catalytic cysteine half-domain are immediately 
adjacent to each other, as are the inactive adenylation domain and the active adenylation 
domain. The ubiquitin fold domain allows UBA1 to bind E2 enzymes and the cysteine 
residue that binds ubiquitin (C632) resides within the second catalytic cysteine half-domain. 
The specific amino acid domains in this figure are based on the mouse UBA1 sequence. The 
mouse and human UBA1 sequences are 95% identical at the amino acid level; all amino 
acids that surround the borders of domains, that are mutated in XL-SMA and that are in the 
NLS and P-residues are fully conserved between mouse and human UBA1 sequences. 
Figure adapted from (Groen and Gillingwater, 2015). 
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1.2.4.b Alterations to UBA1 in SMA 
Although XL-SMA is a rare form of SMA, as previously mentioned, it has recently 
been shown that ubiquitin homeostasis is altered in SMN1-dependent SMA. Central 
to this disruption in ubiquitin homeostasis is a downregulation of UBA1 levels 
following SMN depletion. It was initially shown that in late-symptomatic severe 
SMA mice UBA1 levels are reduced by approximately 50% in spinal cord and by 
more than 60% in skeletal muscle compared to age-matched controls. This was 
extended to show that in skeletal muscle from early-symptomatic Taiwanese SMA 
mice UBA1 protein levels were reduced by approximately 30% (Wishart et al., 
2014). Subsequently, it has been shown that the time course of UBA1 reduction 
correlates with disease progression in SMA mice with changes in several organs 
occurring during pre-symptomatic stages of the disease. These disruptions to UBA1 
occurred in spinal cord and muscle along with a range of systemic organs, including 
heart and liver. Importantly, UBA1 is also significantly reduced in SMA patient-
derived iPSC motor neurons compared to control (Powis et al., 2016). Although 
these reductions in UBA1 have been demonstrated in whole tissues in models of 
SMA, reduction of UBA1 has also been seen at the single cell level with significant 
reductions in UBA1 expression occurring in myelinating Schwann cells 
(Aghamaleky Sarvestany et al., 2014). However, further investigation is required to 
identify whether UBA1 is reduced in other cell types.  
Although little is known about how UBA1 leads to these SMA phenotypes, it 
has been demonstrated that UBA1 and SMN bind to each other in the cytoplasm 
(Wishart et al., 2014) and that the ubiquitin proteasome system (UPS) mediates SMN 
degradation (Chang et al., 2004). Furthermore, reduction in SMN levels leads to 
alterations in the splicing of UBA1 (Wishart et al., 2014) suggesting a complex 
interaction of these proteins involving multiple potential routes. It has also been 
shown in SMA spinal cord that there is a significant increase in beta-catenin levels 
(Wishart et al., 2014), a known downstream target of ubiquitylation. This suggests 
that altered function of the downstream targets of UBA1 could be contributing to 
UBA1-mediated degeneration in SMA. Interestingly, suppression or pharmacological 
inhibition of UBA1, induces an SMA-like neuromuscular phenotypes in zebrafish 
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(Wishart et al., 2014) and similarly, it has been shown that pharmacological 
inhibition of UBA1 in Schwann cells leads to a defective myelination phenotype that 
is observed in SMA (Aghamaleky Sarvestany et al., 2014; Hunter et al., 2014). 
Together this suggests that decreased UBA1 levels alone are sufficient to induce 
neurodegeneration.  
1.2.4.c Therapeutic strategies targeting UBA1 
Initial therapeutic strategies to target defective ubiquitin homeostasis focused on the 
known downstream targets of UBA1. Treatment with an inhibitor of beta-catenin 
signalling (quercetin) was sufficient to rescue the motor axon branching phenotypes 
seen in both SMA zebrafish and zebrafish treated with a UBA1 inhibitor. Similarly, 
treatment of SMA mice with quercetin increased motor neuron number in the spinal 
cord, rescued muscle fibre diameter, improved motor function and increased 
innervation of NMJs (Wishart et al., 2014).  
Therapies targeted directly at UBA1 also had beneficial effects on 
neuromuscular phenotypes in SMA models. For example, co-injection of human 
UBA1 mRNA with Smn morpholino in zebrafish rescued the motor axon branching 
phenotype and improved motor behaviour compared to zebrafish injected with Smn 
morpholino (Powis et al., 2016). Likewise, treatment of SMA mice with AAV9-
UBA1 increased weight and survival compared to untreated SMA mice. The SMA 
mice treated with AAV9-UBA1 also showed rescue of neuromuscular, heart and 
liver pathology. There was an increase in the number of motor neuron cell bodies in 
the spinal cord, an increase in muscle fibre diameter and rescue of NMJ innervation 
in AAV9-UBA1 treated SMA mice compared to untreated SMA mice (Powis et al., 
2016). Taken together these pre-clinical therapeutic trials indicate that UBA1 and 
ubiquitin homeostasis is amenable to therapeutic intervention and a viable strategy to 
treat SMA. 
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1.3 Summary 
The first disease modifying therapy has recently been approved for treatment of all 
types of SMA. This treatment is designed to augment full-length SMN protein levels, 
as are several other therapies currently in clinical trial for SMA. However, there is a 
second wave of SMN-independent therapies in development that target cellular and 
molecular pathways dysregulated downstream of SMN reduction in SMA. One of the 
promising SMN-independent therapeutic strategies for SMA is targeting defective 
ubiquitin homeostasis. Central to the alteration of ubiquitin homeostasis in SMA is a 
reduction of the ubiquitin-like modifier activating enzyme 1. UBA1 is responsible 
for activating ubiquitin as the first step in the ubiquitin conjugation process, marking 
unwanted proteins for degradation by the proteasome. While it is known that 
therapies targeting UBA1 rescue neuromuscular phenotypes in SMA models, the 
mechanism by which UBA1 mediates neurodegeneration is unclear. 
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1.4 Aims 
Based on the current literature, to understand the cellular and molecular mechanisms 
underlying UBA1-mediated pathogenesis of SMA and investigate the hypothesis that 
UBA1 is a key regulator of neuropathological changes in SMA via modulation of 
novel pathways, this thesis will address the following aims: 
1. Investigate whether UBA1 is specifically disrupted within motor neurons 
during disease pathogenesis in SMA. 
2. Identify and validate novel downstream targets of UBA1. 
3. Investigate whether downstream targets of UBA1 are relevant for UBA1-
mediated pathogenesis of SMA. 
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Chapter 2 Materials and Methods 
2.1 Ethics statement 
All experimental procedures were conducted in accordance with UK Animals 
(Scientific Procedures) Act 1986. Animal procedures and breeding were approved by 
a University of Edinburgh internal ethics committee and performed in accordance 
with institutional guidelines and Home Office regulations under project licence 
number 6004569 and personal licence number I4AFF2A01.  
2.2 Mouse model and in vivo experiments 
2.2.1 Taiwanese SMA mouse model and colony maintenance 
Taiwanese SMA mice (Hsieh-Li et al., 2000; Riessland et al., 2010), on a congenic 
FVB background, were originally obtained from Jackson Laboratories (Jackson 
Laboratories strain no. 005058) and maintained according to breeding protocols as 
previously described (Riessland et al., 2010). The Taiwanese SMA mouse colony 
was maintained as two separate strains that were bred together to generate SMA mice 
and control littermates (Figure 2-1A). The first strain was maintained by breeding 
wild-type FVB mice (obtained from University of Edinburgh breeding stocks) with 
mice heterozygous for Smn (referred to as Thet mice: Smn+/-). This produced 
homozygous Smn+/+ mice and Thet mice (Smn+/-). Mice with these genotypes were 
phenotypically normal. Smn+/- mice generated in these breeding pairs were used for 
further breeding (Figure 2-1A). 
The second strain of mice was referred to as Thom and were bred to maintain 
a homozygous deletion of Smn (HRTP knock-out of Smn exon 7) and four copies of 
the human SMN2 transgene (Smn-/-; SMN2tg/tg; Figure 2-1A) (Hsieh-Li et al., 2000). 
Thom mice show a mild phenotype of distal necrosis of the tails and ears and in 
some cases, older mice develop scoliosis. To generate experimental mice, breeding 
pairs were set up using male Thet and female Thom mice. The offspring from these 
breeding pairs were either SMA mice (Smn-/-; SMN2tg/0) or phenotypically normal 
heterozygous (Smn+/-; SMN2tg/0) littermates that were used as controls. Both SMA 
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and control mice have two copies of the human SMN2 transgene (Figure 2-1A) 
(Hsieh-Li et al., 2000). For all mice used in this study the day of birth was counted as 
postnatal day 1 (P1) following standard protocol in the lab. 
Wild-type FVB mice were maintained alongside the SMA mouse colony: 
wild-type FVB mice were obtained from University of Edinburgh breeding stocks 
and bred together or with Smn+/+ mice obtained from Thet breeding pairs (Figure 
2-1B). Wild-type CD1 and C57BL/6J mice were obtained from in-house breeding 
stocks. Throughout this thesis, mice with the genotype Smn+/-; SMN2tg/0 will be 
referred to as control mice, wild-type FVB mice will be referred to as FVB and other 
wild-type strains used will be referred to by their background strain. All mice were 
maintained under standard specific pathogen free conditions at the University of 
Edinburgh.  
 
Figure 2-1 Breeding scheme and example genotypes of Taiwanese SMA mice 
A Breeding scheme of Thet and Thom mouse line maintenance and generation of 
experimental SMA and control mice. B Breeding scheme showing maintenance of wild-type 
FVB mice used in this study. C Example Smn genotyping for all mice used in these breeding 
schemes: FVB, Thet, Thom, control and SMA. 1050bp band corresponds with the Smn+ 
allele and the 950bp band represents the Smn- allele. 
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2.2.2 Genotyping 
For DNA extraction, 500µl of lysis buffer (100mM Tris pH 8, 200mM NaCl, 5mM 
EDTA pH 8, 0.2% SDS in ddH2O) containing 2.5µl Proteinase K (Life 
Technologies) was added to ear punches or tail tips which were then left to digest 
overnight at 55°C. Samples were then mixed by vortex and centrifuged for 15 
minutes at 14,000 rpm. DNA was precipitated by pouring the supernatant into 500µl 
of isopropanol and mixed by inversion until a white precipitate formed. The samples 
were then centrifuged for 5 minutes at 14,000 rpm to pellet the DNA and washed 
twice with 1ml of 70% ethanol with a 30 seconds spin at 14,000 rpm after each wash. 
DNA pellets were then dried for a minimum of 30 minutes and dissolved in 200µl 
(tail tips) or 50µl (ear punches) of deionised water for at least 1 hour. Following this, 
multiplex PCR was performed using the following primers for Smn (Sigma Aldrich), 
PCR product size and allele indicated in brackets: 
Forward:  ATAACACCACCACTCTTACTC 
Reverse 1: GTAGCCGTGATGCCATTGTCA  (1050bp: Smn+) 
Reverse 2: AGCCTGAAGAACGAGATCAGC  (950bp: Smn-) 
PCR master mix, per reaction, for genotyping Smn was as follows (all reagents 
Promega): 
3µl 5x green Taq buffer 
0.9µl MgCl2 
0.15µl dNTPs 
0.2µl Taq DNA polymerase 
1.5µl 10µM Forward Smn primer 
1µl 10µM Reverse 1 Smn primer 
1µl 10µM Reverse 2 Smn primer 
6.25µl ddH2O 
For each sample, 1µl of DNA was added to the master mix to generate a total 
reaction mixture volume of 15µl. Amplification was then performed using the 
following program on a T100 BIO-RAD thermo cycler: 
  Understanding the role of UBA1 in SMA 
Materials and methods 33 
Step: 1 2 3 4 5 6 
Temp: 94°C 94°C 58°C 72°C 72°C 12°C 
Time: 3 min 30 secs 30 secs 30 secs 5 mins hold 
  36 cycles of steps 2 to 4   
 
PCR products were then separated by gel electrophoresis using 1% agarose 
(Scientific Laboratory Supplies) in 1x TAE (diluted from 10x UltraPure TAE; Life 
Technologies) gels containing SYBR safe DNA gel stain (Life Technologies). 
Genotypes were determined based on the presence or absence of the 1050bp and 
950bp bands. For reference, Smn genotypes for all mice used to maintain the 
Taiwanese SMA mouse colony have been included (Figure 2-1C). 
2.2.3 Phenotypic characterisation of SMA mice 
Before control and SMA mice were sacrificed for tissue harvesting, weight was 
determined and motor performance was assessed. A righting test was performed to 
assess motor ability in the neonatal mice. The righting test is a commonly used 
simple assay in which mice are placed on their back on a flat surface and the time 
taken for the mice to turn over and place all four paws on the surface is recorded 
(Feather-Schussler and Ferguson, 2016). If a mouse did not respond within 30 
seconds the test was terminated. 
Representative control and late-symptomatic SMA mice as used throughout 
this thesis are shown in Figure 2-2A, illustrating a typical smaller appearance in 
SMA compared to control littermates. Representative weights and righting times for 
control and SMA mice in this colony have also been included (Figure 2-2B, C). The 
weight of SMA mice at postnatal day 5 (P5) begins to decline while the weight of 
control mice continues to increase (Figure 2-2B). This corresponds with the time 
point at which righting times begin to increase in SMA mice compared to control 
(Figure 2-2C). Furthermore, the onset of symptoms starts to become visibly apparent 
at P5. Therefore, throughout this study, P5 mice will be used as an early-
symptomatic stage of disease progression, while P2 and P8 mice will be used as pre- 
and late-symptomatic stages of disease respectively. 
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Figure 2-2 Phenotypic characterisation of SMA and control mice 
A Control (left) and SMA (right) mice at P8 (late-symptomatic) showing smaller size of the 
SMA mouse and indicating the motor defects and weakness of the SMA mouse as its back 
legs are out to the side. B Weight and C righting time of control and SMA mice from day of 
birth (P1) to late-symptomatic stage of the disease (P8). N=3 litters per time point, n=9 mice 
per condition for each time point (3 mice per condition from each litter); data was collected 
over a 2 and a half year period showing stability of the SMA phenotype over this time period. 
2.2.4 UBA1 overexpression in vivo 
To overexpress UBA1 in vivo mice were injected with AAV9-UBA1 intravenously 
on the day of birth as previously described (Powis et al., 2016). Adeno-associated 
virus serotype 9 (AAV9) expressing full-length human UBA1 cDNA was custom-
produced by Vigene and administered at a concentration of 7x1013 vg. Before 
injection, mice were weighed to check they were >1.3g (determined to be the 
minimum weight for safe injection of virus) and placed on crushed ice for 2 minutes 
for general chilled anaesthesia. Mice were then placed on a WeeSight 
transilluminator (Philips) to visualise the vasculature and 10µl of AAV9-UBA1 was 
injected into the facial vein using a Hamilton 702 RN 25µl syringe fitted with a 
Hamilton 33 guage RN needle. Pressure was applied to the injection site while mice 
were warmed in hand before returning them to their mother or a foster mouse. Mice 
were checked twice daily for three days to monitor health following injection of 
AAV9-UBA1; they were then checked daily until sacrifice at postnatal day 8. 
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2.2.5 Tissue preparation 
SMA mice and control littermates were sacrificed by overdose of anaesthetic 
(sodium pentobarbitone, 300mg/kg) at post-natal day (P) 2, P5, P7 or P8. FVB mice 
and mice (FVB or SMA) injected with AAV9-UBA1 were sacrificed at P8 by 
overdose of anaesthetic. In all cases, death was confirmed by exsanguination. For 
immunohistochemistry of spinal cords, spinal columns were roughly dissected and 
1xPBS was injected into the spinal canal through the sacral end of the column, using 
a 23-gauge needle on a 5ml syringe, so that the intact spinal cord was ejected through 
the cervical end of the spinal column. The spinal cords were fixed in 4% PFA 
(Electron Microscopy Sciences) in phosphate buffered saline (PBS) for 24 hours then 
transferred to 30% sucrose overnight at 4°C for cryoprotection. The lumbar regions 
of the spinal cords were embedded in optimal cutting temperature compound (OCT; 
Cell Path), sectioned at 25µm on a cryostat (Leica 3050S) and immediately collected 
onto superfrost plus microscope slides (Thermo Scientific) in a serial manner so that 
each section on each slide was at a 200µm interval. Slides were stored at -20°C. 
For immunohistochemistry of lumbar dorsal root ganglia (DRG), spinal 
columns were carefully dissected from P8 mice and a scalpel was used to cut 
transversely at the T13 vertebrae. Spinal columns were then fixed for 6 hours in 4% 
PFA (Electron Microscopy Sciences) in PBS then transferred to 30% sucrose at 4°C 
for 24 hours for cryoprotection. The lumbar and lower thoracic regions of the spinal 
columns were embedded in OCT and sectioned at 12µm on a cryostat. Using the T13 
DRGs, spinal columns were aligned so that the DRGs were symmetrical on both 
sides of the column. For each DRG pair from lumbar segment 1 to lumbar segment 4 
serial sections were collected onto superfrost plus microscope slides and stored at -
20°C. Example images of DRGs throughout this thesis show a single DRG, 
therefore, for reference, a spinal column section showing a pair of DRGs stained with 
Toluidine blue has been included (Figure 2-3A). All example images of DRGs are 
from the L2 segment. 
For quantitative fluorescent Western blot analysis and fractionation 
preparations, spinal cord (using the same method as above), heart and gastrocnemius 
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muscle (referred to as muscle for the rest of this thesis) were rapidly dissected and 
quickly frozen on dry ice. Lumbar dorsal root ganglia were dissected out of the 
spinal cord using a previously described method (Sleigh et al., 2016). Briefly, the 
spinal column was dissected and a scalpel was used to perform a transverse cut at the 
level of T13 and then a sagittal cut through the caudal half of spinal column, starting 
from the dorsal surface. Each half of the spinal column was then pinned in a Sylgard-
lined petri dish (VWR) containing ice-cold 1xPBS and the spinal cord and meninges 
were removed in a rostral to caudal direction (Figure 2-3B). Forceps were then used 
to grasp the distally projecting axon bundles lateral to the DRGs allowing the dorsal 
root ganglia to be carefully scooped out of the spinal column along with the 
connecting nerves (Figure 2-3B). These were then transferred to a separate Sylgard-
lined dish with fresh ice-cold 1xPBS (Figure 2-3C) and projecting axons were 
carefully removed from the DRGs along with any remaining meninges (Figure 
2-3D). The DRGs were then rapidly frozen on dry ice. For each mouse, three DRGs 
from each half of the lumbar spinal column were dissected so that a Western blot 
could be performed on six DRGs per mouse. All tissue was stored at -80°C. 
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Figure 2-3 Preparation of dorsal root ganglia for immunohistochemistry and Western 
blot 
A Example section of a spinal column containing dorsal root ganglia (indicated by white 
asterisks); section of DRGs from lumbar segment 2, stained with Toluidine blue solution for 3 
minutes, dipped in running water and immediately mounted in 10% Mowoil solution 
(Polyscience). Image was captured on a Leica DMR equipped with a Retiga 2000R camera. 
Scale bar: 200µm. B-D Images of DRG dissection from P8 control mouse captured on Leica 
M60 dissection microscope equipped with a Leica MC170 HD camera. Scale bars: 1mm. B 
Spinal column with spinal cord and meninges removed showing DRG (green arrow) and 
spinal column after removal of DRG (red arrow). C DRG with projecting axons, D which were 
then carefully removed close to the DRG. 
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2.3 Zebrafish 
Morpholino injections and protein extraction from zebrafish were performed by Dr 
Penelope Boyd. 
Adult wildtype zebrafish were maintained in a fish facility at the University of 
Edinburgh according to standard methods. Zebrafish embryos were maintained using 
standard protocols at 28.5°C and were staged by hours post fertilisation (hpf). 
2.3.1 UBA1 knockdown in vivo 
To perform UBA1 knockdown in vivo, single cell-stage zebrafish embryos were 
injected with 6 ng uba1 MO in aqueous solution containing 0.05% phenol red using 
age-matched un-injected embryos as controls. A previously published uba1 
morpholino (MO) (Wishart et al., 2014) was designed against the 5’ start sequence of 
the uba1 gene (Gene Tools LLC); 5’ACAGCGGCGAGCTGGACATCGTTTC-3’ 
For microinjection, adult pairs were set up using barriers in a pair mating 
tank. The barriers kept the females and males apart thereby controlling when they 
mated. This meant that fresh 1 cell stage embryos could be obtained throughout the 
duration of microinjection allowing for maximum numbers of embryos to be 
injected. Glass capillaries (Harvard apparatus, GC120T-10) were individually placed 
in a flaming/Brown p-97 micropipette puller which used a heated filament to pull a 
single glass capillary into two microinjection needles. The needle was filled with the 
appropriate solution using Eppendorf microloader pipette tips, and the needle end 
was blunted using sharp forceps. The microinjector was calibrated using a graticule, 
after which embryos were harvested and brushed individually in wells of a 1.5% 
agarose mould. Embryos were aligned to have the cell away from the injection 
manipulator so that the needle entered the embryo through the yolk and injected into 
the cell to minimise damage. Embryos were injected in rows of 25 and batches of 
100 in the first 30 minutes of development, after which they were placed in fresh egg 
water and left to develop at 28°C. Un-injected embryos were kept as controls and 
fresh embryos were collected for each injection round. 
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2.3.2 Preparation of zebrafish for Western blot analysis 
Embryos were dechorionated and deyolked in 1ml of deyolking buffer (1/2 Ginzburg 
Fish Ringer without Calcium: 55 mM NaCl, 1.8 mM KCl, 1.25 mM NaHCO3). 
Embryos were pooled into batches of 30 fish, with three replicate batches per 
experimental group. Zebrafish were pelleted at 300x g for 30 seconds and the 
supernatant was discarded. Zebrafish were washed twice with wash buffer (110mM 
NaCL, 3.5 mM KCl, 2.7 mM CaCl2, 10 mM Tris pH 8.5) and pelleted again at 300x 
g for 30 seconds. The supernatant was removed and the zebrafish pellets were stored 
at -80°C. Western blot protocol was followed from 2.11.1. 
2.4 In vitro experiments 
2.4.1 Culture of HEK293 cells 
HEK293 cells (human embryonic kidney cells) were originally obtained from the 
European Collection of Authenticated Cell Cultures (Public Health England, cat no: 
85120602). HEK293 cells were grown in high glucose Dulbecco’s modified Eagle 
medium (DMEM; Life Technologies) supplemented with 10% heat inactivated fetal 
bovine serum (FBS; Sigma), 1 x penicillin/streptavidin (pen/strep; Invitrogen) and 1x 
L-glutamine (Invitrogen). For immunocytochemistry experiments, HEK293 cells 
were seeded at a density of 100,000 cells per well onto 19mm2 coverslips (VWR) 
and fixed at 2 days in vitro (DIV). For transfection, HEK293 cells were seeded at a 
density of 200,000 cells per well in a six well plate and grown for 48 hours before 
transfection. 
2.4.2 Transfection of HEK293 cells 
2.4.2.a UBA1 knockdown in vitro 
HEK293 cells were transfected with RNAiMax (Invitrogen) and Silencer Select 
Validated UBA1 siRNA (s601, targeted against exons 24 and 25; Life Technologies). 
The following transfection mixtures were made up per well: 5µl RNAiMax 
transfection reagent was added to 125µl DMEM, 2.5µl of 10µM UBA1 siRNA was 
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added to 125µl DMEM. The siRNA solution was then added to the lipofectamine 
solution and incubated for 5 minutes before being added to the cells. For 
optimisation of UBA1 siRNA, scrambled siRNA and fluorescent siRNA (negative 
control 1, Integrated DNA technologies) were used as controls and transfected in the 
same manner. Cells were collected 48 hours after transfection. 
2.4.2.b UBA1 overexpression in vitro 
HEK293 cells were transfected using lipofectamine (Invitrogen) and pCMV6-XL4-
UBA1 plasmid (Origene). For optimisation of UBA1 overexpression, either 6µl, 9µl, 
12µl or 15µl of lipofectamine transfection reagent was added to 150µl DMEM, per 
well. For subsequent transfections, 7.5µl of lipofectamine was added to 125µl of 
DMEM, per well, and incubated for 5 minutes. This was then added to 150µl of 
DMEM with 3.5µg UBA1 plasmid for optimisation, or 125µl DMEM with 3µg 
UBA1 plasmid for subsequent transfections. The transfection mixture was incubated 
for a further 20 minutes before being added to the cells. Cells were harvested 24 
hours after transfection.  
2.4.2.c Co-transfections 
All co-transfections were performed on HEK293 cells seeded at a density of 240,000 
cells per well in a 6-well plate. For co-transfection of multiple plasmids, 1.25µg of 
each plasmid was added to 125µl of DMEM and 2.5µl of lipofectamine per plasmid 
was added to 125µl of DMEM. Incubation times and mixing of the transfection 
solutions was carried out as described in 2.4.2.b. For co-transfection of siRNA and 
multiple plasmids, the plasmid transfection solutions were made up and incubated as 
specified above and the siRNA transfection solutions were made up and incubated as 
specified in 2.4.2.a. Both transfection solutions were added onto the cells at the same 
time. For co-transfections, the same amount of DNA and lipofectamin/RNAiMax 
was added to each well, therefore, empty vectors and control siRNA were used when 
the respective constructs were not transfected to keep transfection amounts and ratios 
constant (Table 2-1). For all co-transfections, cells were harvested 48 hours after 
transfection. 
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Table 2-1 Constructs and respective control vectors 
Constructs with supplier and respective control vectors used to maintain DNA concentration 
during transfections. pcDNA3.1-HA-Ubiquitin construct is as published (Kamitani et al., 
1997); pEGFP-GARS-N2 construct is as published (Griffin et al., 2014). 
2.4.3 Preparation of HEK293 cells for Western blot analysis 
To collect HEK293 cells for Western blot, media was carefully aspirated off the cells 
which were then washed in pre-warmed 1xPBS (10x Dulbeccos Phosphate Buffered 
Saline, diluted in ddH2O; Life Technologies) to remove remaining media. Cells were 
then washed off the wells using 1ml ice-cold 1xPBS and transferred to a 1.5ml tube. 
HEK293 cells were then pelleted by centrifugation at 500x g for 5minutes in a pre-
cooled centrifuge (4°C). PBS was then removed from the cell pellets which were 
snap-frozen on dry ice and stored at -80°C. 
2.4.4 Cortical neuron culture 
Cortical neurons used in this study for the purpose of antibody optimisation and 
distribution analysis method optimisation were cultured by Dr Ewout Groen. 
Cortical neurons were prepared as previously described (Groen et al., 2013). Briefly, 
cortices were dissected from wild-type CD1 embryonic day (E)14.5 embryos, 
trypsinized, triturated in DMEM/F12 medium (Life Technologies) containing 10% 
FBS and 2µg/ml DNaseI (Sigma) and cultured in neurobasal medium (Life 
Technologies) supplemented with 0.25mM glutamax (Life Technologies), 2% B27 
(Invitrogen), 1x pen/strep and 18mM Hepes. Cortical neurons were fixed at DIV4 for 
optimisation experiments. 
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2.4.5 Motor neuron culture 
Motor neurons used in this study to investigate UBA1 distribution were cultured by 
Dr Fiona Lane. 
Motor neurons were prepared as previously described (Blokhuis et al., 2016). 
Briefly, the ventral half of spinal cords were dissected from wild-type C57BL/6J 
E13.5 embryos, trypsinized, dissociated in L15 medium (Life Technologies) 
containing 4% bovine serum albumin (BSA) and 0.1µg/ml DNaseI, and cultured in 
glial conditioned medium (neurobasal medium with 2% B27 which had been 
incubated on glial cells for 24 hours) supplemented with 10ng/ml BDNF, GDNF and 
CNTF. For longer-term cultures, half of the medium was changed at DIV6. Motor 
neurons were fixed at DIV4, DIV8 or DIV12. 
2.4.6 Culture of glial cells 
Glial cells were obtained during motor neuron preparations from dissociation of 
embryonic spinal cord ventral horns from wild-type C57BL/6J embryos and 
subsequent centrifugation during which glial cells were pelleted to isolate the motor 
neurons. Glial cells were then cultured in minimum essential medium (MEM; Life 
Technologies), supplemented with 10% FBS, 10mM Hepes (Invitrogen), 1x 
pen/strep and 10mM glucose. For immunocytochemistry, glial cells were seeded at a 
density of 20,000 cells per well onto 13mm2 coverslips (VWR). For longer-term 
cultures, half of the medium was changed at DIV6. Glial cells were fixed at DIV4, 
DIV8 or DIV12. 
2.5 Antibodies 
A table of primary and secondary antibodies used throughout this thesis has been 
compiled detailing the antibodies and the manufactures along with the techniques 
which the antibodies were used for. For primary antibodies, the concentration for 
each technique and the use of the antibody (i.e. as a loading control, cytoplasmic 
marker, nuclear marker, motor neuron marker, sensory neuron subtype marker, 
protein tag or protein of interest) have also been included. 
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Antibody Manufacturer Technique Use Concentration
a-tubulin abcam WB Loading	control 1:5000
b-III tubulin abcam ICC Cytoplasmic	marker 1:1000
b-III tubulin Sigma ICC Cytoplasmic	marker 1:1000
ChAT Millipore IHC Motor	neuron	and	cytoplasmic	marker 1:100
CoxIV abcam WB Loading	control 1:1000
GAPDH abcam WB Loading	control/	cytoplasmic	marker 1:2500
GARS abcam IHC Protein	of	interest 1:500
WB 1:5000
GFP abcam IP Tag/experiment	control 1µg/150µl
WB 1:5000
H3 abcam WB Loading	control/	nuclear	marker 1:5000
HA CST WB Tag	on	protein	of	interest 1:1000
IPO4 CST WB Protein	of	interest 1:2500
NF200 Sigma IHC Sensory	neuron	subtype	marker 1:500
PDCD4 CST WB Protein	of	interest 1:1000
Peripherin Merck IHC Sensory	neuron	subtype	marker 1:500
RanBP1 ThermoFisher WB Protein	of	interest 1:1000
SMI32 Covance IHC Cytoplasmic	marker 1:1000
SMN BD	transduction IP Protein	of	interest 1µg/150µl
WB 1:1000
UBA1	(discontinued) abcam IHC Protein	of	interest 1:600-1:1000
UBA1a ThermoFisher IHC Protein	of	interest 1:100
ICC 1:50
WB 1:1000
UBA1a CST IHC Protein	of	interest 1:200
ICC 1:100
WB 1:1000
UBA1a,b ThermoFisher WB Protein	of	interest 1:1000
UBA6 CST WB Protein	of	interest 1:1000
Ube1 abcam IHC Protein	of	interest N/A
Ube1 Sigma IHC Protein	of	interest 1:800
ICC 1:200
WB 1:1000
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Table 2-2 Primary and secondary antibodies 
All primary and secondary antibodies used in this thesis with manufacturer and application; 
concentrations and use also shown for primary antibodies. IHC: immunohistochemistry; ICC: 
immunocytochemistry; WB: Western blot; IP: Immunoprecipitation; N/A: not applicable (this 
antibody did not work for specified technique). For NF200 and peripherin IHC method was 
2.6.2; for all other antibodies IHC method 2.6.1 was used. For ICC method 2.7 was used for 
all antibodies; for WB method 2.11 was used for all antibodies; for IP method 2.10.2 was 
used for all antibodies. 
2.6 Immunohistochemistry 
2.6.1 Standard immunohistochemistry protocol 
Immunohistochemistry on sectioned tissues was performed using the Sequenza 
(Thermo Scientific) slide rack for optimal consistency. This protocol is based on 
optimisation of Choline Acetyltransferase (ChAT) (Powis and Gillingwater, 2016). 
Spinal cord and spinal column sections were permeabilised in 0.3% Triton X-100 
(Sigma) in PBS for 10 minutes at RT, washed for 3 x 5 minutes in PBS and blocked 
in standard blocking solution (4% BSA, 0.1% Triton X-100 in PBS) for 1 hour. 
Subsequently the sections were incubated in the appropriate primary antibodies 
(Table 2-2) in a 1:4 dilution of the standard blocking solution at 4°C for 24 hours. 
After 3 x 10 minute PBS washes, sections were incubated with the appropriate Alexa 
Fluor-labelled secondary antibodies (1:400, Table 2-2; Life Technologies) in a 1:4 
dilution of the standard blocking solution, for 1 hour at RT, washed for 3 x 10 
minutes, incubated in 1x DAPI (Life Technologies) for 10 minutes and then washed 
in PBS for 3 x 10 minutes. The slides were mounted and coverslipped in a 10% 
Mowoil solution (Polyscience). This protocol was used when performing 
immunohistochemistry for all antibodies except NF200 and peripherin. 
2.6.2 Immunohistochemistry for NF200 and peripherin 
Spinal column sections were thawed at room temperature for 1 hour and then 
permeabilised in 0.3% Triton X-100 in PBS (PBST) for 3 x 10 minutes at RT, and 
blocked in 10% BSA in PBST for 1 hour. Subsequently the sections were incubated 
with NF200 (1:500, Sigma; Table 2-2) and peripherin (1:500, Merck; Table 2-2) in 
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blocking solution, at 4°C for 24 hours. After 3 x 10 minute PBS washes, sections 
were incubated with the appropriate Alexa Fluor-labelled secondary antibodies 
(1:400, Table 2-2; Life Technologies) in PBS, for 1 hour at RT, incubated in 1x 
DAPI for 10 minutes and then washed in PBS for 3 x 10 minutes. The slides were 
mounted and coverslipped in a 10% Mowoil solution (Polyscience). 
2.7 Immunocytochemistry 
Primary motor neurons, cortical neurons, glial cells and HEK293 cells were fixed in 
4% PFA with 4% sucrose to preserve morphology in PBS for 10 minutes, 
permeabilised in 0.1% Triton X-100 for 5 minutes, washed twice in PBS and blocked 
in PBS containing 2.5% BSA for 30 minutes. They were subsequently incubated 
with primary antibodies (Table 2-2) in 2.5% BSA for 1 hour at RT. After 3 washes in 
PBS cells were incubated with a mixture of the appropriate Alexa Fluor-labelled 
secondary antibodies (1:400, Table 2-2), and phalloidin against F-actin (1:40; 
conjugated to Alexa Fluor 555; Life Technologies) for glial cells, in 2.5% BSA for 
one hour at RT. Then the cells were washed three times, incubated with 1x DAPI for 
5 minutes, washed four times in PBS and mounted onto microscope slides (Thermo 
Scientific) using a 10% Mowoil solution. 
2.8 Image acquisition and analysis 
Imaging of glial cells was performed using a Nikon A1R FILM confocal microscope; 
images of HEK293 cells for cell counts was performed on a Leica DMi8 fluorescent 
microscope. Unless otherwise mentioned in the figure legend, all other imaging was 
performed on a Zeiss LSM710 confocal microscope. For intensity analysis, all 
imaging was performed at constant confocal settings for all samples in that 
experiment; the settings used ensured that no samples had oversaturated pixels in the 
channel of the protein of interest as this would preclude analysis of the intensity of 
signal from the antibodies detecting the proteins of interest. 
To perform distribution analysis on HEK293 cells, glial cells and cultured 
motor neurons, Z-stack images were taken and then 3D projected (Max Intensity) to 
generate the images used for analysis. This ensured that UBA1 localised to different 
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areas of the cells would be included in the distribution analyses. Both HEK293 cells 
and glial cells were selected for analysis on the basis of a single nucleus per 
discernible cell with no overlapping of other cell bodies. At least 40 glial cells and 80 
HEK293 cells from across 3 different coverslips were analysed per experimental 
condition. Motor neurons were selected for imaging on the basis of nuclear integrity 
with clearly discernible and intact axons and dendrites; at least 25 motor neurons 
from across 3 different coverslips were imaged and analysed per experimental 
condition. 
To perform intensity and distribution analysis on lumbar spinal motor 
neurons, Z-stack images were taken for 8 spinal motor neuron pools per mouse. The 
Z-stacks were set up so that images from five different planes through the section 
were taken per motor neuron pool. Individual motor neurons were selected for 
analysis based on an intact nucleus and an intact cell body, as ascertained by DAPI 
and ChAT respectively, and were analysed in the plane where the nuclear outline 
was most defined.  
Whole DRGs were imaged in a single plane and were selected for imaging 
and subsequent analysis based on structural integrity. Only sections that were a full 
cross-section through the centre of the DRG were imaged, i.e. sections taken from 
the middle of the DRG. One left and one right DRG were imaged per lumbar 
segment form L1-L4 for each mouse. For distribution analysis of sensory neurons, 7 
larger area neurons and 7 smaller area neurons were analysed per DRG for 4 DRGs 
per mouse (one DRG for each of the lumbar segments 1-4). 
2.8.1 Intensity and distribution analysis 
Intensity and protein distribution analyses were performed in ImageJ. A nuclear 
marker and a cytoplasmic marker were used to draw around the circumference of the 
nucleus and cell body, respectively (yellow lines, Figure 2-4A). These outlines were 
then imposed onto the channel of the protein of interest (yellow lines, Figure 2-4A) 
and the XOR function was used to generate an area that contained the cytoplasm but 
not the nucleus, so that intensity measurements for the protein of interest in the 
nucleus and cytoplasm could be obtained separately (Figure 2-4B). The mean 
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intensity of the antibody signal for the protein of interest per area (cytoplasm only or 
nucleus only) was then measured using the measurement function (Figure 2-4B). The 
area of the nucleus, the cytoplasm and the whole cell was also measured at the same 
time. Results were recorded in Microsoft Excel and the ratio of the intensity of the 
protein of interest labelling in the nucleus to the cytoplasm (nuclear to cytoplasmic 
ratio [NCR]) was then calculated (Figure 2-4B). 
Some distribution analysis (on HEK293 cells and cultured motor neurons) was 
performed by Amr Maani as part of a student project. 
 
Figure 2-4 Intensity and distribution analysis 
Intensity and distribution analysis optimisation was performed on DIV4 cortical neurons 
labelled with DAPI (nuclear marker), b-III tubulin (cytoplasmic marker) and pan-UBA1. A 
Nuclear and cytoplasmic markers were used to outline the nucleus and cell body 
respectively (yellow lines). These outlines were then imposed onto the channel of the protein 
of interest. Scale bar: 20µm. B The XOR function was used so that the intensity of the 
protein of interest labelling could be measured separately in the nucleus and the cytoplasm. 
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The intensity can then be presented as the absolute intensity for each cellular compartment 
or the ratio of nuclear to cytoplasmic intensity (NCR). 
2.8.2 Sensory neuron and HEK293 cell counts  
The cell counter plugin in ImageJ was used to count the number of sensory neurons 
positive for NF200, peripherin or both NF200 and peripherin. This avoided 
recounting any neurons. The total numbers of neurons positive for each antibody 
labelling were exported into Microsoft Excel where they were converted into a 
percentage of each labelling per DRG. The total numbers of neurons positive for 
each labelling were also added together to generate a total number of neurons per 
DRG. For control and SMA mice, 8 DRGs comprising 4 left-right pairs for lumbar 
segments 1-4 were analysed. For SMA mice and SMA mice injected with AAV9-
UBA1, 4 DRGs comprising 2 left-right pairs for lumbar segments 1 and 2 were 
analysed. The cell counter plugin was also used to count HEK293 cells in eight 
150µm2 areas from across four coverslips. 
2.8.3 Neuron area measurements 
For analyses involving intensity or distribution analysis, the neuron area was 
measured at the same time of the mean intensity of the antibody labelling of the 
protein of interest (see 2.8.1). To investigate the area of NF200 positive and 
peripherin positive sensory neurons, the labelling of these markers was used to draw 
around the circumference of cell profiles in ImageJ. The measurement function was 
then used to measure area of the whole sensory neuron cell body. 
2.9 Subcellular fractionation 
For biochemical fractionation of late-symptomatic mouse spinal cords (P8 control 
and SMA mice), a modified version of the protocol by Cox and Emili (Cox and 
Emili, 2006) was used (Figure 2-5). Spinal cords were washed three times by 
centrifugation at 100x g for 1 minute in ice-cold PBS and then they were washed 
once in lysis buffer containing 0.25 M sucrose, 50 mM Tris-HCl, 5 mM MgCl2, 1 
mM DTT, 25µg ml-1 spermine, 25µg ml-1 spermidine and 1% protease inhibitor 
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cocktail (Life Technologies). The spinal cords were then gently homogenised on ice 
in 250µl of the lysis buffer using a glass dounce homogenizer. The homogenates 
were centrifuged at 800x g for 15 minutes at 4°C to pellet nuclei from the soluble, 
cytoplasmic lysate which was subsequently cleared of contaminants by 
centrifugation at 1000x g for 15 minutes at 4°C (Figure 2-5A). The supernatant 
contained a pure cytoplasmic fraction and was stored on dry ice while nuclei were 
extracted. 
Although it was not possible to present data from nuclear fractions in this 
thesis (due to limitations of tissue quantity; see 3.3), for completeness: the crude 
nuclear pellet was re-homogenised in lysis buffer and centrifuged at 800x g for 15 
minutes at 4°C. The pellet contained a clean nuclear pellet which was then 
resuspended in lysis buffer containing 2M sucrose and pure nuclei were isolated by 
ultracentrifugation at 80,000x g for 35 minutes (Figure 2-5A). The nuclei were lysed 
and soluble nuclear proteins were extracted in buffer containing 20% glycerol, 
0.02M HEPES, 50 mM Tris-HCl, 5 mM MgCl2, 1 mM DTT and 1% protease 
inhibitor cocktail. The lysed nuclei were centrifuged at 9,000x g for 30 minutes at 
4°C and the resulting supernatant contained soluble nuclear proteins (Figure 2-5A) 
which were then Western blotted immediately along with the cytoplasmic fractions; 
Western blot method was followed from section 2.11.2. An example Western blot of 
cytoplasmic and nuclear fractions from P60 FVB spinal cords for cytoplasmic 
(GAPDH) and nuclear (Histone H3) markers has been included for reference (Figure 
2-5B). 
  Understanding the role of UBA1 in SMA 
Materials and methods 50 
 
Figure 2-5 Schematic of subcellular fractionation protocol with example Western blot 
A Schematic of fractionation protocol, showing extraction of a pure cytoplasmic fraction and 
a soluble nuclear protein fraction. B Example Western blot of cytoplasmic and nuclear 
fractions from P60 FVB spinal cords for a cytoplasmic marker (GAPDH) and a nuclear 
marker (histone H3 [H3]) showing purity of sample preparation method and generation of 
clean nuclear fractions. MW of proteins detected by antibodies indicated in kDa. 
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2.10 Ubiquitylation assay 
2.10.1 Sample processing 
Following transfection for 48 hours, 10µM of MG132 proteasome inhibitor was 
added to each well of HEK293 cells for 90 minutes. Cells were then lysed in the 
wells with 150µl of radioimmunoprecipitation assay (RIPA) buffer (Fisher 
Scientific) containing 1% protease inhibitor cocktail (Life Technologies), 1% 
phosphatase inhibitor (Life Technologies) and 10mM N-Ethylmaleimide. Cells were 
left on ice for 10 minutes and then centrifuged at 14,000 rpm for 10 minutes at 4°C. 
The supernatant was then used for immunoprecipitation (2.10.2). 
2.10.2 Immunoprecipitation 
From the supernatant prepared above, 7.5µl was removed and added to 7.5µl 2x 
NuPAGE LDS sample buffer (Life Technologies) for use as input control. The rest 
of the supernatant was incubated with primary antibody (Table 2-2) on a rotor at 4°C 
for 1 hour and 20 minutes. Solution was separated from Dynabeads protein A (for 
rabbit primary antibody) or Dynabeads protein G (for mouse primary antibody; both 
Life Technologies) using a magnetic stand. The protein/primary antibody solution 
was added to the Dynabeads and incubated on a rotor at 4°C for 40 minutes. The 
Dynabeads (now bound to the primary antibody/protein complexes) were then 
washed four times in 400µl NP40 buffer consisting of 20mM Tris-HCl [pH 7.5], 
150mM NaCl, 1% Nonidet P-40 substitute and 10% glycerol. All remaining NP40 
buffer was removed and the Dynabeads were gently suspended in 25µl of 1x 
NuPAGE LDS sample buffer and incubated at 95°C for 5 minutes to separate the 
primary antibody/protein complexes from the Dynabeads. The Dynabeads were then 
separated on a magnetic stand and the sample was transferred to a new tube. Samples 
and input control samples were subsequently Western blotted to detect proteins; 
Western blot method was followed from section 2.11.3. 
  Understanding the role of UBA1 in SMA 
Materials and methods 52 
2.11 Quantitative fluorescent Western blotting 
2.11.1 Protein extraction 
Protein was extracted from tissue and cell pellets in RIPA buffer with 1% protease 
inhibitor cocktail. Tissue was homogenised using a motorised disposable pestle 
mixer (VWR) and cell pellets were homogenised by repeated pipetting with a P200 
pipette; all homogenisation was performed on ice. Dorsal root ganglia were 
homogenised in 25µl of buffer, zebrafish were lysed in 50µl of buffer, all other 
tissues and cell pellets were homogenised in at least 100µl of buffer, depending on 
tissue size and quantity of cells, with same amount of lysis buffer used for all 
samples in one experiment. 
2.11.2 Protein quantification 
Protein concentration was then determined by bicinchoninic acid (BCA) assay 
(Thermo Scientific). Extracted protein was then diluted to a final concentration of 
30µg per well (for HEK293 cells, heart, spinal cord and muscle) in deionised water 
and NuPAGE LDS sample buffer. The final protein concentration for dorsal root 
ganglia was 17µg per well and the final protein concentration for cytoplasmic 
fractions of spinal cords was 25µg per well. For reducing Western blot conditions 
5mM of dithiothreitol (DTT, Life Technologies) or 5% b-mercaptoethanol was 
added to the sample buffer. Following dilution to appropriate final concentrations, 
protein samples were incubated at 70°C for 10 minutes and then mixed by vortex. 
2.11.3 Polyacrylamide gel electrophoresis, protein 
detection and Western blot analysis 
Extracted protein was then separated by SDS-polyacrylamide gel electrophoresis at 
150 volts on precast NuPage 4-12% BisTris gradient gels (Invitrogen). Samples were 
run alongside a Novex sharp pre-stained protein standard (3.5-260 kDa; Life 
Technologies). Gel embedded proteins were then transferred to polyvinylidene 
difluoride (PVDF) membranes using an iBlot 2 device (Life Technologies), with a 6 
minutes 30 seconds semi-dry blotting program. The membranes were incubated in 
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Ponceau solution (0.2% Ponceau, 30% acetic acid; total protein stain) for 20 minutes 
and then transferred to blocking solution (LI-COR Biosciences) for 30 minutes at 
RT. Quantitative western blots were performed using primary antibodies (Table 2-2) 
diluted in blocking solution at 4oC overnight. 
A loading control protein was included during primary antibody incubation. 
For Western blots on samples used for the proteomics screen due to variability of 
histone H3 in UBA1 knockdown samples and reduction of CoxIV in UBA1 
overexpression samples, it was necessary to use different loading controls for control 
compared to UBA1 knockdown (CoxIV) and control compared to UBA1 
overexpression (histone H3; Figure 2-6A). For tissue the loading control was 
normally GAPDH or a-Tubulin, however, sometimes it was necessary to use 
Ponceau total protein stain as the loading control (for example when performing 
Western blot on control and SMA heart; Figure 2-6B). In Western blot figures where 
Ponceau has been used as the loading control, a representative section of Ponceau 
staining has been shown; full lanes of Ponceau stain were quantified for 
normalisation. Loading controls were also diluted in blocking solution and incubated 
with the membranes at 4oC overnight. 
After 6 x 5 minute washes in PBS, membranes were incubated in the 
appropriate secondary antibodies (1:5000, Table 2-2; LI-COR Biosciences) in 
blocking solution for 1 hour at RT. The membranes were then washed in PBS for 3 x 
30 minutes, dried and imaged using an Odyssey Infrared Imaging System (LI-COR 
Biosciences) with Image Studio software (LI-COR Biosciences). Analysis was 
performed in Image Studio where the intensity of the fluorescent band was measured 
for the protein of interest and the loading control. The intensity of the protein of 
interest was then normalised to the intensity of the loading control to determine 
relative protein expression for each sample; experimental conditions were then 
normalised to the control condition for that experiment. 
Some quantitative fluorescent Western blots (on zebrafish, hearts from FVB mice and 
HEK293 cells for ubiquitylation experiments) were performed by Dinja van der 
Hoorn as part of a student project. 
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Figure 2-6 Loading controls for Western blot analysis 
Example loading controls used for quantitative fluorescent Western blot analysis. A Western 
blot on HEK293 cells with UBA1 overexpression or UBA1 knockdown and control showing 
reduction of CoxIV following UBA1 overexpression and variability of histone H3 (H3) 
following UBA1 knockdown. B Western blot on heart and spinal cord from P8 control and 
SMA mice (30µg protein loaded per sample). GAPDH and a-Tubulin were both suitable 
loading controls for spinal cord. Neither a-Tubulin nor GAPDH were appropriate loading 
controls for heart, therefore it was necessary to normalise to the total protein stain 
(Ponceau). MW of proteins detected by antibodies indicated in kDa. Ponceau is shown for 
whole lane. 
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2.12 Label-free proteomic screen and analysis  
2.12.1 Protein extraction 
For the label-free proteomic screen HEK293 cells were collected as previously 
described (see 2.4.3) except three wells of cells were collected into one 15ml tube so 
that for each condition (control, UBA1 overexpression and UBA1 knockdown) there 
were three samples each containing the cells from three separate wells. Protein was 
extracted from the HEK293 cell pellets in SDT lysis buffer containing 100 mM Tris-
HCl (pH 7.6; Sigma), 4% (W/V) Sodium dodecyl sulfate (VWR) by repeated 
homogenisation using a P200 pipette. Protein concentration was determined using a 
BCA assay (ThermoScientific). 
2.12.2 Label-free proteomics 
HEK293 cell lysates were sent to Douglas Lamont at the ‘FingerPrints’ Proteomics 
Facility, University of Dundee, where the mass spectrometry and necessary 
preparations were performed for the label-free proteomics screen. Assignment of 
proteins in Mascot was also performed by Dr Douglas Lamont. 
2.12.2.a Mass spectrometry 
Aliquots (100 µg) of each HEK293 lysate were processed through FASP (filter-aided 
sample preparation) involving buffer exchange to 8M urea and alkylation with 
50mM iodoacetamide. Double digestion with trypsin (Roche, sequencing grade) was 
then performed, initially for 4 hours, then overnight, both at 30°C. Samples were 
then desalted to remove unwanted buffer salts by washes with 0.1% trifluoroacetic 
acid and then 70% acetonitrile. Each sample was then separated by injecting it onto a 
nanoflow LC-MS/MS Ultimate 3000 RSLC (Thermo Scientific) system coupled to a 
linear ion trap Orbitrap hybrid mass spectrometer (LTQ- Orbitrap Velos Pro, Thermo 
Scientific) via a nanoelectrospray ion source (Thermo Scientific). The peptides from 
each digest were separated with a linear gradient of 2-40% acetonitrile, 0.1 % formic 
acid over 124 minutes with a constant flow of 300 nL/min. Full-scan MS survey 
spectra were acquired in the LTQ Oribitrap with a resolution of 60,000; this was 
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followed by IT-MS/MS scans for the 15 most intense peptide ions. Data were 
acquired using Xcalibur software. Alongside the nine samples, four quality control 
samples were processed, each of which consisted of a mixture of the nine samples. 
2.12.2.b Assigning peptides and proteins in Progenesis and Mascot 
The raw proteomic data was then imported into Progenesis for analysis of relative 
ion abundance and peptide characterisation. The MS/MS output were converted into 
2D representations for each sample; these were then aligned to one of the quality 
control samples (quality control sample 3) with all alignment scores >90%. The data 
was subsequently filtered where all ions with a charge >5 were removed from the 
dataset, as were features detected below 23 minutes and above 137 minutes (Figure 
2-7A); this filter on retention time corrected for elution variability. The runs for the 
different biological replicates of each condition were combined and statistical p-
values were automatically generated for the peptides in Progenesis software through 
a One-way ANOVA on the ArcSinh transform of the normalized data. The peptides 
were then filtered and those with a p-value > 0.05 or a power < 0.8 were removed 
(Figure 2-7A). 
The remaining data was then exported for identification of individual proteins 
using the IPI-Homo sapiens database via Mascot Search Engine (V2.3.2) in which 
712 proteins were identified (Figure 2-7A); the statistical analysis of this data was 
carried out automatically in Mascot. The proteins identified in Mascot were then 
imported into Progenesis for filtering and further analysis. Peptide conflicts were 
removed and proteins were filtered to eliminate those with < 2 unique peptides; 
proteins with a p-value < 0.05 or a fold change < 1.1 in both UBA1 overexpression 
compared to control and knockdown compared to control were also removed (Figure 
2-7A). This resulting dataset contained the 222 proteins which showed the largest 
significant variation in expression following modulation of UBA1 expression levels 
(Figure 2-7A-C; Appendix 2). During data processing in Progenesis, a correlation 
analysis of proteins (following filtering) was performed to group the proteins based 
on the similarity of their expression profiles across the three conditions. 
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Graphs showing the fold-change of proteins following UBA1 overexpression 
compared to control (Figure 2-7B) and UBA1 knockdown compared to control 
(Figure 2-7C) were generated to indicate the spread of proteins both pre- and post-
filtering. UBA1 was highlighted in red and was the protein with the most significant 
fold-change compared to control in both datasets post-filtering. UBA1 was removed 
from the dataset for all subsequent analysis so that the results would not be skewed 
by the manipulation of protein expression used to generate the samples for this 
proteomic screen. 
 
Figure 2-7 Filtering of the proteomics dataset 
A Filtering steps performed in progenesis during filtering of the raw data, the peptides 
identified and then the filtering of the proteins that were identified in Mascot. Overall this 
generated a dataset of 222 proteins. B Fold change of proteins changed following UBA1 
overexpression compared to control and C UBA1 knockdown compared to control, both pre-
filtering (after identification of protiens in Mascot) and post-filtering (dataset used for 
subsequent analysis). UBA1 is indicated by a red dot and was removed from the dataset for 
all subsequent analysis. 
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2.12.3 In silico analysis of the proteomic screen  
2.12.3.a Gene ontology term enrichment in DAVID 
The Database for Annotation, Visualization and Integrated Discovery 
(DAVID; available at http://david.abcc.ncifcrf.gov) provides a comprehensive set of 
functional annotation tools to identify biological meaning for large datasets (Huang 
da et al., 2009a, b). DAVID was used to identify enriched biological themes within 
the filtered proteomics dataset; both functional annotation clustering and gene 
functional annotation were performed. Both of these analyses rely on grouping 
together enriched terms to identify either enriched functional clusters or functionally 
related groups of genes. In both cases, the protein list is compared against a 
background list (in this case H. sapiens) and enriched terms associated with the gene 
list are identified. Modified Fischer’s exact p-values for each term are automatically 
calculated during this analysis; these are used to determine the enrichment of each 
term. To then generate either a functional annotation clustering or gene functional 
classification report, annotation terms that belong to the same gene group or the same 
proteins are grouped. This group of annotations or gene group is then assigned an 
enrichment score (ES) which is the geometric mean of the p-values for all the terms 
in that cluster. The ES is the -log10 of the p-value and so represents the significance 
of the enrichment of that gene group or functional group in this dataset compared to a 
generic background dataset. For reference, an ES of 1.3 is equivalent to a p-value of 
0.05. This software was also used to characterise the functions associated with the 
protein clusters generated in BioLayout (see 2.12.3.b); for this analysis, functional 
annotation clustering was performed. 
2.12.3.b Protein expression profiling in Biolayout 
BioLayout (developed at the Roslin Institute, University of Edinburgh, 
http://www.biolayout.org) was used to identify UBA1-dependent clusters of proteins 
based on the expression of the proteins across UBA1 overexpression, control and 
UBA1 knockdown. This software uses a pattern recognition algorithm to enable the 
visualisation and analysis of network graphs based on the expression profiles of the 
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proteins. The network graphs in this study were generated using a Pearson 
correlation (set to 0.98) and Markov clustering algorithm (Enright et al., 2002). Each 
protein is represented by a coloured node and the proximity to its neighbour indicates 
the similarity in protein expression. The colour of the node indicates the cluster that 
protein belongs to; all proteins in one cluster have a similar expression profile. The 
expression profiles are displayed as mean normalised abundance (on a pareto scale) 
with SEM for each condition. These clusters can be further analysed for functional 
annotation using other in silico tools such as DAVID (see 2.12.3.a).  
2.12.3.c Network and canonical pathway analysis in IPA 
Ingenuity pathway analysis (IPA; 
www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/) was used as 
previously described (Wishart et al., 2010; Wishart et al., 2007). Data analysis and 
interpretation of expression analysis experiments in IPA is based on the manually 
curated Ingenuity Knowledge Base in which more than 90% of the information in the 
database is drawn from the full text of peer reviewed journals; less than 10% of 
interactions have been identified by natural language processing and subsequent 
manual verification. Two different analysis platforms in IPA were used during this 
study. The first was network analysis which identifies causal relationships within the 
dataset based on the curated Knowledge Base; the analysis also includes regulators 
not present within the dataset. Within each network relative expression changes of 
the proteins are displayed: red symbols indicate upregulated proteins and green 
symbols indicate downregulated proteins compared to control. 
The canonical pathways function and functional annotation tool were also 
used for the identification of known biological pathways within this dataset. 
Canonical pathway analysis compares the library of published biological pathways 
within the curated Knowledge Base with the dataset being analysed. The significance 
of the association between the dataset and the canonical pathway is defined by a 
Fischer’s exact p-value (generated during the analysis) that determines if the 
probability of association between the proteins in the dataset and in the canonical 
pathway are due to chance, along with the overlap of the number of proteins from the 
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dataset that are present in the canonical pathway (Savli et al., 2008). A 1.1 fold-
change threshold filter was applied in IPA to each dataset analysed and only 
experimentally observed interactions were selected for each analysis. 
2.13 Statistical analysis 
All statistical analyses were performed in Microsoft Excel and Prism 6 
(GraphPad), individual statistical tests are reported in figure legends. For all 
analyses, statistical significance was considered to be P≤0.05. Data are reported as 
mean ± standard error of the mean (SEM) throughout this thesis. All frequency 
distributions were generated as relative frequencies and are presented as percentages. 
Figures were created using Adobe Photoshop CS6 or Adobe Illustrator CS6 software. 
Flowcharts were created in Microsoft PowerPoint. 
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Chapter 3 Characterising the distribution of 
UBA1 
3.1 Introduction 
Spinal muscular atrophy (SMA) is a motor neuron disease characterized by the loss 
of lower motor neurons from the anterior horn of the spinal cord (Kolb and Kissel, 
2011). SMA primarily affects children and is the most common genetic cause of 
infant mortality (Lunn and Wang, 2008; Sugarman et al., 2012). It is now well 
characterised that ubiquitin homeostasis is altered in SMA and that reduction of 
ubiquitin-like modifier-activating enzyme 1 (UBA1) is central to this disruption 
(Aghamaleky Sarvestany et al., 2014; Fuller et al., 2015; Wishart et al., 2014). While 
it is known that therapies targeting UBA1, or downstream proteins, rescue 
neuromuscular phenotypes in SMA models (Powis et al., 2016; Wishart et al., 2014), 
the mechanism by which UBA1 mediates degeneration in SMA is unclear. In fact, 
very little is known about the function of UBA1 in cells beyond its canonical role in 
the ubiquitylation pathway (Groen and Gillingwater, 2015). 
In SMA, the reduction of UBA1 is well characterised at late-symptomatic 
stages of the disease when reduction of UBA1 occurs in the neuromuscular system 
and in non-neuronal organs (Aghamaleky Sarvestany et al., 2014; Powis et al., 2016; 
Wishart et al., 2014). As previously mentioned (see 1.2.4.b), the time course of 
UBA1 reduction correlates with disease progression in SMA mice with changes in 
several organs occurring during pre-symptomatic stages of the disease (Powis et al., 
2016). The characterisation of UBA1 pathology in SMA has been conducted on 
whole tissues and while changes in the whole spinal cord are modest compared to 
UBA1 reduction in other organs such as heart and liver (Powis et al., 2016), the 
primary pathological target in SMA is the motor neuron (Lunn and Wang, 2008; 
Powis and Gillingwater, 2016). Therefore, to tease out the role of UBA1 reduction in 
SMA pathogenesis it is now necessary to go beyond the whole tissue level and 
examine UBA1 distribution and function at the single cell level.  
One of the few known functions of UBA1 is its involvement in regulation of 
the cell cycle, with mutations in UBA1 leading to cell cycle arrest and apoptosis (Lao 
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et al., 2012; Lee et al., 2008). Indeed, UBA1 distribution is well characterised 
throughout the cell cycle in dividing cultures of cells. UBA1 exists as two isoforms, 
UBA1a and UBA1b. UBA1a contains 40 amino acids at its N-terminal that are 
lacking from UBA1b (Figure 1-3) (Groen and Gillingwater, 2015; Handley-Gearhart 
et al., 1994). The first 40 amino acids (unique to UBA1a) contain a nuclear 
localization sequence (NLS) and a series of serine residues that are phosphorylated 
(Figure 1-3) in a cell cycle dependent manner by cyclin-dependent kinase 1 (Cdk1) 
(Cook and Chock, 1995; Handley-Gearhart et al., 1994; Rona et al., 2014; Stephen et 
al., 1997). Due to the NLS, UBA1a is mainly localized to the nucleus, while UBA1b 
is mostly cytoplasmic (Grenfell et al., 1994; Handley-Gearhart et al., 1994). Cdk1 
has maximal activity in the nucleus during G2 where it phosphorylates UBA1a 
(Rona et al., 2014). This phosphorylation ensures that after mitosis, UBA1a is 
exclusively localized in the nuclei of the daughter cells enabling the degradation of 
mitotic cyclins to occur (Grenfell et al., 1994; Seufert et al., 1995). Following the G1 
phase, UBA1a becomes more cytoplasmic until G2 when it returns to the nucleus 
(Grenfell et al., 1994). 
Furthermore, using immunoelectron microscopy it has been shown that 
UBA1 localises to different subcellular compartments. In HepG2 cells, 37% of 
UBA1 was present in the nucleus (primarily localised to the heterochromatin), 56% 
was present in the cytosol and 7% resided within the mitochondria. Within the 
cytosol, UBA1 showed enhanced association with desmosomal junctions, with the 
cytoplasmic surfaces of lysosomes, and the rough endoplasmic reticulum (Schwartz 
et al., 1992). This information gives a clear overview of the subcellular localisation 
of UBA1 during interphase. 
Interestingly, redistribution of UBA1 in neuronal populations has been 
observed in several neurodegenerative diseases (Lopez Salon et al., 2000; Wade et 
al., 2014; Wishart et al., 2014). In SMA, UBA1 is initially lost from the neuronal 
cytoplasm (as evidenced by experiments on hippocampal synaptosomes) of pre-
symptomatic SMA mice (Wishart et al., 2014), suggesting that subtle pre-
symptomatic changes in UBA1 levels or subcellular distribution may be involved in 
SMA pathogenesis. Furthermore, in both Huntington’s disease (HD) and 
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Alzheimer’s disease (AD), redistributions of UBA1 occur in specific neuronal 
populations (Lopez Salon et al., 2000; Wade et al., 2014). For example, there is a 
reduction of UBA1 in the cytosolic fraction of AD patients’ cortex (Lopez Salon et 
al., 2000). In HD, UBA1 expression levels decline during disease progression in the 
nuclear fraction of mouse cortex (Wade et al., 2014). Together this suggests that 
subcellular changes in UBA1 distribution may play a role in the pathogenesis of a 
range of neurodegenerative diseases. However, although the distribution of UBA1 in 
dividing cells has been well characterised (Grenfell et al., 1994; Groen and 
Gillingwater, 2015; Stephen et al., 1997), little is known about the distribution and 
localisation of UBA1 in healthy neuronal populations in vitro or in vivo. 
To better understand the role of UBA1 in motor neuron degeneration it will 
be vital to characterise UBA1 distribution in healthy populations of post mitotic 
cells. This will enable the investigation of UBA1 distribution in SMA motor neurons 
throughout disease progression, which may help to identify when UBA1 reduction 
becomes important in SMA pathogenesis. In this study, tools to investigate UBA1 
were optimised and used to confirm published distribution profiles of UBA1. The 
expression patterns of UBA1 in cultured motor neurons were then characterised to 
provide a baseline for the distribution of UBA1 in post-mitotic cells. Finally, to 
better understand the role of UBA1 in SMA pathogenesis, UBA1 distribution in 
spinal motor neurons was characterised throughout disease progression.  
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3.2 Results 
3.2.1 Optimisation of UBA1 antibodies 
To investigate the distribution and role of UBA1 in SMA, the availability of 
antibodies that produce reliable and reproducible results across a range of laboratory 
techniques is essential. The manufacturer has since discontinued the anti-UBA1 
antibody used previously in the lab and it was not clear which commercially 
available antibodies can reliably differentiate between the different isoforms of 
UBA1. Therefore, several antibodies that detect UBA1 or UBA1a (according to 
manufacturer specifications) were purchased in order to identify ‘gold standard’ 
UBA1 antibodies that work well for immunohistochemistry (IHC), 
immunocytochemistry (ICC) and Western blot (Table 3-1). Due to the extra 40 
amino acids (Stephen et al., 1997), the UBA1a isoform can be detected if antibodies 
are directed against this sequence and, in contrast, antibodies directed against any 
other part of the protein detect both UBA1a and UBA1b isoforms (referred to here as 
pan-UBA1 antibodies). Because it had previously been identified that the limiting 
function of the antibody was its ability to work for IHC, all antibodies were initially 
screened for their suitability for IHC. Subsequently, those that worked were tested 
for ICC and Western blot suitability. 
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Table 3-1 Overview of UBA1 antibodies  
UBA1 antibodies with screening results for immunohistochemistry (IHC), 
immunocytochemistry (ICC) and Western blot suitability, including optimal antibody 
concentrations. Mono: monoclonal; poly: polyclonal.  
 
For IHC, all antibodies were tested on spinal cord sections from control mice 
(Smn+/-; SMN2tg/0) to identify their suitability for IHC. Antibodies 1 and 2 were 
produced from the same hybridoma clone and raised against full-length recombinant 
UBA1 protein. For both antibodies, positive nuclear and cytoplasmic staining was 
observed (Figure 3-1A and D). Antibody 2 also non-specifically labelled the 
vasculature (Figure 3-1D). Using the other pan-UBA1 antibodies (3 and 4) specific 
UBA1 staining could not be identified, although pronounced non-specific labelling 
of the vasculature was observed for antibody 4 (Figure 3-1B and E). The specific 
epitope sequence that the UBA1a antibodies (5 and 6) were raised against was not 
disclosed but was confirmed to be within the first 40 amino acids by the 
manufacturers. Antibody 6 appeared to have a better signal-to-noise ratio and more 
pronounced nuclear staining than antibody 5 (Figure 3-1C and F).  
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Figure 3-1 Immunohistochemistry screen of UBA1 antibodies on spinal cord 
Antibodies 1, 2, 5 and 6 showed specific UBA1 staining on 25µm spinal cord sections from 
P8 control mice (Smn+/-; SMN2tg/0). A, D Positive nuclear and cytoplasmic staining. B, D 
Non-specific staining of the vasculature. B, E No specific UBA1 staining. C Positive nuclear 
and diffuse cytoplasmic staining. F Pronounced nuclear staining with low background. Scale 
bars: 20µm. 
 
 Subsequently, the antibodies that were suitable for IHC (antibodies 2, 5 and 
6), were tested for ICC on cortical neurons in vitro. Antibody 2 showed positive 
nuclear, cytoplasmic and axonal staining (Figure 3-2A) while, in contrast, the 
UBA1a antibodies (5 and 6) both showed bright nuclear staining with minor amounts 
of cytoplasmic staining (Figure 3-2B, C). Therefore, antibody 2 will be used for 
detection of both UBA1 isoforms for IHC and ICC. Although both antibodies 5 and 6 
show clear and consistent staining patterns for both techniques, due to the reduced 
signal to noise ratio for IHC, antibody 6 will be used for detection of UBA1a for IHC 
and ICC. 
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Figure 3-2  Immunocytochemistry screen of UBA1 antibodies 2, 5 and 6  
Primary cortical neurons cultured from wild-type CD1 embryos were fixed at 4 days in vitro, 
beta III-tubulin was used as a cytoplasmic marker. A Positive nuclear, cytoplasmic and 
axonal staining. B, C bright nuclear staining and weak cytoplasmic staining. Scale bars: 
20µm. 
 
Following this, antibodies 2, 5 and 6 were tested on brain and spinal cord 
dissected from control mice (Smn+/-; SMN2tg/0) to identify their suitability for 
Western blot. Previously in the lab, antibody 4 had been the standard antibody for 
detecting pan-UBA1 in quantitative fluorescent Western blotting; therefore antibody 
4 was used for comparison with the other antibodies. Antibody 4 showed a clear 
doublet with two bands at 110 and 117kDa representing UBA1 and UBA1 bound to 
ubiquitin (UBA1~Ub), respectively (Figure 3-3). This doublet was also seen with 
antibody 2, however, non-specific bands were also observed. The UBA1a antibodies 
(5 and 6) both showed the 110 and 117kDa bands without any non-specific bands 
(Figure 3-3); due to antibody 6 being used for IHC and ICC, antibody 6 will also be 
used to detect the UBA1a isoform on Western blots. 
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Figure 3-3 Western blot screen for UBA1 antibodies 4, 2, 5 and 6  
UBA1 antibodies were tested on brain and spinal cord lysates from P7 control mice (Smn+/-; 
SMN2tg/0). Antibodies 4, 5 and 6 showed two clear bands at 100kDa (UBA1) and 117kDa 
(UBA1~Ub). Antibody 2 detected two bands at 100kDa and 117kDa along with some non-
specific bands. Alpha-tubulin (a-Tub) used as loading control for antibodies 4 and 2; GAPDH 
used as loading control for antibodies 5 and 6. 
 
 It has previously been reported that the 117kDa band of UBA1~Ub is not 
present on a Western blot under reducing conditions, as this breaks the UBA1~Ub 
thioester bond (Kitagaki et al., 2009; Xu et al., 2010). Indeed, when a reducing agent 
was added the 117kDa band was not present with any of the antibodies tested. This 
was observed across all the tissues for both SMA and control mice (Figure 3-4). The 
difference between non-reducing and reducing conditions was particularly 
pronounced for antibody 2 in muscle. This antibody produced more non-specific 
bands in muscle than in the other tissues that were tested, resulting in the UBA1 
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doublet being unclear in non-reducing conditions (Figure 3-4). Antibody 4 detected 
pan-UBA1 without producing the non-specific bands of antibody 2; therefore, 
antibody 4 will be used to detect UBA1 for quantitative fluorescent Western blot. 
 
Figure 3-4 Reducing Western blot conditions break the UBA1~Ub thioester bond 
Representative fluorescent Western blot bands for UBA1 in brain, spinal cord and muscle 
lysates from P8 Taiwanese control and SMA mice, with GAPDH as a loading control. DTT 
was used as a reducing agent. Antibody 4 and antibody 6 show two clear bands in non-
reducing conditions and one band at 110kDa in reducing conditions. Reducing conditions 
with antibody 2 removed non-specific bands as well as the 117kDa band. 
 
To summarise, antibody 2 will be used to detect both isoforms of UBA1 for 
IHC and ICC as it showed clear distribution patterns with positive staining following 
the optimisation of antibodies for immunolabelling on spinal cord sections and 
primary cortical neurons. Similarly, antibody 6 showed clear nuclear localisation and 
easily discernible distribution patterns for both IHC and ICC and so this antibody 
will be used to detect the UBA1a isoform for these techniques. Antibody 4 will be 
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used to detect both isoforms of UBA1 on Western blot as this gave a clear doublet 
band which became a single band under reducing conditions. Antibody 6 will be 
used to detect UBA1a for Western blot as this showed a clear doublet band and 
responded well to reducing conditions under which it produced a single band.  
When mentioning UBA1 in the subsequent text of this thesis, I refer to the 
protein; when using pan-UBA1 or UBA1a I refer to the different antibodies that will 
be used to detect UBA1. Antibodies 2 and 4 will be referred to as pan-UBA1 while 
antibody 6 will be referred to as UBA1a. Unless otherwise stated, reducing 
conditions will be used for Western blots of UBA1 to ensure accurate quantification 
of total UBA1 protein levels. 
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3.2.2 Characterisation of UBA1 distribution in cultures of 
dividing cells 
3.2.2.a UBA1a and pan-UBA1 antibodies show different distribution 
patterns 
After defining which antibodies to use for detection of UBA1, the antibodies were 
used to confirm the distribution of UBA1 reported in the literature and to establish a 
method for distribution analysis (see 2.8.1). To do this, UBA1 distribution was 
initially investigated in a culture of dividing cells. HEK293 cells were chosen due to 
their clear cellular morphology and rapidly dividing nature. The cells were fixed at 
two days in vitro (DIV2) and labelled for pan-UBA1 or UBA1a in conjunction with 
cytoplasmic (tubulin) and nuclear (DAPI) markers after which the absolute intensity 
of pan-UBA1 and UBA1a in the nucleus and cytoplasm was quantified.  
Consistent with the literature (Grenfell et al., 1994; Handley-Gearhart et al., 
1994; Stephen et al., 1997), pan-UBA1 revealed both nuclear and cytoplasmic 
localisation of UBA1 with uniform distribution across the cell. There was no 
discernible localisation of UBA1 to subcellular structures (Figure 3-5A). In contrast, 
UBA1a showed a strong nuclear localisation with very little UBA1a in the cytoplasm 
(Figure 3-5A). These observations were then quantified to allow comparison of the 
absolute intensity of pan-UBA1 and UBA1a. Consistent with these observations, 
UBA1a was significantly more nuclear than pan-UBA1 (UBA1a=42.33a.u., pan-
UBA1=25.55a.u; P≤0.0001; Figure 3-5B). In the cytoplasm, there was less UBA1a 
than pan-UBA1 (UBA1a=6.39a.u., pan-UBA1=21.14a.u.; P≤0.0001; Figure 3-5C).  
The nuclear to cytoplasmic ratio (NCR) of intensity can also be a useful 
measure to, for example, compare samples across different time points or when 
quantifying absolute intensities is not suitable or feasible. The closer the NCR is to 1, 
the more evenly distributed the protein was between the nucleus and the cytoplasm. 
In line with the above observations and quantifications, pan-UBA1 had an NCR of 
1.27 indicating a slightly higher intensity in the nucleus than in the cytoplasm. 
Conversely, UBA1a had a much higher NCR (6.64) because it preferentially detects 
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UBA1a, which was primarily localised to the nucleus rather than the cytoplasm 
(Figure 3-5D).  
In the literature, the distribution patterns of UBA1 at different stages of the 
cell cycle have been described (Grenfell et al., 1994). To ensure the variation in 
distribution patterns was captured, the number of cells suitable for intensity analysis 
was quantified. For a cell to meet analysis criteria, it had to have an intact nucleus as 
established by DAPI, thereby excluding cells undergoing division. In a 150µm2 area, 
on average 88.2% of cells were suitable for intensity analysis, while the remaining 
11.8% were classified as undergoing mitosis based on their nuclear morphology 
(Figure 3-5E). Therefore, it was the distribution of UBA1 during interphase that was 
observed and analysed here, and the variation in distribution patterns throughout 
interphase was captured in this analysis. Overall, these results are consistent with the 
published literature, where UBA1a shows a predominantly nuclear localisation while 
pan-UBA1 reveals both nuclear and cytoplasmic localisation of UBA1 (Grenfell et 
al., 1994; Handley-Gearhart et al., 1994). Importantly, these observations can be 
quantified to reliably identify differences in distribution patterns, allowing the 
antibodies to be used for further investigation of UBA1 distribution. 
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Figure 3-5 Distribution patterns of UBA1 and UBA1a antibodies in dividing cells 
HEK293 cells were fixed at DIV2 and labelled with pan-UBA1 or UBA1a, cytoplasmic (bIII-
tubulin) and nuclear (DAPI) markers. A Pan-UBA1 showed evenly distributed staining across 
the cell body, UBA1a showed specific nuclear localisation. B Quantification of the absolute 
intensity of pan-UBA1 and UBA1a in the nucleus. C Quantification of the absolute intensity of 
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pan-UBA1 and UBA1a in the cytoplasm. D Nuclear to cytoplasmic ratio for pan-UBA1 and 
UBA1a. B-D Pan-UBA1, N=3 coverslips, n=82 cells; UBA1a, N=3 coverslips, n=95 cells. E 
Percentage of dividing cells per 150µm2, classified by nuclear morphology based on DAPI. 
n=8 150µm2 areas. Scale bar: 25µm. Unpaired 2-tailed Student’s t test; **** P ≤ 0.0001. 
3.2.2.b UBA1 distribution patterns were consistent over time in culture 
To investigate UBA1 distribution in a long-term culture of cells, glial cells were 
cultured from wild-type C57BL/6J E13.5 embryos, fixed at DIV4, DIV8 or DIV12 
and labelled for pan-UBA1 or UBA1a in conjunction with cytoplasmic and nuclear 
markers. Glial cells were chosen as they could be kept in culture for longer than 
HEK293 cells yet also have clear cellular morphology. At all time-points, pan-UBA1 
revealed both nuclear and cytoskeletal staining (Figure 3-6A). UBA1a was 
predominantly nuclear with few cells showing cytoplasmic UBA1a (Figure 3-6B). 
As previously observed in HEK293 cells, this indicates that the antibodies detect 
different combinations of the UBA1 isoforms. On quantification, the NCR of UBA1a 
was significantly more nuclear than that for pan-UBA1. This difference was 
consistent over time in culture with the NCR for pan-UBA1 ranging from 3.29 to 
4.89 whilst the NCR for UBA1a ranged from 10.60 to 13.93 (P≤0.0001 at all time 
points; Figure 3-6C). Again, pan-UBA1 had a NCR closer to 1 than that for UBA1a, 
as it detects both the nuclear and cytoplasmic UBA1 isoforms, while UBA1a detects 
the nuclear isoform. 
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Figure 3-6 UBA1 distribution in a long-term culture of dividing cells 
Glial cells were fixed at DIV4, DIV8 or DIV12 and labelled with pan-UBA1 or UBA1a, 
cytoplasmic (phalloidin) and nuclear (DAPI) markers. A Pan-UBA1 revealed cytoskeletal and 
variable nuclear localisation. B UBA1a showed variable nuclear intensity, very little 
cytoskeletal localisation. A, B Clearly discernible, bright nuclei (red arrows), less intense 
nuclear staining (yellow arrows). C Nuclear to cytoplasmic ratio of pan-UBA1 and UBA1a at 
each time point. UBA1a was consistently more nuclear than pan-UBA1. N=3 coverslips, 
n>40 glial cells per age per antibody. Scale bars: 100µm. One-way ANOVA with Tukey’s 
post-hoc test; **** P ≤ 0.0001. 
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3.2.2.c UBA1 is differentially distributed in cultures of dividing cells 
It has previously been reported that UBA1 has different distribution patterns within 
dividing cultures of cells dependent on the stage of the cell cycle (Grenfell et al., 
1994; Trausch et al., 1993). To investigate whether this could be detected with pan-
UBA1 and UBA1a, the variation of UBA1 localisation in glial cells was observed. A 
variety of distribution patterns were identified for both pan-UBA1 and UBA1a. 
Some glial cells showed clearly discernible nuclei (red arrows, Figure 3-6A, B) and 
others had nuclei with the same intensity of UBA1 as the cytoplasm, or with very 
little UBA1 (yellow arrows, Figure 3-6A, B). This is consistent with the published 
literature discussing the changes of UBA1 distribution patterns throughout the cell 
cycle, with strongly nuclear localisation of UBA1 during the G2 phase and less 
nuclear UBA1 in the S phase when there is an increase in its cytoplasmic localisation 
(Grenfell et al., 1994). 
Also of note is the difference in staining patterns between HEK293 cells and 
glial cells (Figure 3-5A, Figure 3-6A, B). Overall, UBA1 was present in the 
cytoplasm of HEK293 cells to a greater extent than in glial cells, reflected by the 
differences in NCR values for the two cell types; this was evident for both pan-
UBA1 and UBA1a, suggesting differential requirements of cell types for UBA1. 
Indeed, it has previously been reported that, in dividing cultures of cells, UBA1 
distribution varies between different cell types (Trausch et al., 1993); therefore, the 
antibodies used here reliably detect distribution patterns and behaviours of UBA1 
previously described in the literature. 
To summarise, I have shown that, consistent with the literature, pan-UBA1 
and UBA1a present different distribution patterns (Handley-Gearhart et al., 1994). I 
expanded on this finding and demonstrated that these differences are consistent in 
longer-term cultures of dividing cells. Furthermore, I have also demonstrated that the 
optimised antibodies showed a range of distribution patterns, as previously reported 
(Grenfell et al., 1994; Handley-Gearhart et al., 1994; Trausch et al., 1993), and that 
the distribution patterns vary between different cell types. 
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3.2.3 Characterisation of UBA1 distribution in motor neurons 
in vitro 
3.2.3.a Characterising UBA1 distribution in motor neurons in vitro 
Next, to assess the distribution of UBA1 in post-mitotic cells, intensity analysis was 
performed on wildtype primary motor neurons. Motor neurons were cultured from 
wild-type C57BL/6J E13.5 mouse embryos, fixed at DIV4, DIV8 or DIV12 and 
labelled for pan-UBA1 or UBA1a along with cytoplasmic (bIII-tubulin) and nuclear 
(DAPI) markers. As observed for glial cells, pan-UBA1 was more cytoplasmic than 
UBA1a, which was predominantly localised to the nucleus. For pan-UBA1, axonal 
localisation was observed (Figure 3-7A) whereas UBA1a was only observed in the 
proximal axon (Figure 3-7B). The respective distribution patterns of pan-UBA1 and 
UBA1a in motor neurons were consistent and significantly different, with UBA1a 
showing a more nuclear distribution (NCR=3.81-1.87) than pan-UBA1 (NCR=1.80-
1.32; P ≤0.0001 at DIV4 and DIV8; P≤0.05 at DIV12; Figure 3-7C). Interestingly, 
the NCR for both pan-UBA1 and UBA1a decreased over time in culture, indicating 
an increase in cytoplasmic UBA1 (Figure 3-7C). 
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Figure 3-7 UBA1 distribution in cultured primary motor neurons 
Motor neurons were fixed at DIV4, DIV8 or DIV12 and labelled with pan-UBA1 or UBA1a, 
cytoplasmic (bIII-tubulin) and nuclear (DAPI) markers. A Pan-UBA1 revealed cytoplasmic 
and nuclear localisation with a reduction in nuclear intensity over time in culture. B UBA1a 
showed clear nuclear localisation with an increase of cytoplasmic intensity over time in 
culture. C Nuclear to cytoplasmic ratio of pan-UBA1 and UBA1a at each time point. UBA1a 
was consistently more nuclear than pan-UBA1. Both pan-UBA1 and UBA1a showed a 
reduction in NCR over time in culture. N=3 coverslips, n>25 motor neurons per time point per 
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antibody. Scale bars: 20µm. One-way ANOVA with Tukey’s post-hoc test; *P≤ 0.05, **** P ≤ 
0.0001. 
3.2.3.b UBA1 distribution changes over time in motor neurons in vitro 
To further dissect the extent of the shift of UBA1 distribution in motor neurons, 
UBA1 distribution in a long-term culture of dividing cells (glial cells) was used as a 
baseline to compare with the distribution of UBA1 in a culture of motor neurons. In 
glial cells, the NCR for pan-UBA1 increased between DIV4 (NCR=3.29) and DIV8 
(NCR=4.89, P≤0.0001) but there was no significant difference in the NCR between 
DIV8 and DIV12 (Figure 3-8A). In motor neurons, the NCR of pan-UBA1 reduced 
from 1.80 at DIV4 to 1.32 at DIV12 (P≤0.0001; Figure 3-8A). Similarly, for UBA1a, 
glial cells showed a small shift towards a more nuclear localisation between DIV4 
(NCR=10.60) and DIV8 (NCR=13.60, P≤0.05) with no significant difference 
between DIV8 and DIV12 (Figure 3-8B). In motor neurons, there was a consistent 
and significant decrease in the NCR between all time-points investigated. The NCR 
for UBA1a dropped from 3.81 at DIV4 to 2.68 at DIV8 and then to 1.87 at DIV12 
(P≤0.0001; Figure 3-8B). Therefore, there was a consistent reduction in UBA1 NCR 
in motor neurons over time that did not occur in glial cells. While the same trend was 
observed for pan-UBA1 and UBA1a in motor neurons, the relative reduction in 
nuclear staining was more pronounced for UBA1a (Figure 3-8A, B). As the shift in 
NCR was detected by both antibodies, it suggests that it was due to a redistribution 
of UBA1a from the nucleus into the cytoplasm rather than an increase in the 
translation of UBA1b, the cytoplasmic isoform. 
As mentioned above, UBA1 distribution varies between different cell types 
(Trausch et al., 1993), however, only dividing cultures of cells have previously been 
investigated. Here, UBA1 distribution was investigated in long-term cultures of both 
dividing and post-mitotic cells. In dividing cultures, pan-UBA1 NCR was 
consistently more nuclear than in motor neurons (NCR=3.29-4.89 for glial cells, 
NCR=1.32-1.80 for motor neurons; Figure 3-8A). This difference also occurred with 
UBA1a, which was exclusively nuclear in glial cells but showed nuclear and 
cytoplasmic localisation in motor neurons (NCR=10.60-13.93 for glial cells, 
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NCR=1.87-3.81 for motor neurons; Figure 3-8B). Overall, it can be seen that UBA1 
was more cytoplasmic in motor neurons than in glial cells; this differential 
distribution of UBA1 could influence the relative susceptibility of the cell type to 
UBA1 reduction in conditions such as SMA (Powis et al., 2016). 
 
Figure 3-8 UBA1 distribution changes over time in primary motor neurons  
A Nuclear to cytoplasmic ratio (NCR) of pan-UBA1 in glial cells and primary motor neurons 
over time in culture. B NCR of UBA1a in glial cells and primary motor neurons over time in 
culture. A, B Motor neurons showed a consistent reduction in NCR, glial cells showed a 
small increase in NCR between DIV4 and DIV8. One-way ANOVA with Tukey’s post-hoc 
test; ns – not significant, * P≤ 0.05, ** P≤ 0.01, *** P≤ 0.001, **** P ≤ 0.0001. 
 
Here, UBA1 distribution in post-mitotic cells was characterised revealing that 
differences between UBA1 and UBA1a were consistent over time in cultured motor 
neurons. Both UBA1a and pan-UBA1 showed a consistent reduction in NCR 
overtime in motor neurons and UBA1 was consistently more cytoplasmic in motor 
neurons than in glial cells at each time point investigated.  
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3.2.4 Characterisation of UBA1 distribution in vivo 
3.2.4.a Reduction of UBA1 levels in pre- and late-symptomatic SMA 
motor neurons 
To better understand the role of UBA1 in motor neuron pathology in SMA and to 
characterise UBA1 distribution in motor neurons in vivo, lumbar spinal cord sections 
from SMA mice and control littermates at P2 (pre-symptomatic) and P8 (late-
symptomatic) (Figure 2-2) were labelled for UBA1a, a motor neuron specific marker 
(Choline Acetyltransferase; ChAT) and a nuclear marker (DAPI). Spinal motor 
neuron pools were imaged at constant confocal settings to allow quantification of 
nuclear and cytoplasmic UBA1. The UBA1a antibody was used due to the clear 
staining patterns and reliability of identifying changes in distribution of UBA1 
(Figure 3-1C). Furthermore, pan-UBA1 showed non-specific labelling of blood 
vessels (Figure 3-1D) that could interfere with distribution analysis. 
It has previously been shown that UBA1 is reduced across a wide range of 
tissues at various stages of disease progression in SMA mice (Powis et al., 2016). 
Previously, UBA1 levels in spinal motor neurons have been reported in SMA 
(Wishart et al., 2014), however, since publication, the manufacturer changed the 
description of the antibody used in that study; it is now understood that the antibody 
used detects UBA7. Therefore, a comprehensive characterisation of UBA1 levels in 
spinal motor neurons throughout disease progression is essential. 
At both pre- and late-symptomatic time points UBA1a was reduced in the 
nucleus and cytoplasm of SMA motor neurons compared to control (Figure 3-9A, B). 
Pre-symptomatically there was a 48.3% reduction of nuclear UBA1a and a 41.4% 
reduction of cytoplasmic UBA1a (Figure 3-9C). Similarly, the late-symptomatic 
reduction of nuclear UBA1 in SMA was 44.1%; however, the cytoplasmic reduction 
of UBA1a (28.2%) was less than in pre-symptomatic mice (Figure 3-9D). Whilst at 
the whole tissue level the reduction of UBA1 in the spinal cord can only be observed 
late-symptomatically, here, UBA1 was reduced, at the single cell level, in motor 
neurons at both pre- and late-symptomatic stages of disease. Furthermore, the pre-
symptomatic reduction was greater than that seen at late-symptomatic stages. 
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Overall, this suggests that UBA1 reduction in SMA motor neurons is implicated in 
the early stages of disease pathogenesis. Moreover, as studies in Drosophila have 
shown that motor neurons are particularly susceptible to perturbations in UBA1, 
changes in UBA1 expression may contribute to the motor neuron susceptibility in 
SMA (Liu and Pfleger, 2013). 
 
Figure 3-9 UBA1 is reduced in pre- and late-symptomatic SMA spinal motor neurons 
Spinal cord sections from SMA and control mice at P2 (pre-symptomatic) and P8 (late-
symptomatic) were labelled with UBA1a, a cytoplasmic and motor neuron specific marker 
(ChAT), and a nuclear marker (DAPI). A Pre-symptomatic SMA spinal motor neurons 
showed a reduction of UBA1a in the nucleus and cytoplasm compared to control mice. B 
Late-symptomatic SMA spinal motor neurons showed a reduction of nuclear and cytoplasmic 
UBA1a compared to control mice. Scale bars: 5µm. C Quantification of absolute intensity of 
nuclear and cytoplasmic UBA1a in pre-symptomatic SMA motor neurons showed significant 
reduction of UBA1. Control N=3 mice, n=188 motor neurons; SMA N=3 mice, n=244 motor 
neurons. D Quantification of absolute intensity of nuclear and cytoplasmic UBA1a in late-
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symptomatic SMA motor neurons showed significant reduction of UBA1. Control N=3 mice, 
n=262 motor neurons; SMA N=2 mice, n=168 motor neurons. SMA normalised to control. 
One-way ANOVA with Tukey’s post-hoc test; **** P ≤ 0.0001. 
3.2.4.b UBA1 levels are increased in early-symptomatic SMA motor 
neurons 
To investigate why UBA1 reduction in SMA motor neurons is more pronounced at 
pre- rather than late-symptomatic stages of disease, UBA1 protein levels and 
distribution at an additional intermediate time point were characterised. To do this, 
P5 (early-symptomatic) (Figure 2-2) lumbar spinal cords from SMA and control 
mice were stained for UBA1a and absolute intensity analysis was performed. 
Surprisingly, at early-symptomatic stages of disease progression a prominent 
increase in both nuclear and cytoplasmic UBA1a levels was observed (Figure 
3-10A). When quantified, the nuclear increase in UBA1a was 41.7% and the 
cytoplasmic increase was 61.7% compared to controls (P≤0.0001; Figure 3-10B). 
This is the opposite of what was seen at both pre- and late-symptomatic stages of 
disease (Figure 3-9), suggesting that this may be the result of an attempted 
compensatory response by the motor neurons during the early stages of disease. 
To investigate this increase in UBA1 levels, NCRs were compared for control 
and SMA mice at all time points to see if UBA1 distribution was consistently 
changed over time. There was a significant reduction in the NCR of UBA1a at both 
pre- and late-symptomatic time points but at early-symptomatic stages there was no 
significant difference (Figure 3-10C). At pre- and late-symptomatic stages of disease 
SMA motor neurons had an NCR indicative of more cytoplasmic staining to less 
nuclear staining compared to controls (pre-symptomatic control=3.16, SMA=2.53, 
P≤0.01; late-symptomatic control=4.25, SMA=3.69, P≤0.05). This is consistent with 
the absolute intensity results which show a larger reduction of nuclear than 
cytoplasmic UBA1a in SMA mice compared to control (Figure 3-9). 
 Interestingly, both control and SMA mice showed an increase in NCR over 
time: the highest NCR for both control and SMA mice was at the late-symptomatic 
stage of disease progression (control=4.25, SMA=3.69; Figure 3-10D). For control 
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mice, there was no significant difference in UBA1a NCR between P2 and P5, 
however, between P5 and P8 there was a significant increase in NCR (P5=3.39, 
P8=4.25; P≤0.0001, Figure 3-10D). In SMA, UBA1a NCR significantly increased 
between pre- and early-symptomatic stages (P2=2.53, P5=3.46; P≤0.0001). 
However, there was no significant difference in NCR between early-and late-
symptomatic stages of disease progression (Figure 3-10D). To summarise, UBA1a 
became more nuclear over time in both control and SMA mice, however, the change 
in control mice occurred between P5 and P8 and the change in SMA mice occurred 
between P2 and P5. 
 
Figure 3-10 UBA1 expression is increased in early-symptomatic SMA spinal motor 
neurons 
Spinal cord sections from SMA and control mice at P5 (early-symptomatic) were labelled 
with UBA1a, a cytoplasmic and motor neuron specific marker (ChAT), and a nuclear marker 
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(DAPI). A Early-symptomatic SMA spinal motor neurons showed an increase of nuclear and 
cytoplasmic UBA1a compared to control mice. Scale bar: 5µm. B Quantification of absolute 
intensity of nuclear and cytoplasmic UBA1a showed a significant increase of UBA1 levels in 
early-symptomatic SMA motor neurons. Control N=3 mice, n=229 motor neurons; SMA N=3 
mice, n=243 motor neurons. SMA normalised to control. One-way ANOVA with Tukey’s 
post-hoc test; **** P ≤ 0.0001. C Nuclear to cytoplasmic ratio (NCR) of UBA1a for control 
and SMA mice at each stage of disease progression. Significant reduction in NCR at pre- 
and late-symptomatic stages of disease progression in SMA mice compared to control. D 
NCR of UBA1a for control and SMA mice at each stage of disease progression, showing 
increasing NCR for control and SMA from P2 to P8. C, D One-way ANOVA with Tukey’s 
post-hoc test; ns – not significant, *P ≤ 0.05, **P ≤ 0.01, **** P ≤ 0.0001. 
3.2.4.c Biochemical validation of cytoplasmic specific reduction of 
UBA1 
To biochemically confirm the changes in UBA1 levels observed in vivo using 
IHC, subcellular fractionation was performed on spinal cords from SMA mice and 
littermate controls at late-symptomatic stage of disease. Late-symptomatic mice were 
used for these experiments due to the larger volume of tissue available. Spinal cords 
were homogenised and centrifuged, as previously described (Cox and Emili, 2006) 
(Figure 2-5), to extract the cytoplasm and quantify UBA1a protein expression by 
Western blot. The UBA1a antibody was used to allow for reliable comparison 
between the independent techniques used to study UBA1 distribution in vivo. This 
preparation produced a clean cytoplasmic fraction with minimal nuclear 
contamination (Figure 3-11A). A clear reduction in UBA1a was seen in the SMA 
spinal cord cytoplasmic fraction compared to controls (Figure 3-11A), when 
quantified the cytoplasmic reduction of UBA1a was 46.6% (Figure 3-11B, Exp 1). 
To ensure this reduction was not due to an artefact of the preparation or technical 
error, two more preparations were conducted, both of which showed a significant 
reduction in UBA1a expression. On average, UBA1a was significantly reduced by 
38.0% in the cytoplasmic fraction of SMA spinal cords compared to controls (Figure 
3-11B).  
The reduction in cytoplasmic UBA1a as detected by IHC and biochemically 
by subcellular fractionation was then compared (Figure 3-11C). There was a 10% 
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difference in the reduction of cytoplasmic UBA1a detected by IHC (28.2%) and 
subcellular fractionation (38.0%). However, while both techniques showed a 
significant reduction in cytoplasmic UBA1a compared to control, there was no 
significant difference between the two techniques (Figure 3-11C). Subcellular 
fractionation of SMA and control spinal cords therefore provides a biochemical 
validation of the cytoplasmic reduction of UBA1 in vivo. 
 
Figure 3-11 Subcellular fractionation of spinal cords confirms cytoplasmic reduction 
of UBA1 in late-symptomatic SMA mice 
Subcellular fractionation was performed on spinal cords from late-symptomatic SMA mice 
and control littermates to extract the cytoplasmic fraction. A Representative quantitative 
fluorescent Western blot of cytoplasmic fraction from control and SMA spinal cords showed a 
reduction in UBA1a; cytoplasmic marker (GAPDH), nuclear control (Histone H3), loading 
control (a-Tubulin). Protein sizes are as indicated (kDa). B Quantification of UBA1a in 
cytoplasmic fraction from SMA and control spinal cords for 3 preparations (experiment [Exp] 
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1 to 3) and the average. Normalised to a-Tubulin loading control, and then normalised to 
control mice. N=3 preparations, n=3 mice per condition per preparation. Unpaired 2-tailed 
Student’s t test per preparation and for average; * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. C 
Comparison of UBA1a reduction in the cytoplasmic compartment of late-symptomatic SMA 
spinal cord or spinal motor neurons, quantified by immunohistochemistry (IHC) and 
fractionation followed by Western blot, with a control shown for reference. Unpaired 2-tailed 
Student’s t test; ns – not significant. 
In this section, I demonstrated that UBA1 levels were reduced in SMA spinal 
motor neurons at both pre-symptomatic and late-symptomatic stages of disease 
progression. However, at an intermediate stage of disease, UBA1 levels were 
elevated in SMA mice motor neurons when compared to control mice. Interestingly, 
both control and SMA spinal motor neurons showed an overall increase in NCR over 
time; however, this increase occurred at different time points in SMA and control 
mice. Finally, subcellular fractionation of spinal cords was used to biochemically 
validate the cytoplasmic reduction of UBA1 in late-symptomatic SMA spinal cords. 
  
  Understanding the role of UBA1 in SMA 
Characterising UBA1 distribution 88 
3.3 Discussion 
Despite the fact that redistribution of UBA1 in specific neuronal populations has 
been identified in several neurodegenerative diseases (Lopez Salon et al., 2000; 
Wade et al., 2014; Wishart et al., 2014), the distribution of UBA1 in healthy neuronal 
cells has until now remained uncharacterised. To improve our understanding of 
UBA1 distribution, I optimised antibodies to study the localisation of UBA1 for 
immunolabelling of spinal cord sections and primary neurons, as well as for Western 
blot. I then validated these antibodies by characterising UBA1 distribution in 
dividing cultures of cells, which showed the same patterns as described in the 
literature (Grenfell et al., 1994; Handley-Gearhart et al., 1994; Trausch et al., 1993). 
I also extended this to show that these differences are consistent over time in culture. 
Furthermore, I demonstrated that different distribution patterns exist within dividing 
cultures of cells and I used this finding to establish a quantification method that 
captures this variation. Next, I determined UBA1 distribution in post-mitotic cells 
and found that in primary motor neurons UBA1 consistently becomes more 
cytoplasmic over time, this does not occur in cultures of dividing cells. Finally, to 
further characterise the role of UBA1 in SMA pathogenesis, I investigated the 
distribution of UBA1 in spinal motor neurons from control and SMA mice. I 
observed a reduction of UBA1 in pre- and late-symptomatic SMA mice; however, 
intriguingly, I identified a prominent increase in UBA1 in early-symptomatic SMA 
mice. Overall, this indicates that UBA1 reduction in motor neurons is an early 
pathological feature in SMA and suggests that changes in UBA1 distribution could 
be an important factor during normal growth and development of neonatal mice. 
After having optimised antibodies to reliably detect UBA1, it was possible to 
observe and quantify variations in UBA1 distribution patterns between different cell 
types. For example, in glial cells, a range of distribution patterns were observed at all 
time points investigated, however, there was little change between the different time-
points. Conversely, in motor neurons, whilst at each time point there was a relatively 
specific distribution pattern, this pattern was different for each time point with UBA1 
becoming more cytoplasmic the longer the neurons were kept in culture. In glial 
cells, UBA1 was localised to the nucleus as detected with both antibodies, while in 
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motor neurons UBA1 showed relatively more cytoplasmic localisation. In 
comparison to both HEK293 cells and the localisation of UBA1 reported in HepG2 
cells (Schwartz et al., 1992), the drastically different localisation of UBA1 isoforms 
between different cell types and throughout development of specific cell types is 
striking (Appendix 1). The differential distribution of UBA1 between different cell 
types could influence the susceptibility of the cell type to UBA1 reduction. As 
previously mentioned (see 1.1.5), one working theory for the presence of extra-
neuronal pathology in SMA is the ‘threshold hypothesis’ where differential 
thresholds for low SMN levels exist in different cell types (Hamilton and 
Gillingwater, 2013; Sleigh et al., 2011). It is plausible that cell type-specific UBA1 
distribution patterns could contribute to the sensitivity of that cell type to low levels 
of SMN. 
Furthermore, on investigating UBA1 distribution patterns in spinal motor 
neurons it became evident that there are clear differences between UBA1 localisation 
in vitro and in vivo. In primary motor neurons, UBA1 becomes relatively more 
cytoplasmic than nuclear over time. This might, for example, correspond to the 
sustained growth of motor axons possibly requiring a higher demand of UBA1 in the 
cytoplasm for protein turnover. Interestingly, a different distribution change is 
observed over time in motor neurons in vivo. As neonatal mice grow and begin to 
mature, UBA1 becomes relatively more nuclear. One reason that could account for 
this difference is that primary motor neurons are cultured from E13.5 embryos while 
the spinal motor neurons analysed were from neonatal mice, suggesting that the 
developmental stage could influence UBA1 distribution. It would be interesting to 
investigate UBA1 distribution in spinal motor neurons from control mice during 
embryonic development and after post-natal day 8 to extend the time course of 
UBA1 distribution in spinal motor neurons. Not only would this allow the role of 
UBA1 during development to be further investigated, but would also help to tease 
apart the differences between primary motor neurons and spinal motor neurons and 
identify whether these differences are due to the stage of development investigated. 
Investigating UBA1 distribution in spinal motor neurons also highlighted the 
changes in UBA1 protein levels and localisation throughout SMA disease 
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progression. Initially, UBA1 was reduced pre-symptomatically before a potential 
compensatory response of increased UBA1 levels at the early-symptomatic stage of 
disease corrected the altered UBA1 distribution. Despite this, due to the large change 
in the distribution of UBA1 in control mice between P5 (early-symptomatic) and P8 
(late-symptomatic), this potential compensatory response may not be sufficient to 
correct UBA1 protein levels, to remain at control levels between these time points. In 
this situation, it is possible that the reduction in UBA1 levels may exhibit its main 
downstream damage during the pre-symptomatic phase, when UBA1 protein levels 
exhibited their greatest reduction in SMA motor neurons compared to control.  
Previously, pre-symptomatic implication of UBA1 in SMA was restricted to 
neuronal populations outside the spinal cord or to non-neuronal organs (Powis et al., 
2016; Wishart et al., 2014). Here reduction of UBA1 was observed in spinal motor 
neurons for the first time, showing a significant reduction of UBA1 pre-
symptomatically. Not only does this suggest that UBA1 reduction could be a driving 
force in motor neuron degeneration in SMA but also supports the idea that for full 
therapeutic correction SMA must be treated before clinical symptoms appear (Kariya 
et al., 2014; Robbins et al., 2014). Furthermore, UBA1 is also differentially 
distributed between motor neurons of pre-symptomatic SMA and control mice, 
suggesting that mislocalisation of UBA1 may be harmful during development.  
Interestingly, subcellular fractionation of spinal cords biochemically 
validated the late-symptomatic reduction of UBA1 seen in the cytoplasm of SMA 
mice. While subcellular fractionation of P8 spinal cords produces robust and reliable 
data that can be suitably quantified from cytoplasmic fractions, several technical 
limitations prevented this from being possible for nuclear fractions. The primary 
issue was tissue quantity, when performing subcellular fractionation on spinal cords 
of this size, the amount of protein present in the final nuclear fraction was too 
minimal to detect UBA1. Therefore, while the cytoplasmic fraction can be easily and 
reliably quantified, the nuclear fraction did not lend itself to quantification in this 
situation. In contrast to this, nuclear UBA1 can be reliably quantified by distribution 
analysis on IHC of spinal cord sections. In fact, while the nuclear analysis is based 
on DAPI which provides a clear outline to the nucleus, the cytoplasmic outline is 
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based on ChAT staining which provides a less clear-cut edge of the cell body. 
Therefore, while fractionation can accurately measure cytoplasmic UBA1 levels to 
validate the IHC cytoplasmic results, the nuclear results from IHC are likely to be 
more accurate than those for the cytoplasm. 
In conclusion, a robust set of antibodies for both in vivo and in vitro work to 
study UBA1 have been identified. Existing data on the distribution of UBA1 in 
dividing cultures of cells has been extended to confirm that differences between 
UBA1 and UBA1a localisation are consistent over long-term cultures of cells. 
Moreover, for the first time UBA1 distribution has been investigated in a healthy 
neuronal population, which showed pronounced variation and changes over time in 
distribution patterns compared to long-term cultures of dividing cells. Finally, a 
novel characterisation of UBA1 distribution throughout disease progression in SMA 
spinal motor neurons has been performed and validated by biochemical fractionation. 
From this work, it is evident that UBA1 reduction may be an important pre-
symptomatic molecular feature of SMA in motor neurons. To understand the role of 
UBA1 in motor neuron degeneration it will be essential to determine what causes the 
reduction of UBA1 and what effect the reduction in UBA1 has on the proteome. As 
the primary canonical function of UBA1 is to charge the ubiquitin system (Bedford 
et al., 2011; Groen and Gillingwater, 2015), it will be interesting to investigate if 
defects in the ubiquitin proteasome system occur downstream of UBA1 reduction or 
whether other protein families and pathways are disrupted following changes in 
UBA1 protein levels. 
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Chapter 4 Identification of downstream targets 
of UBA1 
4.1 Introduction 
The ubiquitin-like modifier activating enzyme 1 (UBA1) is a major downstream 
target of the SMN protein with clear applications as a therapeutic target in SMA 
(Powis et al., 2016; Wishart et al., 2014). In Chapter 3 of this thesis I showed that 
UBA1 expression is reduced pre-symptomatically in SMA spinal motor neurons 
implicating UBA1 in the pathogenesis of SMA. Moreover, I demonstrated that there 
is also an early-symptomatic compensatory phase where UBA1 protein levels 
increase within the spinal motor neurons in SMA. In order to understand the role of 
UBA1 in motor neuron degeneration it will be important to unravel the relevance of 
these changes in UBA1 expression and the effect these changes in UBA1 expression 
have on the rest of the proteome. 
UBA1 is the enzyme at the apex of the ubiquitylation cascade, being 
responsible for the activation of ubiquitin and thus functionality of ubiquitin 
signalling pathways (Bedford et al., 2011). It is therefore not surprising that UBA1 
accounts for ~2% of the protein in all cells (Clague et al., 2015; Yang et al., 2013). 
Despite the abundance of UBA1, very little is known about the functions of the 
enzyme outside the ubiquitin proteasome system. Indeed, even within the pathway 
where UBA1 has its canonical function, there are still large gaps in our knowledge. 
While the role of UBA1 itself is well defined within the ubiquitin-proteasome 
system (see 1.2.1), the relationship between UBA1 and the other enzymes in the 
system is less well understood. To elaborate, there are approximately 40 E2 enzymes 
known to conjugate ubiquitin downstream of UBA1 and around 600 E3 enzymes that 
ligate ubiquitin to the substrate protein (Bedford et al., 2011). The E2 enzymes are 
not only responsible for delivering the activated ubiquitin to the E3 ligase but they 
also determine the topology of ubiquitin-chain linkage and switch between initiation 
and elongation of polyubiquitin chains (Kulathu and Komander, 2012; Ye and Rape, 
2009). Thus, E2 enzymes are responsible for mediating ubiquitin chain assembly. 
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Despite this, the selectivity of E2 enzymes for the much greater number of E3 
enzymes remains uncharacterised. 
The E3 ubiquitin ligase enzymes are reasonably well characterised in terms of 
their general properties and can be split into four categories based on their structure 
and function. Three classes of E3 enzymes function as adaptors by binding a 
ubiquitin loaded E2 and a substrate protein to promote ubiquitylation, these are U-
box E3s, monomeric RING finger E3s and multi-subunit E3 complexes containing a 
RING finger protein (Bedford et al., 2011). The fourth class of E3 enzymes are 
HECT domain E3s which form a thioester intermediate with ubiquitin before 
transferring the ubiquitin to a substrate (Ambrozkiewicz and Kawabe, 2015; Bedford 
et al., 2011). Regardless of the subclass of the E3 enzyme, the enzyme is responsible 
for the recruitment of specific substrate proteins to enable ubiquitylation. Although 
there is an increasing number of protein substrates whose E3 enzymes are known, 
these are generally one-to-one relationships without understanding or knowing the 
full range of substrates for each E3 (Kwon et al., 2013; Teixeira et al., 2016). 
Likewise, some E2-E3 pairs have been identified but again without characterising 
how the wide range of E3 enzymes relates to the smaller number or E2 enzymes 
(Clague et al., 2015). 
Although several E2 enzymes have been shown to mediate ubiquitylation 
downstream of UBA1, other E2s have been shown to associate with another E1 that 
also activates ubiquitin (Liu et al., 2017b). The ubiquitin-like modifier activating 
enzyme 6 (UBA6) is the only other E1 enzyme that has been shown to activate 
ubiquitin. Although, until recently, it was thought that UBA6 was merely a ‘back-up’ 
ubiquitin activating enzyme with its main function to activate FAT10, a ubiquitin-
like protein (UBL) (Bedford et al., 2011). Indeed, FAT10ylation mediated by UBA6 
is responsible for signalling UBA1 for degradation (Bialas et al., 2015). A recent 
study has, however, shown that UBA6-mediated ubiquitylation may be more 
common place that initially thought; identifying that UBA6 may be responsible for 
mediating ubiquitylation of 697 substrates with only 258 of these substrates 
overlapping with UBA1. The study also identified two UBA6 specific E2 enzymes 
and a further four E2 enzymes that mediate ubiquitylation by both UBA1 and UBA6 
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(Liu et al., 2017b). This adds further complexity to understanding the relationships 
between E1, E2 and E3 enzymes. Moreover, due to the increased understanding of 
the possible role of UBA6 in ubiquitin conjugation pathways and the overlap of these 
two E1 enzymes, to identify UBA1-dependent substrates it will be necessary to 
investigate whether or not UBA6 may be influencing the ubiquitylation of the 
substrates. 
Interestingly, specific downstream pathways dependent on UBA1 mediated 
ubiquitylation have been identified. As previously described (see 3.1), UBA1 has 
differential localisation throughout the cell cycle, this corresponds to the 
ubiquitylation and deubiquitylation of proteins required for progression through the 
cell cycle; for example, p53 and Histone H2A (Joo et al., 2007; Kitagaki et al., 2009; 
Yang et al., 2007). Temperature-sensitive mutations of UBA1 show that loss of 
UBA1 leads to cell cycle arrest due to reduction in overall ubiquitylation and protein 
degradation (Ghaboosi and Deshaies, 2007; Sugaya et al., 2014). Interestingly, 
UBA1 has also been shown to be essential for ubiquitylation-mediated repair of 
double-strand DNA breaks, thus implicating UBA1 in DNA repair pathways 
(Moudry et al., 2012). The influence of UBA1 on these pathways require its ability to 
activate ubiquitin and the canonical ubiquitylation pathway.  
There are, however, suggestions that UBA1 may have functions outside the 
canonical ubiquitylation cascade. For example, it has been demonstrated that there 
may be crosstalk between UBA1 and autophagy: the normal E1 (Atg7) and E2 
(Atg3) enzymes required for autophagy are bypassed and Uba1 instead is required 
for Atg8-dependent autophagy, although not by direct activation of the UBL Atg8 
(Chang et al., 2013). Moreover, it has also been demonstrated that Uba1 is required 
for axon development in Drosophila and that inhibition of Uba1 leads to increased 
miniature and spontaneous synaptic currents in cultured hippocampal neurons 
(Rinetti and Schweizer, 2010; Watts et al., 2003). Although it is uncertain how this is 
mediated (whether through ubiquitylation or a non-canonical function of UBA1) it 
indicates the broad range of pathways in which UBA1 is implicated and the 
possibility of UBA1 having multiple non-canonical functions. 
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In order to understand the role of UBA1 in the pathogenesis of SMA it will 
be essential to identify the key consequences of the widespread reduction of UBA1 
expression. Similarly, it is still unclear whether the primary consequence of 
disruption to UBA1 expression is dysfunction to the ubiquitin-proteasome system or 
pathways downstream of the ubiquitylation cascade. Interestingly, very little is 
known about the specificities of E2 and E3 enzymes and therefore, it is unclear 
which E2s, E3s or indeed protein substrates might be relevant for UBA1-mediated 
degeneration in SMA. However, there remains the possibility that reduction of 
UBA1 might be altering a non-canonical function of the enzyme and thus 
contributing to pathogenesis of SMA. Therefore, to delineate the effects of changes 
in UBA1 expression levels on downstream proteins and to identify UBA1-dependent 
pathways that may be relevant for SMA, a proteomics screen was performed. To do 
this, a model system where UBA1 protein levels could be modulated was optimised 
and a label-free proteomics screen was performed to identify the effects of changes 
in UBA1 expression on the proteome. Proteins from UBA1-dependent protein 
families were then validated both in vitro and in vivo with the aim of understanding 
the downstream effects of UBA1 dysregulation in SMA.  
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4.2 Results 
4.2.1 Experimental design for proteomic profiling of the 
effects of UBA1 modulation in vitro 
4.2.1.a Optimisation of UBA1 overexpression and knockdown 
To investigate downstream targets of UBA1 by performing a proteomics screen, a 
suitable in vitro model system was required. As UBA1-dependency of downstream 
targets will be key to understanding the role of UBA1 in SMA, the model system 
needed to be amenable to both overexpression and knockdown of UBA1. HEK293 
cells were chosen as high transfection efficiencies can be achieved, which is essential 
to achieve a homogeneous population of cells necessary for the proteomics screen. 
Overexpression of UBA1 was tested with different concentrations of transfection 
reagent (Lipofectamine 2000), to identify the optimal conditions for maximum 
transfection efficiency. UBA1 overexpression increased with increasing amounts of 
the transfection reagent (Figure 4-1A), 9µl of transfection reagent was selected for 
use in the proteomics experiments due to the robust overexpression achieved (Figure 
4-1C). For UBA1 knockdown, untreated, transfection reagent only, and scrambled 
siRNA control conditions were compared to siRNA targeting exons 24 and 25 of 
UBA1 (Figure 4-1B). Transfection with the UBA1 siRNA led to a 71.87% 
knockdown of UBA1 compared to average control levels (Figure 4-1D), comparable 
to the SMN-dependent reduction in UBA1 seen in SMA (Powis et al., 2016; Wishart 
et al., 2014). Use of a fluorescent siRNA indicated that transfection efficiency of 
siRNA was greater than 95% (data not shown). Overall, this system is suitable to 
achieve robust overexpression and knockdown of UBA1 in an experimentally 
tractable cell system. 
  Understanding the role of UBA1 in SMA 
Identifying downstream targets of UBA1 97 
 
Figure 4-1 Optimisation of UBA1 overexpression and knockdown in vitro 
Optimisation of UBA1 overexpression and knockdown was performed on HEK293 cells. A 
Representative fluorescent Western blot of HEK293 cells: control cells, lipofectamine only 
control, HEK293 cells transfected with UBA1 plasmid and increasing volume of lipofectamine 
(values shown as µl) showing increasing overexpression of UBA1. B Representative 
fluorescent Western blot of HEK293 cells: control cells, RNAiMax only control, scrambled 
siRNA control, and siRNA directed against UBA1 showing reduction of UBA1 protein levels. 
A and B GAPDH used as a loading control, protein sizes are as indicated (kDa).  C 
Quantification of UBA1 protein levels (normalised to GAPDH loading control), control 
represents control cells and lipofectamine only control. D Quantification of UBA1 knockdown 
(normalised to GAPDH loading control) control represents the first three bands from panel B. 
4.2.1.b Validation of changes in UBA1 protein levels in samples to be 
used for proteomics analysis 
Following optimisation of UBA1 overexpression and knockdown, samples for label-
free proteomics were generated by applying the same experimental design from the 
optimisation phase. HEK293 cells were transfected 48 hours after plating. For 
overexpression samples, the cells were collected 24 hours after transfection and 
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knockdown samples were collected 48 hours after transfection (Figure 4-2A). Three 
biological replicates were included for each experimental condition along with three 
control (non-transfected) samples. 
To confirm UBA1 protein expression in the samples used for the proteomics 
screen, Western blots using both pan-UBA1 and UBA1a antibodies were performed. 
The UBA1 plasmid encoded full-length UBA1 i.e. UBA1a, however, the siRNA 
used was targeted against exons common to both isoforms of UBA1. Therefore, 
UBA1 protein levels were quantified with both antibodies to get an accurate 
assessment of the changes to UBA1 protein levels in the HEK293 cells. Again, as 
with optimisation, there was a robust knockdown of UBA1 (Figure 4-2B), detected 
by both antibodies with reduction of 76.15% (P£0.01) detected by pan-UBA1 and of 
74.22% (P£0.001) with UBA1a (Figure 4-2C). Similarly, the overexpression of 
UBA1 was significant, with a 10.11 fold change increase (P£0.001) detected by pan-
UBA1 and an increase of 4.37 fold (P£0.01) detected by UBA1a (Figure 4-2D, E). 
Interestingly pan-UBA1 detected the greatest relative overexpression (Figure 4-2E), 
which could be due to antibody affinity. This demonstrates that UBA1 levels were 
significantly up- and down-regulated in the proteomics samples. Importantly, 
however, following UBA1 knockdown, UBA1 protein levels were not knocked-
down beyond biologically relevant levels (e.g. completely depleted) with respect to 
reduction in UBA1 protein that is seen in SMA (Powis et al., 2016; Wishart et al., 
2014). 
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Figure 4-2 UBA1 protein levels in samples to be used for proteomic analysis 
Quantification of UBA1 protein levels in HEK293 cells used for the proteomics screen. A 
Timeline of sample preparation. B Fluorescent Western blot of UBA1 protein levels, detected 
by pan-UBA1 and UBA1a, after knockdown of UBA1. CoxIV as loading control. C 
Quantification of UBA1 protein levels after UBA1 overexpression showing significant 
downregulation detected by both antibodies. D Fluorescent Western blot of UBA1 protein 
levels, detected by pan-UBA1 and UBA1a, after overexpression of UBA1. Histone H3 (H3) 
as loading control. E Quantification of UBA1 protein levels after UBA1 overexpression 
showing significant downregulation detected by both antibodies. B, D Samples run on the 
same gel in non-contiguous lanes. Protein sizes are as indicated (kDa). C, E Samples were 
normalised to loading control and then overexpression and knockdown samples were 
normalised to control. Unpaired two-tailed Student’s t-test; ** P ≤ 0.01, *** P ≤ 0.001; n=3 
separate transfections per condition. 
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4.2.1.c Characterising SMN and UBA6 protein levels in samples to be 
used for proteomic analysis 
After validating the changes in UBA1 protein levels in the samples used for the 
proteomics screen, protein levels of SMN and UBA6 were characterised in the 
proteomics samples. As the aim of this chapter is to tease out UBA1-dependent 
pathways that may be relevant for SMA it was necessary to investigate whether 
protein expression changes are independent of changes in SMN expression. It was 
also important to determine UBA6 protein levels in these samples due to its role in 
degradation of UBA1 and the recent identification of its wider role in the 
ubiquitylation process (Bialas et al., 2015; Liu et al., 2017b). 
Interestingly, following knockdown of UBA1, the protein levels of both SMN 
and UBA6 remained unchanged (Figure 4-3A, B). This indicates that any changes in 
protein levels following UBA1 knockdown were not due to influences from either 
SMN or UBA6. Following UBA1 overexpression, SMN protein levels remained 
unchanged (Figure 4-3C, D) however, UBA6 was upregulated by 65.13% (P£0.05) 
compared to control HEK293 cells (Figure 4-3D). This upregulation of UBA6 could 
be due to a feedback mechanism to mediate a reduction in the protein levels of 
UBA1. However, due to the increase in its expression it needs to be noted that UBA6 
may influence proteins changed upon UBA1 overexpression. Despite this it can be 
seen that neither SMN nor UBA6 are influencing proteins changed upon knockdown 
of UBA1 which is of particular importance as UBA1 reduction is the primary 
dysregulation of UBA1 seen in SMA (Wishart et al., 2014). 
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Figure 4-3 UBA6 was upregulated following UBA1 overexpression 
Quantification of SMN and UBA6 protein levels in HEK293 cells used for the proteomics 
screen. A, C Fluorescent Western blot of SMN and UBA6 protein levels after (A) knockdown 
and (C) overexpression of UBA1. A CoxIV, C Histone H3 (H3) as loading control. B, D 
Quantification of SMN and UBA6 protein levels after (B) knockdown and (D) overexpression 
of UBA1. D Significant upregulation of UBA6 following UBA1 overexpression. A, C Samples 
run on the same gel in non-contiguous lanes. Protein sizes are as indicated (kDa). B, D 
Samples were normalised to loading control and then overexpression and knockdown 
samples were normalised to control HEK293 cells. Unpaired two-tailed Student’s t-test; ns – 
not significant, * P ≤ 0.05; n=3 separate transfections per condition. 
 
To summarise, here I optimised transfection conditions for overexpression 
and knockdown of UBA1 in HEK293 cells and used this experimental design to 
generate samples for a label-free proteomics screen. I validated that UBA1 
expression was significantly changed in the samples used for the proteomics screen. 
Then I identified that SMN expression was not changed in these samples, but that 
UBA6 may affect the expression of proteins changed on UBA1 overexpression.  
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4.2.2 Proteomic analysis 
In order to identify downstream targets of UBA1, whether they be E2 and E3 
enzymes, specific protein substrates, or targets of non-canonical functions of UBA1, 
label-free proteomics was performed on HEK293 cells with modulated UBA1 
protein levels. Label-free proteomics was chosen due to the larger proteome 
coverage attained compared to proteomic approaches relying on labelling, as well as 
the better quantitation that can be achieved as the output is an average absolute 
abundance for each protein instead of a relative abundance (Gstaiger and Aebersold, 
2009). The analysis of the proteomics dataset focused on identifying proteins that 
were changed in opposite directions in the two experimental conditions compared to 
control. Therefore, proteins that were upregulated following UBA1 overexpression 
and downregulated following UBA1 knockdown, compared to control, were 
classified as UBA1-dependent, as were proteins downregulated following UBA1 
overexpression and upregulated following UBA1 knockdown, compared to control. 
This analysis focuses on identifying pathways and proteins that behave in one of 
these UBA1-dependent manners. For reference, the filtered dataset (see method 
2.12.2.b, Figure 2-7) can be found in Appendix 2 and a table containing proteins with 
a change in expression greater than 20% following both UBA1 overexpression and 
knockdown can be found in Appendix 3. 
4.2.2.a Gene ontology term enrichment 
To generate an initial overview of the protein families and pathways changed in the 
dataset, gene ontology term enrichment analysis was performed in DAVID (see 
method 2.12.3.a). Both gene functional classification and functional classification 
were performed, where the first identifies gene families that are enriched and the 
latter identifies enrichment of specific protein functions otherwise known as gene 
ontology (GO) terms. The enrichment score (ES) represents the enrichment of the 
different terms in this dataset compared to a generic background dataset. For 
reference, an ES of 1.3 is equivalent to a p-value of 0.05, an ES of 3 is equivalent to 
a p-value of 0.001 and an ES of 4 is equivalent to a p-value of 0.0001. 
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Within the dataset, four gene groups were enriched: tRNA ligases, translation 
elongation factors, small molecule synthesis and nuclear transport. The ESs for these 
groups ranged from 4.14 to 6.17 showing clear significance of the enrichment of 
these gene groups in the dataset. Interestingly, there is no enrichment of genes related 
to the ubiquitin-proteasome system (Table 4-1A). When identifying gene ontology 
term enrichment (protein functions), all of the enriched gene groups were represented 
with ESs ranging from 2.95 to 4.56 (Table 4-1A, B). Gene ontology terms enriched 
with lower ESs included ubiquitin-like conjugation, protein complex assembly, and 
ATP and nucleotide binding (Table 4-1B); functions related to the ubiquitin 
conjugation process. From this initial analysis, it is evident that modulation of UBA1 
protein levels does not cause massive disruption to E2 and E3 enzymes. Therefore, 
this dataset is comprised of novel downstream targets of the ubiquitin conjugation 
process or targets of non-canonical functions of UBA1. 
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Table 4-1 Gene ontology term enrichment 
A Enrichment of different gene families within the dataset. B Enrichment of functional protein 
groups within the dataset. 
4.2.2.b Identification of UBA1-dependent expression profiles 
As the primary aim of this proteomic screen was to detect UBA1-dependent proteins, 
it was necessary to identify groups of proteins with expression profiles that show 
UBA1-dependency. To begin this process, a correlation analysis was performed in 
progenesis (see method 2.12.2.b) to group proteins based on the similarity of their 
expression profiles. The dendrograms in Figure 4-4A and B show all the proteins in 
the dataset with the vertical distance between each protein representing expression 
profile similarity. The left-hand side of the dendrogram was highlighted in blue in 
Figure 4-4A and the bottom panel of Figure 4-4A displays the expression profiles of 
these proteins; similarly, Figure 4-4B shows the expression profiles of proteins on 
the right hand side of the dendrogram. The expression profiles show the standardised 
normalised abundance of each protein. Each line in the expression profile represents 
a protein and each point represents the standardised normalised abundance of that 
protein in one sample (3 replicates per condition). 
The proteins highlighted in Figure 4-4A showed a general trend of 
upregulation following UBA1 overexpression and downregulation following UBA1 
knockdown compared to control. Conversely in Figure 4-4B, where the proteins on 
the right-hand side of the dendrogram were highlighted, the generalised expression 
profile showed a downregulation following UBA1 overexpression and upregulation 
following UBA1 knockdown. Interestingly, and perhaps counterintuitively, more 
proteins were upregulated on UBA1 overexpression than downregulated (Figure 
4-4A, B). Although the broad generalised expression profiles were clear for each of 
the two main clusters in the dendrogram, there were proteins that did not conform 
completely to either of these expression profiles and therefore do not classify as 
UBA1-dependent. Thus, it will be necessary to further subdivide the groups of 
proteins into clusters with greater similarity or more refined protein expression 
profiles to tease out UBA1-dependency. 
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Figure 4-4 Characterisation of protein expression profiles 
Overview of protein expression profiles across control, UBA1 overexpression and UBA1 
knockdown conditions. A Top panel: left side of dendrogram highlighted in blue showing 
similarity of expression profiles. Bottom panel: protein expression profiles displayed as 
standardised normalised abundance of proteins on left side of dendrogram. Proteins have a 
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trend of increased expression following UBA1 overexpression and decreased expression 
following UBA1 knockdown compared to control. B Top panel: right side of dendrogram 
highlighted in blue. Bottom panel: protein expression profiles displayed as standardised 
normalised abundance of proteins on right side of dendrogram. Proteins have a trend of 
decreased expression following UBA1 overexpression and increased expression following 
UBA1 knockdown compared to control. 
4.2.2.c Analysis in Biolayout identified two UBA1-dependent protein 
clusters 
In order to identify groups of UBA1-dependent proteins, the protein groups were 
further divided into clusters based on their expression profiles by performing analysis 
in Biolayout (see method 2.12.3.b). This software allows the visualisation and 
analysis of network graphs based on the relationship between proteins: in this case 
the networks and derived clusters were based on the similarity of the protein 
expression profiles. Each protein was represented by a coloured node, and the 
relationships between the proteins were represented by edges (pale blue). The colour 
of the node indicates the cluster that protein belongs to.  
As was seen in Figure 4-4, the analysis reveals two main groups of proteins 
(Figure 4-5A), each of which can be further subdivided, generating 6 smaller clusters 
of proteins. Three proteins do not fit into a cluster (turquoise, left of top group; 
Figure 4-5A). Each cluster showed its own expression profile which was displayed as 
the mean expression profile for that cluster with SEM (Figure 4-5B-D). Two of the 
clusters showed UBA1-dependent expression profiles (Figure 4-5B, C), while the 
other four clusters showed a prominent expression change in one experimental 
condition (Figure 4-5D). The first UBA1-dependent cluster of proteins, Cluster 1, 
contained proteins that are upregulated following UBA1 overexpression and 
downregulated following UBA1 knockdown (Figure 4-5B). Subsequent analysis 
using DAVID revealed that the proteins in this cluster function in glycolysis, 
translation elongation, assembly of protein complexes or as tRNA ligases (Table 
4-2). Cluster 4 also showed a UBA1-dependent expression profile with proteins 
downregulated following UBA1 overexpression and upregulated following UBA1 
knockdown (Figure 4-5C). Proteins in Cluster 4 function in transport and localisation 
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of protein, RNA and nucleic acids (Table 4-2). Interestingly, the functions of the 
UBA1-dependent clusters overlap with the enriched gene ontology terms (Table 4-1). 
Thus, indicating that these are key protein families and functions changed on 
modulation of UBA1 protein levels. 
Although the other clusters do not show UBA1-dependency they provide 
useful information about the proteomic screen and the function of UBA1. Based on 
the expression profiles, it can be suggested that Clusters 2 and 3 may be affected by 
changes in ubiquitin activation by UBA1 (Figure 4-5D). Cluster 3 showed an 
expression profile with the main change in the samples with UBA1 overexpression 
(Figure 4-5D), as UBA6 was upregulated in these samples (Figure 4-3D) this E1 
enzyme may influence the expression profile of the proteins in Cluster 3. This was 
the only cluster with a change in expression profile only when UBA1 was 
overexpressed (Figure 4-5B-D), indicating that UBA6 is unlikely to have a 
widespread effect on the proteins in the dataset. Assessing the functions of proteins 
in Cluster 5 suggested that following UBA1 knockdown there was an overall 
reduction in ubiquitylation (Table 4-2), which could be expected on knockdown of 
the key E1 ubiquitin activating enzyme. Furthermore, Cluster 6 highlighted the role 
of UBA1 in the progression of the cell cycle and suggests that disruption to this 
pathway occurs when UBA1 expression is reduced (Figure 4-5D, Table 4-2). 
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Figure 4-5 Analysis in Biolayout revealed two UBA1-dependent protein clusters 
Identification of UBA1-dependent protein expression profiles. A Overview of clustering based 
on similarity of protein expression profiles, two main groups of proteins can be seen. Each 
node represents a protein and the colour of the node indicates the cluster the protein 
belongs to. B Proteins in Cluster 1 (green nodes) show a UBA1-dependent protein 
expression profile. C Proteins in Cluster 4 (silver nodes) show the opposite UBA1-dependent 
protein expression profile to those in Cluster 1. D Clusters 2,3,5 and 6 show other 
expression profiles. B, C, D Protein expression profiles are shown as mean normalised 
abundance on a pareto scale with the SEM for that cluster. 
 
Table 4-2 Functional classification of protein clusters 
Table showing functions of proteins in clusters from Figure 4-5 based on gene ontology term 
enrichment for Clusters 1 to 4 (in DAVID) and manual searching of protein functions for 
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Clusters 5 and 6. For functional annotation classification of Cluster 1, enrichment scores 
(ES) were > 5; for all other clusters analysed in DAVID, ES > 1.5. 
4.2.2.d Ingenuity pathway analysis revealed UBA1-dependency in 
protein networks 
To investigate UBA1-dependency at the level of individual proteins and to assess the 
relationships between the UBA1-dependent protein families, a network analysis was 
performed using the ingenuity pathway analysis (IPA) software (see method 
2.12.3.c). IPA uses both statistical analyses and a curated knowledge base of 
published protein interactions and associations to identify causal relationships within 
the dataset. One of the analysis platforms within IPA can generate networks showing 
associations and relationships between proteins in the dataset, as well as showing 
relative expression changes of the proteins - red symbols indicate upregulated 
proteins and green symbols indicate downregulated proteins. 
Here, networks were generated for proteins changed following UBA1 
overexpression compared to control (Figure 4-6A) and for proteins changed 
following UBA1 knockdown compared to control (Figure 4-6B). Interestingly, the 
network for each condition was composed of the same proteins and of these 35 
proteins only 5 were not present in the dataset (white symbols). From the remaining 
30 proteins, 25 behave in a UBA1-dependent manner (Figure 4-6), suggesting that 
modulations in UBA1 protein levels cause widespread reciprocal changes in 
expression of a range of proteins. These networks include proteins with tRNA ligase 
activity (YARS, GARS, HARS, WARS), translation elongation factors (EEF1G, 
EEF1B2, EEF1A1, EEF1D) and nuclear transport proteins (IPO4), all of which show 
UBA1-dependency across the two conditions (Figure 4-6). This further establishes 
the relevance of these protein families to the dataset and extends this to identify 
specific proteins within these families that are UBA1-dependent. The networks 
shown here also highlight crossover between the proteins from the different UBA1-
dependent protein families. 
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Figure 4-6 Protein networks showed UBA1-dependency 
Networks of proteins generated in Ingenuity pathway analysis for (A) proteins changed on 
UBA1 overexpression compared to control and (B) proteins changed on UBA1 knockdown 
compared to control. A, B Proteins within red shapes are upregulated, proteins in green 
shapes are downregulated, proteins in white shapes are not present in the dataset. The 
shape of the protein in the network depicts the protein function: diamonds represent 
enzymes, triangles represent kinases, hexagons indicate translation regulators, trapeziums 
represent transporters, circles indicate other protein classes and circles with an inner circle 
depict a protein complex. Solid lines show direct binding of proteins, dotted straight lines 
show indirect interaction by protein binding. Solid arrow heads indicate when a protein acts 
on another protein and clear arrow heads show when a protein translocates to another 
protein or complex. Both networks contain the same proteins, most proteins show opposite 
expression changes in the two networks. 
4.2.2.e The canonical pathways RAN signalling and tRNA charging are 
enriched within the dataset 
To further investigate the functions of proteins in the dataset, an analysis using IPA 
was performed to identify canonical pathways that had significant overlap with 
proteins in the dataset. Previously in this chapter, analyses that investigate 
enrichment of specific protein functions were performed (see 4.2.2.a and 4.2.2.c), 
this analysis differs in that it identifies enrichment of pathways in which proteins 
exhibit their known function. The canonical pathway with the greatest overlap with 
the dataset was RAN signalling, a pathway involved in nuclear transport (Table 4-3). 
Importantly, several proteins within this pathway show UBA1-dependency including 
importin b and RanBP1 (Figure 4-7A, B). Furthermore, this analysis also identified 
tRNA charging (a function of tRNA synthetases) as a significantly enriched 
canonical pathway, with 9 of the 39 proteins involved in this pathway present in the 
dataset (Table 4-3). This further reinforces the relevance of both nuclear transport 
proteins and tRNA synthetases as key UBA1-dependent protein families. 
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Table 4-3 Canonical pathways enriched on modulation of UBA1 expression 
Canonical pathways that are enriched in both UBA1 overexpression compared to control and 
UBA1 knockdown compared to control. P-value indicates the significance of enrichment. 
Overlap and number of proteins show the percentage and number, respectively, of proteins 
in the dataset that function in that canonical pathway. 
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Figure 4-7 UBA1-dependency within an enriched canonical pathway 
Schematic of the RAN-signalling canonical pathway – the most significantly enriched 
canonical pathway in the dataset. A, B Proteins in red shapes are upregulated, green 
shapes are downregulated and white shapes are not present in the dataset. The shape of 
the protein depicts its function: trapeziums represent transporters, circles indicate other 
protein classes and circles with an inner circle depict a protein complex. Solid arrowheads 
indicate when a protein acts on another protein and clear arrow heads show when a protein 
translocates to another location or complex. Proteins in the dataset show opposite changes 
in expression following (A) UBA1 overexpression and (B) UBA1 knockdown. 
4.2.2.f Proteomics analysis revealed tRNA synthetases, nuclear 
transport and translation elongation as UBA1-dependent 
pathways of interest 
In order to provide an overview of the proteins in the UBA1-dependent protein 
families and select candidates for further investigation, a table was compiled to 
identify proteins of interest. The table is split into three different groups based on 
gene groups from Table 4-1: tRNA synthetases, proteins involved in nuclear 
transport and proteins involved in translation elongation. Proteins selected for further 
investigation were highlighted in blue. The tRNA synthetases YARS and GARS 
were chosen for validation as they have the largest fold changes in that gene group 
and there were readily available antibodies for these proteins (Table 4-4). Similarly, 
IPO4 and RanBP1 were chosen for validation of nuclear transport pathways due to 
size of their fold changes and as these proteins are active in different aspects of 
nuclear transport (Table 4-4) (Mor et al., 2014). Finally, due to various tissue specific 
and developmental regulation related expression changes of different translation 
elongation factors (Abbott et al., 2009), PDCD4 was chosen for validation of this 
gene group (Table 4-4). PDCD4 inhibits the interaction of EIF4A1 and EIF4G 
causing an inhibition of translation initiation (Loh et al., 2009; Suzuki et al., 2008). 
PDCD4 was also chosen because it is changed in the opposite direction to the other 
proteins selected for further investigation, thus allowing UBA1-dependency to be 
assessed in relation to both possible directional changes of downstream proteins. 
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Table 4-4 Target proteins from UBA1-dependent protein families 
Proteins of interest belonging to the three UBA1-dependent protein families identified in this 
screen: tRNA synthetases, nuclear transport and translation elongation. Proteins highlighted 
in blue were chosen for further investigation. Score indicates the mascot score and the p-
value is the significance of the maximal change between the three conditions. Fold changes 
are represented as overexpression compared to control and knockdown compared to 
control. 
 
To summarise, here a label-free proteomics screen was performed and 
analysed to identify UBA1-dependent protein families. Gene ontology term 
enrichment analysis revealed tRNA synthetases, nuclear transport and translation 
elongation as key functions dysregulated within this dataset. Subsequent analysis 
identified that these protein families behave in a UBA1-dependent manner with 
UBA1-dependency also identified at the level of individual proteins belonging to 
these pathways. Proteins from each UBA1-dependent protein family were chosen for 
further investigation: GARS, YARS, IPO4, RanBP1 and PDCD4. 
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4.2.3 Validation of target protein changes following UBA1 
modulation in vitro 
After identification of UBA1-dependent pathways and selection of proteins to take 
forwards for further investigation it was necessary to validate the proteomics screen 
using an independent methodology. To do this Western blot was performed on the 
samples used for the proteomics screen. There were, however, some technical 
limitations with the Western blot, mainly that the sample size was restricted to the 
three samples used per condition for the proteomics screen and that the samples had 
already been depleted due to their prior use. Furthermore, the fold changes expected 
based on changes seen in proteomics screen are small adding another layer of 
difficulty. It is also worth mentioning that several potential loading control proteins 
were found to be changed in the proteomics screen (including GAPDH and tubulin 
proteins; Appendix 2) and so it was necessary to use different loading controls for 
overexpression and knockdown samples. Therefore, the following data is presented 
separately for overexpression compared to control and for knockdown compared to 
control. 
4.2.3.a Confirmation of changes in tRNA synthetase expression levels 
following UBA1 modulation in vitro 
In order to independently validate the UBA1-dependency of tRNA synthetases, 
GARS and YARS were chosen for Western blot (Table 4-4). Following knockdown 
of UBA1, GARS was downregulated by 48.26% although this was not a significant 
difference (P=0.1690). In the same samples, YARS was reduced to 44.16% of 
control levels following knockdown of UBA1 (P£0.05; Figure 4-8A, B). When 
UBA1 was overexpressed, GARS showed a non-significant up regulation by 43.52% 
(P=0.0788); YARS was also increased by 42.16% compared to control levels 
(P£0.05; Figure 4-8C, D). Interestingly, although GARS did not show a significant 
difference, the directional changes in expression of both GARS and YARS were 
consistent with those seen in the proteomics screen; thereby validating the UBA1-
dependency of these proteins with an independent methodology. 
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Figure 4-8 The tRNA synthetases GARS and YARS showed UBA1-dependency in vitro 
Quantification of GARS and YARS protein levels in HEK293 cells used for the proteomics 
screen. A, C Fluorescent Western blot of GARS and YARS protein levels after (A) 
knockdown and (C) overexpression of UBA1. Samples run on the same gel in non-
contiguous lanes. Protein sizes are as indicated (kDa). A CoxIV as loading control. C 
Histone H3 (H3) as loading control. B, D Quantification of GARS and YARS protein levels 
after (B) knockdown and (D) overexpression of UBA1. Samples were normalised to loading 
control and then overexpression and knockdown samples were normalised to control. B 
Significant downregulation of YARS following UBA1 knockdown. D Significant upregulation 
of YARS following UBA1 overexpression. Unpaired two-tailed Student’s t-test; ns – not 
significant, * P ≤ 0.05; n=3 separate transfections per condition. 
4.2.3.b Validation of expression changes of nuclear transport proteins 
following modulation of UBA1 expression in vitro 
Similarly, two proteins involved in nuclear transport (RanBP1 and IPO4) were 
selected for independent validation of the UBA1-dependency of this protein family 
(Table 4-4). Following knockdown of UBA1, RanBP1 was significantly 
downregulated (20.94%, P£0.05) and IPO4 showed a trend indicating 
downregulation (58.23%, P=0.0827; Figure 4-9A, B). When UBA1 was 
overexpressed neither protein showed a significant difference (Figure 4-9C, D). 
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Despite this, the downregulation of both RanBP1 and IPO4 on UBA1 knockdown 
provides an independent validation of the effect of UBA1 modulation on the 
expression of these proteins. 
 
Figure 4-9 Significant downregulation of RanBP1 following UBA1 knockdown in vitro 
Quantification of RanBP1 and IPO4 protein levels in HEK293 cells used for the proteomics 
screen. A, C Fluorescent Western blot of RanBP1 and IPO4 protein levels after (A) 
knockdown and (C) overexpression of UBA1. Samples run on the same gel in non-
contiguous lanes. Protein sizes are as indicated (kDa). A CoxIV as loading control. C 
Histone H3 (H3) as loading control. B, D Quantification of RanBP1 and IPO4 protein levels 
after (B) knockdown and (D) overexpression of UBA1. Samples were normalised to loading 
control and then overexpression and knockdown samples were normalised to control. B 
Significant downregulation of RanBP1 following UBA1 knockdown. Unpaired two-tailed 
Student’s t-test; ns – not significant, * P ≤ 0.05; n=3 separate transfections per condition. 
4.2.3.c An inhibitor of translation initiation was significantly changed 
following modulation of UBA1 expression in vitro 
Finally, to independently validate the UBA1-dependency of the translation 
elongation protein family, Western blot was performed on the proteomic samples for 
PDCD4. There was a small and variable, non-significant upregulation of PDCD4 
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following UBA1 knockdown (19.01%, P=0.2928; Figure 4-10A, B). Following 
UBA1 overexpression, there was a significant downregulation of PDCD4 expression 
by 50.31% compared to control (P£0.05; Figure 4-10A, C). As PDCD4 expression 
was changed in the opposite direction to the rest of the target proteins investigated, 
here, it has been possible to validate UBA1-dependency in the opposite direction to 
previously shown (see Figure 4-8). 
 
Figure 4-10 PDCD4 was significantly downregulated following UBA1 overexpression 
in vitro 
Quantification of PDCD4 protein levels in HEK293 cells used for the proteomics screen. A 
Fluorescent Western blot of PDCD4 protein levels after (top panels) knockdown and (bottom 
panels) overexpression of UBA1. Samples run on the same gel in non-contiguous lanes. Top 
panel, CoxIV as loading control. Bottom panel, Histone H3 (H3) as loading control. Protein 
sizes are as indicated (kDa). B, C Quantification of PDCD4 protein levels after (B) 
knockdown and (C) overexpression of UBA1. Samples were normalised to loading control 
and then overexpression and knockdown samples were normalised to control. C Significant 
downregulation of PDCD4 following UBA1 overexpression. Unpaired two-tailed Student’s t-
test; ns – not significant, * P ≤ 0.05; n=3 separate transfections per condition. 
 
To summarise, here I used an independent methodology to validate changes 
in protein expression identified in the proteomic screen. Quantitative Western blot 
revealed that the tRNA synthetases GARS and YARS, showed UBA1-dependency 
while the nuclear transport proteins IPO4 and RanBP1 were both downregulated on 
UBA1 knockdown. Finally, PDCD4 also showed UBA1-dependency when 
quantified by Western blot analysis.   
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4.2.4 Investigating UBA1-dependency of target proteins in 
vivo 
4.2.4.a Characterisation of UBA1, UBA6 and SMN expression following 
UBA1 overexpression in vivo 
Following validation of the novel downstream targets of UBA1 in vitro, validation of 
the UBA1-dependent target proteins was performed in vivo. To do this, wild-type 
FVB mice were injected intravenously with AAV9-UBA1 on the day of birth and 
hearts were harvested at postnatal day 8 for Western blot analysis. Hearts were 
chosen as it has previously been shown that a robust overexpression of UBA1 with 
this vector occurs in this organ (Powis et al., 2016). Before analysing the target 
proteins, it was first necessary to confirm UBA1 overexpression and assess whether 
either SMN or UBA6 may influence the expression of the target proteins in vivo. 
UBA1 was significantly overexpressed when detected either by pan-UBA1 (fold 
change increase of 2.05, P£0.001) or by UBA1a (fold change increase of 5.84, 
P£0.01; Figure 4-11A, B), indicating that this was a robust model of UBA1 
overexpression in vivo. There was no change in the expression of SMN; however, 
there was a significant upregulation of UBA6 (25.91%, P£0.05; Figure 4-11C, D). 
This was also the case with Western blot on HEK293 cells overexpressing UBA1 
(see Figure 4-3), again indicating that UBA6 may influence the expression of 
proteins changed following UBA1 overexpression. 
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Figure 4-11 UBA1 and UBA6 protein expression was significantly upregulated in 
AAV9-UBA1 injected FVB mice 
Quantification of UBA1, UBA6 and SMN protein levels in heart from AAV9-UBA1 injected 
wild-type FVB mice. A Fluorescent Western blot of UBA1 protein levels, detected by pan-
UBA1 and UBA1a after overexpression of UBA1 in vivo. B Quantification of UBA1 protein 
levels showing significant upregulation detected by both antibodies; n=3 mice per condition. 
C Representative fluorescent Western blot of SMN and UBA6 protein levels after 
overexpression of UBA1 in vivo. D Quantification of SMN and UBA6 protein levels showing 
significant upregulation of UBA6; n=6 mice per condition. A, C a-Tubulin (a-Tub) as loading 
control. Protein sizes are as indicated (kDa). B, D Protein expression was normalised to 
loading control and then protein expression from AAV9-UBA1 injected mice was normalised 
to control FVB mice. Unpaired two-tailed Student’s t-test; ns – not significant, * P ≤ 0.05, ** P 
≤ 0.01, *** P ≤ 0.001. 
4.2.4.b Target proteins were changed following UBA1-overexpression 
in vivo 
In order to investigate whether the target proteins were also UBA1-dependent in 
vivo, Western blot of the five proteins (GARS, YARS, IPO4, RanBP1 and PDCD4) 
was performed on hearts from mice overexpressing UBA1. The tRNA synthetase 
GARS showed a significant upregulation by 25.51% (P£0.01) following UBA1 
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overexpression in vivo, while there was no change in the expression of YARS 
(Figure 4-12A, B). The nuclear transport protein IPO4 was also upregulated in the 
hearts overexpressing UBA1 (40.85%, P£0.05) but there was no change in the 
expression of RanBP1 (Figure 4-12C, D). Finally, PDCD4 was also upregulated 
following UBA1 overexpression in vivo (41.65%, P£0.05; Figure 4-12E, F). 
Interestingly, neither YARS nor RanBP1 showed any change in expression 
indicating that these proteins may not respond to UBA1 overexpression in vivo. The 
expression of both GARS and IPO4 were changed in the same direction as in the 
proteomics screen; however, PDCD4 was changed in the opposite direction, 
suggesting that other factors are modulating the expression of this protein in vivo. 
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Figure 4-12 GARS, IPO4 and PDCD4 were upregulated following overexpression of 
UBA1 in vivo. 
Quantification of target protein expression levels in heart from AAV9-UBA1 injected wild-type 
FVB mice. A Representative fluorescent Western blot of GARS and YARS and (B) 
quantification of GARS and YARS protein levels after overexpression of UBA1 in vivo, 
showing a significant upregulation of GARS. C Representative fluorescent Western blot of 
IPO4 and RanBP1 and (D) quantification of IPO4 and RanBP1 protein levels after 
overexpression of UBA1 in vivo, showing a significant upregulation of IPO4. E 
Representative fluorescent Western blot and (F) quantification of PDCD4 expression after 
overexpression of UBA1 in vivo, showing a significant upregulation of PDCD4. A, C a-
Tubulin (a-Tub) as loading control; E GAPDH as loading control. Protein sizes are as 
indicated (kDa). B, D, F Protein expression was normalised to loading control and then 
protein expression from AAV9-UBA1 injected mice was normalised to control mice. Unpaired 
two-tailed Student’s t-test; ns – not significant, * P ≤ 0.05, ** P ≤ 0.01. GARS, IPO4, PDCD4 
n=3 mice per condition; YARS, RanBP1 n=6 mice per condition. 
4.2.4.c Expression of the tRNA synthetase GARS was changed in 
neuronal tissue overexpressing UBA1 
To confirm the change in GARS expression and to rule out any tissue specific 
effects, Western blot was performed on nervous tissue from mice overexpressing 
UBA1. To do this, dorsal root ganglia (DRGs) were chosen as they are a more 
refined cell population than heart and are an experimentally accessible part of the 
nervous system (see Figure 2-3 B-D); for further relevance of DRGs see Chapter 5. 
In DRGs from mice injected with AAV9-UBA1 there was an increase in UBA1 
expression by 33.22% (P£0.01) but no change in SMN expression levels (Figure 
4-13A, B). This overexpression of UBA1 in the DRGs led to an upregulation of 
GARS by 42.13% (P£0.01; Figure 4-13A, B) further cementing the relationship 
between UBA1 overexpression and GARS upregulation. 
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Figure 4-13 GARS was upregulated following overexpression of UBA1 in neuronal 
tissue 
Quantification of SMN, UBA1 and GARS expression levels in dorsal root ganglia from AAV9-
UBA1 injected wild-type FVB mice. A Representative fluorescent Western blot of SMN, 
UBA1 and GARS, a-Tubulin (a-Tub) as loading control. Protein sizes are as indicated (kDa). 
B Quantification of SMN, UBA1 and GARS protein levels after overexpression of UBA1 in 
vivo, showing a significant upregulation of UBA1 and GARS. Protein expression was 
normalised to loading control and then protein expression from AAV9-UBA1 injected mice 
was normalised to control. Unpaired two-tailed Student’s t-test; ns – not significant, ** P ≤ 
0.01; n=3 mice per condition. 
4.2.4.d Expression of the tRNA synthetase GARS showed UBA1-
dependency in vivo 
In order to confirm the UBA1-dependency of GARS in vivo, a model system where 
UBA1 could be downregulated was required. Therefore, zebrafish were injected with 
a morpholino directed against Uba1 to knockdown its expression (Wishart et al., 
2014). Interestingly, the knockdown of Uba1 caused a modest but significant 
increase in Smn expression in the zebrafish (15.88%, P£0.05; Figure 4-14A, B), 
suggesting interplay between the regulation of SMN and UBA1 protein levels. The 
morpholino caused a 33.66% reduction of Uba1 expression in the zebrafish (P£0.05) 
which in turn caused a 35.30% reduction in Gars expression (P£0.05; Figure 4-14A, 
B). This confirms the UBA1-dependency of GARS in vivo and demonstrates that of 
the target proteins investigated, the tRNA synthetase GARS was the most 
consistently UBA1-dependent protein on validation (Table 4-5). 
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Figure 4-14 The tRNA synthetase GARS is downregulated on UBA1 knockdown in vivo 
Quantification of SMN, UBA1 and GARS expression levels in zebrafish injected with Uba1 
morpholino (MO). A Representative fluorescent Western blot with SMN, UBA1 and GARS 
antibodies, a-Tubulin (a-Tub) as loading control. Samples run on the same gel in non-
contiguous lanes. B Quantification of Smn, Uba1 and Gars protein levels after knockdown of 
Uba1 in vivo. Significant upregulation of Smn and significant downregulation of Uba1 and 
Gars. Protein expression was normalised to loading control and then protein expression from 
Uba1 MO zebrafish was normalised to control. Unpaired two-tailed Student’s t-test; * P ≤ 
0.05; n=3 batches of zebrafish per condition. 
 
Table 4-5 UBA1-dependency of the tRNA synthetase GARS 
UBA1 and GARS expression changes in different model systems with modulation of UBA1 
levels, detected by Western blot. Expression changes are shown as fold change compared 
to control. Red cells indicate upregulation of the protein, green cells indicate downregulation. 
See 4.2.1.b, 4.2.3.a and 4.2.4.a - d for more information on validation experiments. 
 
Overall, here I have validated changes in target proteins identified in the 
proteomic screen in vivo. Following UBA1 overexpression in vivo, three of the five 
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remaining two target proteins (YARS and RanBP1) did not respond to UBA1 
overexpression in vivo. The expression of GARS was also significantly upregulated 
in DRGs from AAV9-UBA1 injected mice and, following UBA1 knockdown in vivo, 
GARS was significantly downregulated. Thus, clearly showing that GARS behaves 
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4.2.5 UBA1 influences GARS expression through a non-
canonical mechanism 
In this chapter, several novel downstream targets of UBA1 have been identified and 
validated as proteins with UBA1-dependent expression profiles. As the canonical 
role of UBA1 is in the ubiquitylation cascade, the role of ubiquitylation in mediating 
the UBA1-dependency of these downstream targets was investigated. Several studies 
have examined ubiquitylation of UPS target proteins by using ubiquitylation assays 
(Chang et al., 2004; Liu et al., 2017b; Lu et al., 2007; Vingill et al., 2016). This 
consists of transfecting cells with the protein of interest and ubiquitin along with 
modulating the expression of the protein hypothesised to be involved in the 
ubiquitylation of the target protein. Therefore, in this situation, the cells would be 
transfected with GARS, ubiquitin and expression of UBA1 would be modulated. 
Firstly however, it was necessary to investigate whether modulation of UBA1 
expression could lead to changes in ubiquitylation to identify whether UBA1 may 
influence the expression of its downstream targets through its canonical function in 
the UPS. 
4.2.5.a Modulation of UBA1 protein levels causes changes in overall 
ubiquitylation in vitro 
To investigate the effect of modulation of UBA1 expression on overall 
ubiquitylation, HEK293 cells were transfected with ubiquitin conjugated to a 
haemagglutinin tag (Ub-HA) alongside a control vector, or UBA1 overexpression 
vector (Figure 4-15A), or UBA1 siRNA (Figure 4-15B) (see Table 2-1 for control 
vector details). It can be seen that, as expected, following overexpression of UBA1 
overall polyubiquitylation of substrate proteins was increased; interestingly, 
monoubiquitin (free ubiquitin) levels were also increased (Figure 4-15A). Following 
UBA1 knockdown, there was a concomitant but less prominent change in overall 
ubiquitin with a modest reduction in polyubiquitylation of substrate proteins (Figure 
4-15B). Overall, this confirms that modulation of UBA1 levels leads to changes in 
ubiquitylation of substrate proteins, confirming that UBA1 can influence the 
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expression of its downstream targets through differential ubiquitylation in this model 
system. 
 
Figure 4-15 Overexpression of UBA1 increases overall levels of ubiquitylation 
Modulation of UBA1 expression leads to alteration in overall ubiquitylation of substrate 
proteins. HEK293 cells were transfected with ubiquitin-HA (Ub-HA) and (A) pCMV6-UBA1 or 
pCMV6 as a control vector, and (B) UBA1 siRNA or negative control 2 siRNA. 
Representative fluorescent Western blot of pan-UBA1 and ubiquitin (immunoblotted with 
antibody for HA tag); showing polyubiquitylated substrate proteins (Poly-Ub), and free 
Triubiquitin (Tri-Ub), diubiquitin (Di-Ub) and monoubiquitin (Mono-Ub). A Overall 
ubiquitylation is increased following overexpression of UBA1, and B decreased following 
knockdown of UBA1. Molecular weight of protein ladder markers are indicated in kDa. 
4.2.5.b Optimisation of ubiquitylation assay 
To optimise the ubiquitylation assay to ensure that ubiquitylation can be reliably 
detected, SMN was chosen as a positive control, as there are several accounts of a 
clear ubiquitylation pattern for this protein (Abera et al., 2016; Chang et al., 2004). 
HEK293 cells were transfected with a tagged SMN construct (tSMN) and a control 
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vector, or tSMN and Ub-HA; control HEK293 cells were also included (see method 
2.10; Figure 4-16). An IP was then performed for SMN followed by Western blot for 
both SMN and HA to detect ubiquitin. It can be seen that SMN has been successfully 
immunoprecipitated and that ubiquitylated tSMN has been detected (Figure 4-16). 
This replicates known SMN ubiquitylation patterns in the literature (Abera et al., 
2016; Chang et al., 2004) and demonstrates that the ubiquitylation assay can reliably 
detect ubiquitylated target proteins. 
 
Figure 4-16 Optimisation of ubiquitylation assay 
Ubiquitylation of SMN can be reliably detected by performing a ubiquitylation assay. HEK293 
cells were transfected with a tagged SMN construct (tSMN) and Ub-HA or pcDNA3.1 as a 
control vector, SMN was immunoprecipitated (IP) and immunoblot (IB) for both SMN and HA 
tag (to detect ubiquitin) was performed; Ub-tSMN indicates ubiquitylated tSMN. Molecular 
weight of protein ladder markers are indicated in kDa. 
4.2.5.c Modulation of UBA1 expression in vitro does not affect the 
ubiquitylation of GARS 
After optimisation of the ubiquitylation assay, it was possible to investigate whether 
downstream targets identified in the proteomics screen were differentially 
ubiquitylated on modulation of UBA1 expression. GARS was selected for this assay 
as it was the downstream target of UBA1 shown to be most reliably UBA1-
dependent. Like many other proteins in the literature, the ubiquitylation pattern of 
GARS showed a classic polyubiquitylation smear at high molecular weights (Liu et 
  Understanding the role of UBA1 in SMA 
Identifying downstream targets of UBA1 131 
al., 2017b; Lu et al., 2007; Vingill et al., 2016). Following overexpression of UBA1, 
in the presence of both GARS and ubiquitin, there was no change in the overall 
ubiquitylation of GARS (Figure 4-17A). Similarly, following UBA1 knockdown, 
there was also no change in the ubiquitylation of GARS compared to control UBA1 
expression (Figure 4-17B). A negative control GFP vector was included to ensure 
that any changes in ubiquitylation were not due to the presence of the GFP tag on 
GARS; importantly there was no difference in the polyubiquitin smears in these 
control conditions on modulation of UBA1 expression (Figure 4-17A, B). Therefore, 
this shows that modulation of UBA1 expression does not affect the ubiquitylation of 
GARS, suggesting that UBA1 influences the expression of GARS through a non-
canonical mechanism, independent of its role in the ubiquitylation cascade. 
 
Figure 4-17 UBA1 is not required for polyubiquitylation of the tRNA synthetase GARS  
The tRNA synthetase GARS is polyubiquitylated but is not differentially ubiquitylated by 
UBA1. HEK293 cells were transfected with GARS-GFP or GFP as well as Ub-HA and A 
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UBA1 or B UBA1 siRNA or the equivalent control vectors (see Table 2-1). 
Immunoprecipitation (IP) of GFP was performed on all samples. Input control samples were 
immunoblotted (IB) for UBA1 and GARS. IP samples were immunoblotted for GFP, showing 
successful IP of both GARS-GFP and GFP (A and B), and HA (to detect ubiquitin). IgG 
bands and polyubiquitylation (Poly-Ub) smears are indicated. High intensity immunoblots 
show Poly-Ub smears imaged at an increased laser power. A and B There is no change in 
the overall ubiquitylation of GARS following overexpression (A) or knockdown (B) of UBA1. 
Molecular weight of protein ladder markers are indicated in kDa. 
 
Here I have shown that modulation of UBA1 expression can lead to changes 
in overall ubiquitylation of target substrates. This difference is most pronounced 
following UBA1 overexpression compared to control UBA1 expression. I then went 
on to optimise a ubiquitylation assay to successfully detect ubiquitylated SMN. This 
assay was then used to investigate the effect of modulation of UBA1 expression on 
the ubiquitylation of the UBA1-dependent protein GARS. I showed that although 
GARS was polyubiquitylated, changes in UBA1 expression did not lead to 
differential ubiquitylation of GARS. 
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4.2.6 Meta-analysis of UBA1 proteomics in vitro and related 
datasets 
To assess the relevance of the protein families identified here for UBA1-
mediated degeneration in SMA, a comparison of this dataset with screens previously 
performed on SMA tissue or in which UBA1 was dysregulated was conducted (Table 
4-6). One dataset showed UBA1 overexpression and so was compared with the 
expression changes seen following UBA1 overexpression in vitro. The screen was a 
label-free proteomics screen on hearts from wild-type mice that were injected with 
AAV9-UBA1 on the day of birth. Proteins that were dysregulated in hearts from 
mice injected with AAV9-GFP on the day of birth were excluded from the study 
(Powis, 2016). This dataset therefore represents proteins changed following UBA1 
overexpression in vivo (Table 4-6). 
The translation elongation factor EEF2 showed the same directional change 
in both datasets, while EIF4A1 was upregulated in vivo. This was the same 
directional change as the other translation elongation and initiation factors in vitro 
suggesting consistency between the datasets. Proteins involved in nuclear transport 
showed less consistency between the two datasets. The nuclear import factor KPNB1 
was changed in the same direction in both datasets, however, KPNA2 was changed 
in the opposite direction in vivo compared to the other nuclear transport proteins in 
vitro. Although none of the same tRNA synthetases were present in the two datasets, 
all of the tRNA synthetases present in each dataset were upregulated (Table 4-6), 
thus demonstrating consistency of protein families dysregulated following UBA1 
overexpression in vitro and in vivo. Interestingly, some proteins not identified as 
UBA1-dependent in this screen show overlap between the datasets. Importantly, 
CTNNB1 (b-catenin), a known downstream target of UBA1 (Wishart et al., 2014), 
shows downregulation across both datasets (Table 4-6), highlighting the reliability of 
the screen performed in this study. 
To investigate the relevance of UBA1-dependent protein families to SMA, 
comparisons with several screens on SMA tissue were performed. The first study 
was a label-free proteomics screen on pre-symptomatic skeletal muscle (rostral 
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levator auris longus [LALr]) from control and SMA mice (Mutsaers et al., 2011). 
Saravestany et al. performed a label-free proteomics screen on Schwann cells 
isolated from peripheral nerves of control and symptomatic SMA mice (Aghamaleky 
Sarvestany et al., 2014). In the study by Wishart et al., iTRAQ comparative 
proteomics was performed on hippocampal synaptosomes from pre-symptomatic 
SMA and control mice (Wishart et al., 2014). Finally, Boyd et al., performed a 
microarray analysis of differentially vulnerable motor neuron pools (Boyd et al., 
2017). Apart from the study by Mutsaers et al. (2011), UBA1 expression was 
downregulated in all these studies and thus they were compared to the UBA1 
knockdown dataset (Table 4-6). 
As with the UBA1 overexpression comparison, proteins involved in each of 
the UBA1-dependent pathways were dysregulated in these datasets. Translation 
elongation and initiation factors were represented in each dataset; however, two of 
the four datasets show downregulation of EEF1G and EIF4A1 while they were 
upregulated in the UBA1 knockdown dataset. There was considerably less overlap 
between proteins involved in nuclear transport and marked variability in the 
directional changes of proteins involved in this pathway across the datasets (Table 
4-6). Again, several tRNA synthetases were identified in two of the screens, all of 
which were downregulated; this is consistent with the expression changes in the 
UBA1 knockdown dataset (Table 4-6). This comparison therefore, demonstrated the 
consistency of changes to tRNA synthetase expression and implicates the protein 
family as a relevant downstream pathway of UBA1 for SMA. A known downstream 
target of UBA1, UCHL1 (Powis et al., 2014), was changed in opposite directions 
between UBA1 knockdown and the SMA datasets (Table 4-6). Thus, indicating that 
other aspects of SMA molecular pathology may influence or modulate some of the 
proteins downstream of UBA1. 
Overall, there were both considerable overlap and marked variability of 
proteins and transcripts disrupted across these datasets. While the overlap of known 
downstream targets of UBA1 (UCHL1 and b-catenin) demonstrated the reliability of 
this screen, the most consistently changed UBA1-dependent protein family was 
tRNA synthetases, clearly suggesting these proteins are relevant for SMA.  
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Table 4-6 tRNA synthetases are consistently dysregulated across a range of datasets 
Overlap of proteins changed following UBA1 overexpression or UBA1 knockdown with other 
screens performed on SMA tissue or with modulated UBA1 levels. Red cells indicate 
upregulated proteins, green cells indicate downregulated proteins. White cells represent 
proteins changed below the 10% threshold used in this study. Cells with no values show that 
the protein was not detected in that screen or no change was reported in the dataset. UBA1 
OE, AAV9-UBA1 injected (Powis, 2016), UBA1 KD, Mutsaers et al., (2011) and Sarvestany 
et al., (2014) are presented as fold changes compared to control; Wishart et al., (2014) is 
presented as ratios compared to control. Ratios for Boyd et al., (2017) represent the 
transcript changes between motor neurons innervating the extensor digitorum longus 
(resistant to motor neuron pathology in SMA mice) and the tibialis anterior (vulnerable to 
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4.3 Discussion 
The studies described here were initiated to characterise the molecular consequences 
of disruption to UBA1 protein levels and identify pathways that may be relevant for 
UBA1-mediated degeneration in SMA. In the previous chapter, I demonstrated that 
in spinal motor neurons UBA1 expression is first decreased compared to control, 
then increased and then the expression is decreased again as the disease progresses 
(see Chapter 3). Therefore, to understand the effects of disruption to UBA1 levels in 
SMA, a model system where UBA1 could be both up- and downregulated was 
required.  
I began by optimising overexpression and knockdown of UBA1 in HEK293 
cells to generate samples for a label-free proteomics screen. The label-free 
proteomics was performed on control HEK293 cells, UBA1 overexpression and 
UBA1 knockdown samples, thereby allowing identification of UBA1-dependent 
expression profiles. Initial analysis revealed that tRNA synthetases, small molecule 
synthesis, translation elongation and nuclear transport were functions enriched within 
the dataset. On investigation of UBA1-dependent expression profiles, two broad 
groups of proteins were identified with one cluster from each group showing clear 
UBA1-dependency: proteins upregulated following UBA1 overexpression and 
downregulated following UBA1 knockdown or vice versa. Interestingly, the 
functions of the UBA1-dependent clusters of proteins were tRNA synthetases, 
translation elongation and nuclear transport. By generating networks and 
investigating enrichment of canonical pathways, it was possible to see UBA1-
dependency at the level of the individual protein within these protein families. 
Five proteins from the three UBA1-dependent protein families were chosen 
for further investigations: GARS and YARS (tRNA synthetases), RanBP1 and IPO4 
(nuclear transport proteins), and PDCD4 (inhibitor of translation initiation factors). 
Changes in the expression of these proteins were validated by Western blot on 
HEK293 cells with modulated UBA1 levels and then their UBA1-dependency was 
investigated in vivo. Although three of the five proteins showed expression changes 
on UBA1 overexpression in vivo, the tRNA synthetase GARS showed consistency in 
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expression changes across both the in vitro and in vivo validation experiments (Table 
4-5); clearly showing that this protein is UBA1-dependent and amenable to 
experimental modulation of UBA1 levels in vivo. 
As the aim of this screen was to identify UBA1-dependency that may be 
relevant for UBA1-mediated degeneration in SMA it was necessary to ascertain 
whether or not SMN could be having an influence on the proteins in this dataset. As 
there was no change in SMN expression in the samples used for this screen, it was 
possible to tease out UBA1-dependency and identify proteins that may be relevant 
for UBA1-mediated degeneration in SMA. Despite the expression of SMN remaining 
unchanged, due to top functional pathway changes in the dataset being neurological 
disorders, and skeletal and muscular disorders (Appendix 4), it is evident that this 
dataset is relevant for neuromuscular diseases. Interestingly, changes in cell growth 
and proliferation, and cell death and survival are the two most changed functional 
pathways in this dataset which correlates with the known role of UBA1 in the cell 
cycle and the effects of temperature sensitive mutations of UBA1 (Ghaboosi and 
Deshaies, 2007; Joo et al., 2007; Sugaya et al., 2014). Thus, further establishing the 
validity of this dataset as capturing known UBA1 specific effects but extending this 
to be able to identify downstream proteins relevant for disease pathways. 
One of the striking findings of the study was the lack of proteins involved in 
the ubiquitin proteasome system, with only a few proteins related to the UPS 
identified in the screen. These included BAG6, which is involved in ubiquitin-
mediated degradation of newly synthesised defective polypeptides (Minami et al., 
2010), and DCAF7, a substrate receptor for a cullin E3 ligase complex (Peng et al., 
2016). Interestingly, proteins involved in other ubiquitin-like signalling pathways 
were dysregulated within the dataset such as COPS3 (involved in deneddylation) 
(Lyapina et al., 2001) and RanBP2 which as well as being a nuclear import and 
export factor is an E3 ligase enzyme for SUMO (Pichler et al., 2002). Overall, this 
suggests that UBA1 may mediate some overlap between the different UBL pathways 
and indicates that this dataset has largely not identified proteins acting downstream 
of UBA1 within the UPS.   
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Despite this, the proteomic screen performed here may have identified 
proteins that are differentially ubiquitylated following changes in UBA1 protein 
levels, or proteins that are effectors or targets of non-canonical pathways of UBA1. 
UBA1 accounts for ~2% of the protein in all cells and so is thought not to be the 
rate-limiting factor in the UPS (Clague et al., 2015; Yang et al., 2013). Therefore, it 
is potentially unsurprising that very few changes in UPS enzymes have been 
identified. However, it may be possible to infer the role UBA1 had on specific 
clusters of proteins by analysing the expression profiles of these clusters. For 
example, proteins in Cluster 4 (see 4.2.2.c) may be changed due to an increase or 
decrease in the ubiquitylation activity of UBA1, while the expression changes of 
proteins in Cluster 1 may be caused by a different mechanism or function of UBA1. 
Moreover, a protein belonging to Cluster 5, proliferating cell nuclear antigen 
(PCNA), is known to have different functions within DNA repair pathways 
depending on whether it is mono-ubiquitylated or poly-ubiquitylated through K63 
(Cazzalini et al., 2014). This therefore, provides further insight into the role of UBA1 
in DNA-repair pathways and raises the possibility that UBA1 confers different 
functions on its downstream targets by the process of differential ubiquitylation. 
Another pathway that has been highlighted as relevant to UBA1 in this 
dataset is the glycolytic pathway. Interestingly, the glycolytic enzyme 
phosphoglycerate kinase 1 (PGK1) was dysregulated on modulation of UBA1 
protein levels. A recent study has implicated bioenergetics pathways and PGK1 in 
mediating motor neuron vulnerability in SMA (Boyd et al., 2017), therefore, showing 
clear links between the relevance of this study and SMA. As PGK1 is upregulated on 
UBA1 overexpression this also suggests that amelioration of disruption to this 
pathway could be one way UBA1 overexpression has beneficial effects on SMA 
mice (Powis et al., 2016). Moreover, it has previously been shown that a therapy 
targeting PGK1, which improved motor axon branching phenotypes in SMA 
zebrafish (Boyd et al., 2017), may influence HSP90 through PGK1, thus conferring 
protective phenotypes (Chen et al., 2015). Interestingly, heat-shock protein HSP90-
alpha (HSP90AA1) is upregulated on UBA1 overexpression (in vitro and in vivo) 
and down regulated on UBA1 knockdown – as it is in vulnerable pools of motor 
neurons (Boyd et al., 2017) (Table 4-6). Moreover, it has been shown that UBA1 and 
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HSP90 interact in vitro (Falsone et al., 2005). Thus, raising the possibility of UBA1 
overexpression exerting some of its neuroprotective effects through modulation of 
bioenergetics pathways. 
One of the key UBA1-dependent protein families identified in this screen was 
nuclear transport. Although this pathway showed less overlap with SMA datasets 
than other UBA1-dependent pathways identified, several studies have implicated 
defective nuclear transport as a mechanism contributing to motor neuron 
degeneration in amyotrophic lateral sclerosis (ALS) - an adult onset form of motor 
neuron disease. These studies focused on the effects of aggregated proteins on 
nucleocytoplasmic transport and identified that a wide range of proteins involved in 
different aspects of nucleocytoplasmic transport are modifiers of toxicity in ALS 
(Dormann et al., 2010; Freibaum et al., 2015; Jovicic et al., 2015; Woerner et al., 
2016; Zhang et al., 2015). This included proteins involved in RAN signalling such as 
RanGAP (also present in this dataset, see Appendix 2) (Freibaum et al., 2015; Zhang 
et al., 2015) and several importins including KPNA3 and IPO9 (Jovicic et al., 2015). 
Thus, indicating the relevance of defective nucleocytoplasmic transport in motor 
neuron degeneration in both ALS and, potentially, SMA. Although not present in one 
of the UBA1-dependent protein families, it is worth noting the presence of profilin-1 
(PFN1) in the dataset (see Appendix 2). PFN1 is involved in the regulation of actin 
dynamics and mutations in PFN1 have been shown to cause familial forms of ALS 
(Wu et al., 2012). This further establishes the overlap of ALS and downstream 
proteins of UBA1, suggesting relevance of these proteins and pathways for SMA 
pathogenesis. 
In the UBA1-dependent gene group translation elongation, the most 
biological relevance potentially comes from elongation factor 1-alpha 1 (eEF1A1) 
(Abbott et al., 2009; Doig et al., 2013; Newbery et al., 2005). eEF1A1 is an 
individually encoded variant of the translation elongation factor eEF1A, and has 98% 
similarity at the gene level and 92% similarity at the amino acid level with the other 
variant of eEF1A, eEF1A2. It is known that peptides identified during proteomic 
screens are often from completely conserved regions between the two variants 
making the identification of the protein challenging (Abbott et al., 2009). While 
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eEF1A1 is almost ubiquitously expressed, eEF1A2 is only expressed in neurons and 
muscle – with the expression of eEF1A2 replacing the expression of eEF1A1 in 
muscle during postnatal development. Interestingly, mutations in eEF1A2 
specifically cause an early-onset neurodegenerative phenotype in mice referred to as 
the wasted mouse model (Abbott et al., 2009; Doig et al., 2013; Newbery et al., 
2005). This clearly implicates the relevance of proteins identified in this dataset to 
neurodegeneration. However, due to the fact that commercially available antibodies 
for eEF1A recognise both variants equally and that the variants have differential 
distribution and developmental timings (Abbott et al., 2009), it was decided instead 
to further investigate PDCD4 from the translation elongation gene family. 
As previously mentioned, PDCD4 inhibits the interaction between translation 
initiation factors EIF4A1 and EIF4G, thereby inhibiting translation initiation and 
cap-dependent translation (Loh et al., 2009; Suzuki et al., 2008). Along with this 
PDCD4 is a tumour suppressor protein and may have a role in apoptosis 
(Palamarchuk et al., 2005). It is becoming apparent that cell death pathways are 
involved in the neurodegenerative process of the lower motor neurons in SMA 
(Murray et al., 2015; Sareen et al., 2012; Simon et al., 2016). Therefore, this could be 
a very important target to look into, not only because UBA1 has also been implicated 
in cancer but because it may provide more detail on the role of cell death in SMA. 
Moreover, investigating PDCD4 allowed the assessment of UBA1-dependency in the 
opposite direction to the other target proteins investigated and it was possible to 
validate this in vitro, a very important aspect of this study. 
The final UBA1-dependent protein family identified was tRNA synthetases. 
These enzymes function to attach specific amino acids to their corresponding 
tRNA(s), with most enzymes responsible for a single amino acid. For example, 
glycyl-tRNA synthetase (GARS) is responsible for catalysing the ligation of glycine 
to the 3’ end of its cognate tRNAs (Pang et al., 2014). Interestingly, mutations in 
several tRNA synthetases - GARS, YARS, KARS, AARS, MARS and HARS - have 
now been shown to cause Charcot-Marie-Tooth disease (CMT) (Antonellis et al., 
2003; Gonzalez et al., 2013; Jordanova et al., 2006; McLaughlin et al., 2012; 
McLaughlin et al., 2010; Vester et al., 2013). CMTs are hereditary peripheral 
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neuropathies with motor and sensory involvement. They primarily manifest with 
muscle weakness and wasting, and depending on the subtype, greater or lesser 
sensory involvement (Reilly et al., 2011). What was striking about this family of 
proteins was the consistency of their expression changes across a range of datasets 
(see Table 4-6). Furthermore, the range of different tRNA synthetases identified in 
SMA proteomic screens or screens with UBA1 expression changes is intriguing and 
even more so as when detected, the tRNA synthetases behave in exactly the same 
UBA1-dependent manner as each other (Table 4-6). Moreover, throughout the 
validation experiments performed in this study, the tRNA synthetases were the most 
consistently UBA1-dependent of the proteins investigated with GARS showing 
strikingly consistent UBA1-dependency on validation in vitro and in vivo (Table 
4-5). This clearly implicates tRNA synthetases as a protein family consistently 
disrupted in SMA or on modulation of UBA1 levels and suggests the importance of 
disruption to this protein family for UBA1-mediated degeneration in SMA, not least 
because mutations in several tRNA synthetases cause a related neuromuscular 
disease (Reilly et al., 2011). 
Finally, it was identified that UBA1 does not influence the ubiquitylation of 
its downstream target GARS. This is in line with recent work in which an 
interactomics screen to determine the ubiquitylation targets of UBA1 and UBA6 
identified GARS as one of the proteins specifically ubiquitylated by UBA6 (Liu et 
al., 2017b). Although this study did not validate GARS as a specific UBA6 target 
(Chang et al., 2013), the work performed here suggests that UBA1 does not have a 
role in mediating the degradation of GARS, thereby indirectly supporting the fact 
that GARS is specifically targeted for ubiquitylation by UBA6. Overexpression of 
UBA1 seems to have a more pronounced effect on overall protein ubiquitylation than 
UBA1 knockdown (Figure 4-15). This suggests that targets of UBA1 that are 
changed only after overexpression of UBA1 may be changed because of the 
canonical role of UBA1 as the main E1 ubiquitin activating enzyme. In contrast, 
proteins that are changed in a UBA1-dependent manner, including GARS, must be 
influenced by an independent, non-canonical mechanism of UBA1 that remains to be 
determined. 
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Overall, through comparative analysis with SMA and other UBA1 proteomic 
screens and a range of validation experiments, it is apparent that of the UBA1-
dependent protein families, the tRNA synthetases show the most consistent UBA1-
dependency. Furthermore, the alterations of tRNA synthetases in the range of 
datasets investigated here suggest some degree of molecular overlap between the two 
neuromuscular diseases SMA and CMT. There are however, several questions to 
address. Although it is clear that GARS itself behaves in a robustly UBA1-dependent 
manner, it has yet to be seen whether GARS or indeed other tRNA synthetases are 
disrupted in SMA. Finally, in order to investigate whether tRNA synthetases are 
involved in UBA1-mediated degeneration in SMA, it will be essential to ascertain if 
they are contributing to the pathogenesis of this disease. 
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Chapter 5 UBA1-mediated dorsal root ganglia 
pathology in SMA 
5.1 Introduction 
It is now well established that disruption to UBA1 is a key molecular feature of 
SMA. Although the therapeutic applications of UBA1 targeted therapies in SMA 
have been thoroughly investigated, the mechanism by which UBA1-mediates 
degeneration in SMA is unknown. In Chapter 4, I demonstrated that tRNA 
synthetases are one of the main UBA1-dependent protein families, with the tRNA 
synthetases GARS and YARS showing UBA1-dependency in vivo and in vitro 
respectively. The identification of the UBA1-dependency of tRNA synthetases raises 
the possibility of overlap between two neuromuscular disorders: SMA and Charcot-
Marie-Tooth disease (CMT). 
The canonical function of tRNA synthetases is to covalently couple each 
amino acid to its appropriate tRNA molecule (Pang et al., 2014). This happens in a 
two-step reaction whereby the tRNA synthetase first activates the amino acid and 
then it covalently links the amino acid to the tRNA, using ATP in this process. There 
is a different tRNA synthetase for each amino acid; for example, one tRNA 
synthetase will attach glycine to all tRNAs that recognise codons for glycine, this 
tRNA synthetase is called GARS and is encoded by the GARS gene (Ibba and Soll, 
2000). This one-to-one ratio of tRNA synthetase for amino acid is almost entirely 
adhered to with only one bifunctional tRNA synthetase: EPRS which catalyses the 
aminoacylation of both glutamic acid and proline tRNAs. The one-to-one ratio is 
necessary to ensure accurate amino acid selection by tRNA synthetases which, along 
with hydrolytic editing following the aminoacylation reaction, ensures accurate 
protein synthesis (Pang et al., 2014). 
The tRNA synthetases can be divided into two classes based on their 
chemical properties, the architecture of the catalytic domain and the consensus 
sequences. Class I aminoacyl tRNA synthetases mainly function as monomers while 
class II enzymes are almost exclusively oligomeric, functioning as homodimers or 
trimers (Pang et al., 2014). These two classes of tRNA synthetases bind ATP and 
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tRNA in different manners and so carry out the aminoacylation reaction by different 
mechanisms (Ibba and Soll, 2000). Interestingly, there are both cytoplasmic and 
mitochondrial tRNA synthetases and while mutations in mitochondrial tRNA 
synthetases are associated with mitochondrial diseases (Nafisinia et al., 2017; Pang et 
al., 2014), mutations in several cytoplasmic tRNA synthetases cause Charcot-Marie-
Tooth disease (Antonellis et al., 2003; Pang et al., 2014). 
CMT is a group of inherited neuromuscular disorders specifically affecting 
peripheral nerves with an estimated prevalence of approximately 1 in 2500 
worldwide (Reilly et al., 2011). CMT is characterised by progressive motor 
impairment leading to distal muscle weakness, alongside progressive sensory 
degeneration. Skeletal deformities are also present in some cases; however, life span 
is usually unaffected (El-Abassi et al., 2014). CMT can be caused by demyelination 
of axons, referred to as CMT type 1 (CMT1), axonal degeneration (CMT2) or a 
combination of both pathologies, referred to as intermediate CMT. The different 
types of CMT have different propensities for motor and sensory involvement and can 
be further subdivided depending on the gene containing the causative mutation (El-
Abassi et al., 2014; Reilly et al., 2011). 
CMT is genetically diverse with a range of causative mutations identified in 
more than 50 disease associated genes (El-Abassi et al., 2014). Interestingly, the 
gene products do not represent a single functional category with mutations occurring 
in genes encoding everything from myelin proteins and mitochondrial components to 
DNA binding proteins and proteins involved in proteins synthesis (El-Abassi et al., 
2014; Reilly et al., 2011). Not surprisingly therefore, the mechanisms underlying 
sensory and motor dysfunction remain unresolved. The largest gene family 
implicated in CMT is the tRNA synthetases. Mutations in six different tRNA 
synthetases – GARS, YARS, HARS, AARS, KARS and MARS – have been shown to 
cause CMT in patients. Mutations in all of these tRNA synthetases cause axonal 
degenerating or intermediate forms of CMT (Antonellis et al., 2003; Gonzalez et al., 
2013; Jordanova et al., 2006; McLaughlin et al., 2012; McLaughlin et al., 2010; 
Vester et al., 2013). Of these six tRNA synthetases, GARS and YARS are the most 
well documented and characterised. 
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One of the tRNA synthetases that causes CMT is the tyrosyl-tRNA synthetase 
(YARS). Two heterozygous missense mutations and one de novo deletion in YARS 
have been identified in three unrelated families affected with dominant intermediate 
CMT type C (DI-CMTC) (Jordanova et al., 2006; Thomas et al., 2016). DI-CMTC 
takes a slowly progressive course with distal muscle weakness primarily affecting 
lower limbs. Sensory complaints were less common than motor symptoms in DI-
CMTC pedigrees, however, sural nerve biopsies (sensory nerve) showed age-
dependent axonal degeneration and some segmental remyelination indicating the 
presence of some sensory pathology (Thomas et al., 2016). 
Similarly, mutations in the tRNA synthetase GARS cause CMT type 2D 
(CMT2D) (Antonellis et al., 2003). This is an axonal degenerating type of CMT and 
has limited sensory involvement compared to other forms of CMT (Motley et al., 
2010). The typical onset of CMT2D is during adolescence or young adulthood and it 
initially manifests as weakness and atrophy of the hand muscles (Antonellis et al., 
2003; Liao et al., 2015). This is unique within CMTs as they usually present as a 
length dependent peripheral neuropathy affecting the feet more than the hands 
(Reilly et al., 2011). Interestingly, some patients with dominant GARS mutations are 
diagnosed with distal SMA type V (dSMA-V), which is characterised by atrophy and 
weakness of distal muscles in the absence of the mild-to-moderate sensory 
involvement present in CMT2D (Antonellis et al., 2003; Eskuri et al., 2012). 
Moreover, a de novo mutation in GARS (Gly598Ala) has been shown to cause 
infantile SMA (Eskuri et al., 2012; James et al., 2006). This clearly indicates overlap 
between SMA and CMT, suggesting that GARS may have a pathogenic role in SMA. 
GARS was the first tRNA synthetase to be shown to be associated with CMT 
and so it is not surprising that CMT2D is the most studied tRNA synthetase mediated 
CMT to date. In particular, there are more animal models of CMT2D, and it is the 
only tRNA synthetase mediated CMT that currently has published mouse models. 
The mouse models of CMT were caused by spontaneous mutations or ENU 
mutagenesis and interestingly, the mutations in both of the mouse models correspond 
to mutations found in CMT2D patients (Achilli et al., 2009; Seburn et al., 2006). 
Homozygous mutations in GARS can cause embryonic lethality of the mice, while 
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the heterozygous mutations cause a variety of phenotypes ranging from mice with a 
life expectancy of six weeks and sensory and motor deficits to mice with a normal 
life expectancy and poor motor function and mild sensory involvement (Achilli et al., 
2009; Motley et al., 2010; Seburn et al., 2006). 
Interestingly, the sensory pathology in CMT2D is poorly understood. The 
greatest sensory deficit in CMT2D patients is in the perception of vibration 
(Sivakumar et al., 2005), a sensation that is detected by sensory neurons with large 
cell bodies and large diameter axons (Lallemend and Ernfors, 2012; Le Pichon and 
Chesler, 2014). However, biopsies from patient sural nerves show a selective loss of 
small sensory axons (Sivakumar et al., 2005); thus, bringing uncertainty to the 
sensory defects and pathology present in CMT2D. Due to the availability of mouse 
models with differing severity it has been possible to investigate the sensory deficits 
present in CMT2D models caused by different mutations. 
It has recently been shown, in two different mouse models, that there is a 
disruption to the fate of sensory neurons in the dorsal root ganglia (DRGs) in 
CMT2D (Sleigh et al., 2017a). The dorsal root ganglia reside within the spinal 
column and contain the sensory neuron cell bodies. These receive inputs from the 
periphery and synapse onto motor neurons in the ventral horn by sending projections 
into the spinal cord through the dorsal root (Le Pichon and Chesler, 2014; Sleigh et 
al., 2016). Sensory neurons within DRGs can be split into different subtypes 
depending on their function. Large area sensory neurons are generally either 
mechanoreceptors (sense touch) or proprioceptors (sense position and movement) 
both of which stain positive for NF200, a heavy neruofilament protein. Smaller area 
sensory neurons stain positive for peripherin (an intermediate neurofilament protein) 
and are nociceptive neurons sensing either noxious mechanical or noxious thermal 
stimuli (Lallemend and Ernfors, 2012; Le Pichon and Chesler, 2014; Sleigh et al., 
2017a). In CMT2D mice there is a severity dependent disruption to the fate of 
sensory neurons with an increase in the percentage of NF200 positive neurons and a 
decrease in the percentage of peripherin positive neurons. This in turn caused 
heightened sensation to painful stimuli and poor performance on balance specific 
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motor tests (Sleigh et al., 2017a). Thus, providing a clear overview of sensory 
pathology and phenotypes in CMT caused by mutations in GARS. 
I have previously identified that the tRNA synthetases are a major UBA1-
dependent protein family that show UBA1-dependency across multiple wild-type 
systems with modulated UBA1 protein levels (see 4.2.4). Interestingly, a range of 
tRNA synthetases show changes in SMA datasets and related screens (Table 4-6), 
indicating that they may be relevant for UBA1-mediated pathogenesis of SMA. 
However, it has yet to be seen whether GARS or indeed other tRNA synthetases are 
disrupted in SMA and whether they may be contributing to UBA1-mediated 
degeneration in SMA. In order to investigate this, I performed Western blots for 
UBA1, GARS and YARS on a range of tissues from the Taiwanese mouse model of 
SMA. After ascertaining that GARS expression is disrupted in neuronal tissues from 
SMA mice, I identified that the SMA mice have a disruption to sensory neuron fate 
consistent with the phenotype in CMT2D mice and that this phenotype is dependent 
on changes in UBA1 and GARS protein expression. Thus, clearly drawing parallels 
between the two neuromuscular disorders CMT and SMA. 
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5.2 Results 
5.2.1 Characterisation of tRNA ligase protein levels in SMA 
5.2.1.a Reduction of UBA1 protein levels in SMA mice 
To begin to understand the role and relevance of tRNA synthetases in SMA, it was 
first necessary to ascertain whether or not specific tRNA synthetases previously 
identified as being UBA1-dependent (Chapter 4) were also disrupted in SMA. For 
this, GARS and YARS were investigated as these tRNA synthetases are known to 
cause CMT. However, before investigating the expression levels of GARS and 
YARS in SMA models, it was essential to confirm that UBA1 expression was being 
consistently modified across the range of tissues used for these experiments. 
Therefore, the levels of UBA1 were quantified by fluorescent Western blot on spinal 
cord, dorsal root ganglia (DRG), muscle and heart from late symptomatic SMA mice 
and littermate controls. DRGs were chosen due to the recent implication of GARS in 
sensory neuron cell fate (Sleigh et al., 2017a) (see Figure 2-3). Spinal cord, muscle 
and heart were chosen as they represent a range of other tissues previously shown to 
be affected in SMA (Hamilton and Gillingwater, 2013; Powis et al., 2016). UBA1 
protein levels were reduced in SMA across all the tissues investigated, compared to 
control (Figure 5-1A). In spinal cord, DRG and muscle UBA1 was reduced by 
17.57% (P≤0.05), 27.59% (P≤0.05) and 21.45% (P≤0.05) respectively in SMA 
compared to control mice (Figure 5-1B), showing a similar disruption to UBA1 
expression across these tissues. However, the reduction of UBA1 expression in heart 
was much greater, with a reduction of 52.29% in SMA mice compared to control 
(P≤0.001, Figure 5-1B). While this demonstrates variability in the reduction of 
UBA1 protein levels seen at the whole tissue level in SMA, it indicates that in all 
tissues investigated UBA1 was reduced. 
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Figure 5-1 UBA1 expression is reduced in SMA mice 
Quantification of UBA1 protein levels in the Taiwanese mouse model of SMA. A 
Representative fluorescent Western blot of UBA1 protein levels, detected by pan-UBA1, in 
spinal cord, dorsal root ganglia (DRG), muscle and heart from late-symptomatic SMA mice 
and control littermates. GAPDH, a-Tubulin (a-Tub) and total protein (Ponceau) as loading 
controls. Protein sizes are as indicated (kDa). B Quantification of UBA1 protein levels in late-
symptomatic SMA mice showed significant downregulation of UBA1 across all tissues. UBA1 
expression was normalised to loading control, and then expression in SMA tissue was 
normalised to the control tissue. Unpaired two-tailed Student’s t-test; * P ≤ 0.05, *** P ≤ 
0.001; spinal cord: n=6 mice per condition; DRG, muscle, heart: n=3 mice per condition. 
5.2.1.b Dysregulation of tRNA synthetases in a mouse model of SMA 
After confirming that UBA1 expression was reduced in the tissues used for this 
experiment, the protein levels of GARS and YARS were investigated. Interestingly, 
the two tRNA synthetases were both dysregulated across a range of SMA tissues. 
However, the two tRNA synthetases showed different tissue specific effects and 
directional changes (Figure 5-2A, B). GARS showed no change in either muscle or 
heart but was significantly dysregulated in both nervous tissues investigated (Figure 
5-2A, C): in spinal cord GARS showed an increase of 100.02% compared to control 
(P≤0.05) and in DRG the increase was 55.75% (P≤0.05; Figure 5-2C). YARS 
remained unchanged in both DRG and muscle (Figure 5-2B) but the protein was 
significantly downregulated by 36.89% in spinal cord compared to control (P≤0.05) 
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and by 36.00% in heart (P≤0.05; Figure 5-2D). Importantly, increased levels of 
GARS in SMA are consistent with changes in GARS protein levels reported in 
CMT2D (Achilli et al., 2009; Motley et al., 2010), where they are increased during 
neonatal development, further drawing parallels between the two neuromuscular 
diseases of SMA and CMT. 
 
Figure 5-2 GARS and YARS are dysregulated in tissue from SMA mice 
Quantification of GARS and YARS protein levels in the Taiwanese mouse model of SMA. A, 
B Representative fluorescent Western blot of (A) GARS and (B) YARS protein levels in 
spinal cord, dorsal root ganglia (DRG), muscle and heart from late-symptomatic SMA mice 
and control littermates. GAPDH, a-Tubulin (a-Tub) and total protein (Ponceau) as loading 
controls. Protein sizes are as indicated (kDa). C, D Quantification of (C) GARS and (D) 
YARS protein levels in late-symptomatic SMA mice, protein expression was normalised to 
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loading control, and then expression in SMA tissue was normalised to the control tissue. C 
Significant upregulation of GARS in spinal cord and DRGs in SMA mice. D Significant 
downregulation of YARS in spinal cord and heart. Unpaired two-tailed Student’s t-test; ns – 
not significant, * P ≤ 0.05; n=3 mice per condition. 
5.2.1.c SMN is downregulated in dorsal root ganglia from SMA mice 
As protein levels of SMN have not previously been reported for DRGs in SMA, the 
expression of SMN in SMA DRGs was quantified by Western blot analysis. As 
expected, a significant reduction of SMN was seen in the DRG (Figure 5-3A) with an 
overall reduction of 92.27% in SMA compared to control (P≤0.001; Figure 5-3B). 
This is in line with the reduction of SMN protein seen in patients (Lefebvre et al., 
1997) and the lack of Smn transcript in DRGs from delta 7 SMA mice (Mentis et al., 
2011). Thus, this clearly shows that the relationship between SMN reduction and 
UBA1 reduction within the DRG is the same as that reported for other tissues 
previously investigated (Powis et al., 2016; Wishart et al., 2014). 
 
Figure 5-3 SMN protein levels are reduced in DRGs from SMA mice 
Quantification of SMN protein levels in dorsal root ganglia from SMA mice and control 
littermates. A Fluorescent Western blot of SMN protein levels, a-Tubulin (a-Tub) as loading 
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control. Protein sizes are as indicated (kDa). B Quantification of SMN protein levels in late-
symptomatic SMA DRGs showed significant downregulation of SMN. SMN expression was 
normalised to loading control, and then expression in SMA DRGs was normalised to the 
control. Unpaired two-tailed Student’s t-test; *** P ≤ 0.001; n=3 mice per condition. 
 
Here I have shown that UBA1 protein expression is reduced across a range of 
tissues, including dorsal root ganglia, in the Taiwanese mouse model of SMA. I then 
showed that the tRNA synthetases GARS and YARS are dysregulated across a range 
of SMA tissues. Interestingly, GARS expression is changed in the same direction in 
SMA tissue as it is in mouse models of CMT2D. 
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5.2.2 Identification of a novel sensory neuron phenotype in a 
mouse model of SMA 
5.2.2.a SMA mice have fewer mechano- and proprioceptive sensory 
neurons 
To identify whether the disruption to tRNA synthetases in SMA was relevant for 
UBA1-mediated pathogenesis of SMA, the disruption to sensory neuron fate seen in 
GARS mediated CMT was used as a phenotypic readout. To do this, spinal columns 
with DRGs were sectioned at 12µm and labelled for NF200 and peripherin, markers 
of larger area mechano- and proprioceptors, and of the smaller area nociceptors, 
respectively. The percentage of neurons positive for NF200, peripherin or both 
NF200 and peripherin were quantified for each pair of lumbar DRGs from lumbar 
segment 1 to segment 4 (L1-L4) (see Figure 2-3A) for three SMA mice and three 
control littermates. 
In the SMA mice the DRGs appeared smaller and had fewer NF200 positive 
neurons compared to the control mice (Figure 5-4A). There was a 17.41% reduction 
in NF200 positive neurons relative to control (P≤0.01; Figure 5-4B), with a 
concomitant increase in peripherin positive cells by 6.32% relative to control 
(P≤0.01; Figure 5-4C). Interestingly, there was no difference in the percentage of 
cells that stained positive for both NF200 and peripherin between control and SMA 
(Figure 5-4D). This clearly indicates the presence of a disruption to sensory neuron 
fate in SMA mice and therefore highlights symptomatic overlap between SMA and 
CMT2D, indicating that disruption to GARS protein levels may be contributing to 
disease phenotypes in SMA. 
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Figure 5-4 Disruption to sensory neuron fate in SMA dorsal root ganglia 
Spinal column sections from late-symptomatic SMA and control mice were labelled with 
NF200, peripherin and DAPI. A DRGs in SMA and control spinal columns labelled for NF200 
and peripherin; images of L2 DRGs. Top panels: dotted line indicates outline of DRG, box 
indicates area in bottom panel, scale bar = 100µm. Bottom panels: DRGs also labelled for 
DAPI, N indicates NF200 positive neurons, P indicates peripherin positive neruons, scale bar 
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= 10µm. B Quantification of the percentage of NF200 positive (NF200+) sensory neurons, 
showing a reduction in SMA mice. C Quantification of the percentage of peripherin positive 
(peripherin+) neurons, showing an increase in SMA mice. D Quantification of the percentage 
of sensroy neruons positive for both NF200 and peripherin. N=3 mice, n=8 DRGs per 
mouse. Mann-Whitney test; ns – not significant, ** P ≤ 0.01. 
5.2.2.b Sensory neurons and dorsal root ganglia are smaller in SMA 
mice 
The DRGs in SMA mice appeared qualitatively smaller than those in control mice. 
Therefore, to quantify changes in the overall size of the DRGs, the total cell number 
per DRG was analysed. Interestingly, CMT2D mice also showed a reduction in the 
area of sensory neuron cell bodies compared to control and so the area of NF200 and 
peripherin positive neurons was quantified. In SMA mice there was an overall 
reduction in total number of sensory neurons per DRG by 13.76% (P≤0.05), 
representing an average of 32 fewer neurons per DRG compared to control (Figure 
5-5A). The area of NF200 positive cells was also reduced in SMA with an average 
reduction of 105µm2 per NF200 positive neuron compared to control (P≤0.001; 
Figure 5-5B). In contrast, there was no difference in the area of the peripherin 
positive neurons in SMA mice compared to control (Figure 5-5C). This suggests that 
sensitivity to changes in GARS levels in populations of NF200 positive sensory 
neurons drives the DRG phenotypes seen in SMA. 
After measuring the area of sensory neuron cell bodies in SMA and control 
mice, the range of areas of NF200 and peripherin positive neurons was analysed. In 
both control and SMA DRGs there was a clear distinction between the area range of 
peripherin positive and NF200 positive neurons, with a small (100µm2) region of 
overlap between the two (Figure 5-5D, E). Although the smallest peripherin positive 
neurons were the same size in both control and SMA mice, the largest peripherin 
positive neurons were smaller in SMA (Figure 5-5E). Which, along with the smaller 
size of NF200 positive neurons in SMA, resulted in a 50µm2 shift of the overlap 
range of NF200 and peripherin positive neuron area in SMA (Figure 5-5D, E). 
Overall, this provides a useful tool to be able to identify whether a sensory neuron is 
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likely to be NF200 or peripherin positive, based on the neuron area, in both control 
and SMA mice. 
 
Figure 5-5 Reduction in the area of NF200 positive neurons in SMA mice 
Characterisation of DRG phenotypes in late-symptomatic SMA mice. A Quantification of total 
cell number in control and SMA mice, showing a reduction of sensory neuron number in 
SMA mice. N=3 mice, n=8 DRGs per mouse. B, C Quantification of the area of NF200 (B) 
and peripherin (C) positive neurons. N=3 mice, n=20 neurons per mouse. B Reduction in the 
area of NF200 positive neurons. A-C Unpaired two-tailed Student’s t-test; ns – not 
significant, * P ≤ 0.05, *** P ≤ 0.001. D, E Frequency distribution of the area of NF200 and 
peripherin positive neurons for (D) control and (E) SMA mice represented as percentage of 
neurons per 50µm2 area range. Dotted lines indicate range of overlap of areas for NF200 
positive and peripherin positive neurons for both control and SMA mice. 
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5.2.2.c Dorsal root ganglia in lumbar segments 1-2 are preferentially 
affected in SMA 
The sensory neurons within the DRGs of the lumbar region receive inputs from the 
lower limbs and lower aspects of the trunk, with each DRG receiving inputs from a 
defined anatomical region. As an overview, DRGs within the lumbar segments 1 and 
2 (L1-L2) receive inputs from the proximal lower limb, while L3-L4 receive inputs 
from the distal lower limb. As the proximal muscles of the body are primarily 
affected from the motor perspective in SMA, differences between the two groups of 
DRGs were investigated (Hamilton and Gillingwater, 2013; Kolb and Kissel, 2011; 
Ladak et al., 2014). Within L1 and L2 DRGs, there were significant differences in 
the percentages of NF200 (23.57% relative reduction, P≤0.01) and peripherin 
positive neurons (8.47% relative increase, P≤0.05) in SMA compared to control 
(Table 5-1). However, within the L3-L4 DRGs, there was only a significant 
difference in the percentage of NF200 positive neurons (12.01% relative reduction, 
P≤0.05; Table 5-1). This further suggests that the NF200 positive neurons are 
primarily affected in SMA and that the phenotype is more consistent in the L1 and 
L2 DRGs which receive the inputs from the body regions primarily affected in SMA. 
Similarly, there was only a significant difference in the total number of cells 
per DRG within DRGs from lumbar segments 1 and 2 and not in DRGs from lumbar 
segments 3 and 4 (Table 5-1). NF200 positive neurons were significantly smaller in 
SMA mice than in control mice in both L1-L2 and L3-L4 DRGs (Table 5-1), again 
suggesting that the NF200 positive sensory neurons are primarily affected in SMA. 
Interestingly, although there was no significant difference in the area of peripherin 
positive neurons in DRGs from all lumbar regions investigated, peripherin positive 
neurons were significantly smaller in L1-L2 DRGs (Table 5-1). Thereby indicating 
that the primary DRG pathology is present within the L1-L2 DRGs, thus reflecting 
the pattern of muscle weakness seen in SMA. 
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Table 5-1 DRGs in lumbar segments 1-2 are primarily affected in SMA 
Quantification of phenotypes in DRGs from lumbar segments 1-2 (L1-L2) and 3-4 (L3-L4) in 
SMA mice compared to control. Values shown are mean ± SEM. P-values are calculated 
from Mann-Whitney test for percentage of neurons and from unpaired two-tailed Student’s t-
test for total neuron number and neuron area, ns – not significant; * P ≤ 0.05, ** P ≤ 0.01; 
N=3 mice per condition, n=4 DRGs per mouse; for area measurements N=3 mice per 
condition, n=10 neurons per mouse. 
 
Here I have identified that there is a disruption to sensory neuron fate in SMA 
mice. The dorsal root ganglia in SMA have a reduction in the percentage of NF200 
positive neurons with a concomitant increase in the percentage of peripherin positive 
neurons. The area of NF200 positive sensory neurons is also reduced in SMA mice 
compared to control. Importantly, the phenotypes are more pronounced in dorsal root 
ganglia from lumbar regions 1 and 2, which are those that receive inputs from the 
body regions primarily affected in SMA. 
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5.2.3 Changes in UBA1 and GARS protein levels lead to the 
DRG phenotypes seen in SMA 
5.2.3.a Reduction in the nuclear to cytoplasmic ratio of UBA1 in SMA 
dorsal root ganglia 
To investigate whether disruption to UBA1 expression was directly responsible for 
the disruption to sensory neuron fate in SMA, the ratio of UBA1 expression was 
investigated at the level of individual sensory neurons within the DRG. In order to do 
this spinal column sections containing DRGs from late-symptomatic SMA and 
control mice were stained for UBA1 (using the UBA1a antibody), along with SMI32 
as a cytoplasmic marker and DAPI for a nuclear marker. The DRGs were imaged at 
constant confocal settings and an intensity analysis was performed to quantify the 
nuclear to cytoplasmic ratio (NCR) of the intensity of the staining (see method 
2.8.1). In DRGs from SMA mice there was less prominent nuclear labelling and 
more pronounced cytoplasmic labelling of UBA1a, suggesting a shift in the 
distribution of UBA1 (Figure 5-6A). Quantification revealed a reduction of the NCR 
by 23.83% in SMA mice compared to controls (control=5.34, SMA=4.07; P≤0.0001; 
Figure 5-6B). Moreover, the distribution of the NCR showed a clear shift in the 
range from an NCR of 1 to 15 for control to an NCR range of 0 to 11 for SMA 
(Figure 5-6C). Therefore, this indicates that UBA1 protein expression is changed 
within sensory neurons in SMA. 
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Figure 5-6 Nuclear UBA1 expression is reduced in sensory neurons in SMA dorsal 
root ganglia 
Spinal column sections from late-symptomatic SMA and control mice were labelled with 
UBA1a, cytoplasmic (SMI32) and nuclear (DAPI) markers. A DRG sensory neruons show a 
reduction in nuclear UBA1a in SMA mice compared to control; images of L2 DRGs. Top 
panels: dotted line indicates outline of DRG, box indicates area in bottom panels, scale bar = 
100µm. Bottom panels: N indicates NF200 positive-like neurons, P indicates peripherin 
positive-like neruons, scale bar = 10µm. B Late-symptomatic SMA DRG sensory neurons 
show a reduction in the nuclear to cytoplasmic ratio of UBA1a compared to control mice. 
Unpaired two-tailed Student’s t-test; **** P ≤ 0.0001. C Frequency distribution of the NCR of 
UBA1a in sensory neurons from control and SMA mice shows a shift to lower NCR in SMA 
mice; represented as percentage of neurons per NCR range, bin width=1. N=3 mice per 
condition, n=112 sensory neurons per mouse. 
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5.2.3.b The nuclear to cytoplasmic ratio of GARS expression is 
increased in DRGs from SMA mice 
After identifying that UBA1 protein levels were changed within sensory neurons, to 
investigate if downstream changes in GARS expression were responsible for the 
disruption to sensory neuron fate in SMA, GARS expression in sensory neurons was 
quantified. To do this, the same experimental procedure was used as for UBA1 but 
the immunohistochemistry was performed for GARS, SMI32 and DAPI. The sensory 
neurons in the SMA mice showed an increase in the NCR of GARS by 5.06% 
compared to control (control=0.9627, SMA=1.011; P≤0.001; Figure 5-7A, B). 
However, it appeared that the larger area neurons had a selective increase in the 
intensity of GARS labelling (Figure 5-7A). This was confirmed by analysing the 
distribution of GARS NCR, where there was no change in the range of GARS NCR 
but there was an increase in the percentage of neurons with a higher NCR: 43.53% of 
SMA sensory neurons were present in the bin centred on an NCR of 1.2, compared to 
only 34.71% of control sensory neurons (Figure 5-7C). Interestingly, here changes in 
GARS expression occurred in the opposite direction to changes in UBA1 expression 
which was the same trend as seen by Western blot of whole DRGs and spinal cord. 
Therefore, this indicates that changes in the expression of UBA1 and downstream 
changes in GARS expression are likely to be causing the disruption to sensory 
neuron fate in SMA mice. 
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Figure 5-7 Nuclear GARS expression is increased in sensory neurons in SMA dorsal 
root ganglia 
Spinal column sections from late-symptomatic SMA and control mice were labelled with 
GARS, cytoplasmic (SMI32) and nuclear (DAPI) markers. A DRG sensory neruons show an 
increase in GARS intensity in SMA mice compared to control; images of L2 DRGs. Top 
panels: dotted line indicates outline of DRG, box indicates area in bottom panels, scale bar = 
100µm. Bottom panels: N indicates NF200 positive-like neurons, P indicates peripherin 
positive-like neruons, scale bar = 10µm. B Late-symptomatic SMA DRG sensory neurons 
show an increase in the nuclear to cytoplasmic ratio of GARS compared to control mice. 
Unpaired two-tailed Student’s t-test; *** P ≤ 0.001. C Frequency distribution of the NCR of 
GARS in sensory neurons from control and SMA mice show an increase in the percentage of 
neurons with a higher GARS NCR in SMA; represented as percentage of neurons per NCR 
range, bin width=0.4. N=3 mice per condition, n=112 sensory neurons per mouse. 
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5.2.3.c Expression of GARS and UBA1 are consistently changed in 
NF200 positive neurons from lumbar segments 1-2 
In order to investigate whether changes in UBA1 and GARS expression were 
responsible for NF200 positive neurons being primarily affected in SMA, the 
expression of these proteins was quantified in different sub-populations of sensory 
neurons within the DRG. To do this, the area ranges of peripherin positive and 
NF200 positive neurons for both control and SMA were used to classify neurons as 
NF200 positive-like (control ≥ 450µm2; SMA ≥ 400µm2) or peripherin positive-like 
sensory neurons (control ≤ 350µm2; SMA ≤ 300µm2; Figure 5-5D, E). There was a 
significant reduction in UBA1a NCR in NF200 (31.16%; P≤0.0001) and peripherin 
(32.97%; P≤0.0001) positive like neurons in lumbar DRGs from L1-L2 in SMA mice 
compared to control (Table 5-2). In SMA mice there was also a significant reduction 
in the NCR of UBA1a in peripherin positive neurons from DRGs L3-L4 (37.86% 
reduction compared to control; P≤0.0001; Table 5-2). Interestingly, however, the 
NCR of GARS was only significantly changed in the NF200 positive like neurons in 
DRGs from regions L1-L2 (8.41% increase in SMA compared to control; P≤0.01; 
Table 5-2). Consistent with previous findings, UBA1a and GARS expression was 
changed in opposite directions within the NF200 positive sensory neurons in the 
dorsal root ganglia from L1-L2. Therefore, this confirms that NF200 positive 
neurons in DRGs from L1-L2 are primarily affected in SMA and identifies that it is 
changes in UBA1 and GARS expression within these cells that drives this phenotype. 
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Table 5-2 GARS and UBA1 expression are consistently changed in NF200 positive 
neurons in L1-L2 dorsal root ganglia 
Quantification of UBA1 and GARS NCR in sensory neuron cell bodies from SMA mice 
compared to control from lumbar DRGs in segments L1 to L2 and L3 to L4. Values shown as 
mean ± SEM. P-values are calculated from an unpaired two-tailed Student’s t-test; ns – not 
significant, ** P ≤ 0.01, **** P ≤ 0.0001. N=3 mice per condition, the number of sensory 
neurons per condition are recorded in the table as n number. 
 
Here I have shown that UBA1 is dysregulated in sensory neurons in dorsal 
root ganglia from SMA mice compared to control littermates. Likewise, 
dysregulation of GARS was observed in SMA mice sensory neurons, being 
particularly evident in larger area sensory neurons. By using the known area ranges 
of NF200 and peripherin positive neurons, I then identified that the disruption to 
expression of GARS and UBA1 was particularly pronounced in NF200 positive 
neurons from DRGs in lumbar segments 1 and 2. Thus, changes in the expression of 
GARS and UBA1 are likely a key driver of the disruption to sensory neuron fate in 
SMA.  
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5.2.4 Overexpressing UBA1 in SMA mice rescues the 
disruption to sensory neuron fate 
5.2.4.a Overexpression of UBA1 in vivo reduces GARS expression in 
dorsal root ganglia 
To identify whether the disruption to sensory neuron fate in SMA mice was 
dependent on, and not just correlated with, changes in UBA1 and GARS expression, 
the effect of UBA1 overexpression on sensory neuron fate in SMA was investigated. 
To do this, SMA mice were injected with AAV9-UBA1 on the day of birth and 
tissue was harvested at postnatal day 8. Before analysing the proportions of NF200 
and peripherin positive sensory neurons, it was necessary to identify whether the 
overexpression of UBA1 was causing changes in GARS expression. Therefore, 
quantitative Western blot was performed on lumbar DRGs from SMA mice and 
SMA mice treated with AAV9-UBA1 to investigate protein levels of UBA1, GARS 
and SMN. There was no significant difference in SMN expression between SMA 
mice and AAV9-UBA1 SMA mice (Figure 5-8A, B) indicating that SMN was 
unlikely to be causing changes in protein expression or alterations to sensory neuron 
fate in these mice. The expression of UBA1 was increased by 16.60% (P≤0.05) in the 
DRGs from treated SMA mice compared to untreated SMA mice (Figure 5-8A, B), 
confirming that UBA1 had been upregulated in vivo by treatment with AAV9-UBA1. 
This upregulation of UBA1 lead to a reduction in GARS expression by 29.22% 
(P≤0.05; Figure 5-8A, B). This demonstrates that UBA1 overexpression in SMA 
mice leads to a reduction in GARS expression in DRGs, with GARS changed in the 
opposite direction to UBA1 and returning towards expression levels in control mice. 
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Figure 5-8 Overexpression of UBA1 in SMA mice leads to a reduction of GARS protein 
levels in dorsal root ganglia 
Quantification of SMN, UBA1 and GARS protein levels in dorsal root ganglia from SMA mice 
and SMA mice treated with AAV9-UBA1. A Representative fluorescent Western blot of SMN, 
UBA1 and GARS in dorsal root ganglia from late-symptomatic SMA mice and SMA mice 
injected with AAV9-UBA1 (SMA+AAV9-UBA1), a-Tubulin (a-Tub) as loading control. Protein 
sizes are as indicated (kDa). B Quantification of SMN, UBA1 and GARS protein levels 
showing significant upregulation of UBA1 and downregulation of GARS. Protein expression 
was normalised to loading control, and then protein expression in SMA+AAV9-UBA1 DRGs 
was normalised to SMA DRGs. Samples run on the same gel in non-contiguous lanes. 
Unpaired two-tailed Student’s t-test; ns – not significant, * P ≤ 0.05; n=3 mice per condition. 
5.2.4.b Treatment with AAV9-UBA1 rescues the disruption to sensory 
neuron fate in SMA mice 
To investigate whether the reduced GARS expression caused by UBA1 
overexpression in vivo lead to a rescue of sensory neuron fate, the percentage of 
NF200 and peripherin positive neurons was quantified in SMA mice and SMA mice 
treated with AAV9-UBA1. The sensory neuron fate phenotype was investigated in 
DRGs from lumbar segments 1 to 2, as these were the lumbar DRGs in which the 
disruption to sensory neuron fate was present in the SMA mice (see section 5.2.2.c). 
The results from control mice have been included for reference. Overexpression of 
UBA1 in SMA mice fully rescued the disruption to sensory neuron fate (Figure 
5-9A). The percentage of NF200 positive neurons was increased by 45.89% in SMA 
mice treated with AAV9-UBA1 relative to untreated SMA mice (P≤0.01; Figure 
5-9B). There was also a significant reduction in the percentage of peripherin positive 
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neurons in SMA mice treated with AAV9-UBA1 by 8.59% relative to untreated 
SMA mice (P≤0.05; Figure 5-9C). Interestingly, there was no difference in the 
percentage of sensory neurons positive for both NF200 and peripherin (Figure 5-9D). 
Compared to the reference data from control mice, there was no significant 
difference in the percentage of NF200 positive, peripherin positive or NF200 and 
peripherin positive neurons in SMA mice treated with AAV9-UBA1 (Figure 5-9B-
D). This therefore indicates that overexpression of UBA1 in vivo, and the resulting 
reduction in GARS protein levels, fully rescues the disruption to sensory neuron fate 
in SMA mice, thereby confirming that this novel SMA phenotype is dependent on 
disruption to UBA1 and GARS protein levels. 
 
Figure 5-9 UBA1 overexpression in vivo rescues disruption to sensory neuron fate in 
SMA mice 
Spinal column sections from SMA mice and SMA mice treated with AAV9-UBA1 were 
labelled with NF200 and peripherin. Data from control mice is shown as reference. A DRGs 
in spinal columns labelled for NF200 and peripherin, dotted line indicates outline of DRG, 
scale bar = 100µm; images of L2 DRGs. B Quantification of the percentage of NF200 
positive (NF200+) neurons showing an increase in SMA mice treated with AAV9-UBA1 
compared to untreated SMA mice. C Quantification of the percentage of peripherin positive 
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(peripherin+) sensory neurons showing a reduction in SMA mice treated with AAV9-UBA1 
compared to untreated SMA mice. D Quantification of the percentage of sensory neurons 
positive for both NF200 and peripherin. N=3 mice per condition, n=4 DRGs per mouse. 
Kruskal-Wallis test with Dunn’s multiple comparisons test; ns – not significant, * P ≤ 0.05, ** 
P ≤ 0.01. 
5.2.4.c Overexpression of UBA1 in vivo rescues sensory neuron 
number and area in SMA mice 
To investigate whether treatment with AAV9-UBA1 fully rescued the DRG 
phenotypes seen in SMA mice, the total number and area of sensory neurons was 
quantified. In SMA mice treated with AAV9-UBA1 there was an increase by 72.42% 
in the total cell number per DRG in SMA mice overexpressing UBA1 compared to 
untreated SMA mice (P≤0.0001; Figure 5-10A). There was also an increase in the 
area of NF200 positive neurons by an average of 129µm2 per neuron in treated SMA 
mice compared to untreated SMA mice (P≤0.01; Figure 5-10B). Similarly, peripherin 
positive neurons showed an average increase of 40µm2 in the SMA mice injected 
with AAV9-UBA1 (P≤0.01; Figure 5-10C). This therefore shows that treatment with 
AAV9-UBA1 fully rescues the range of dorsal root ganglia phenotypes seen in SMA 
mice. 
 
Figure 5-10 Overexpression of UBA1 rescues DRG phenotypes in SMA mice 
DRG phenotypes are rescued in SMA mice treated with AAV9-UBA1. A Quantification of 
total cell number in SMA mice and SMA mice injected with AAV9-UBA1 (SMA+AAV9-UBA1) 
showed an increase in sensory neuron number following overexpression of UBA1 in SMA 
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mice. N=3 mice per condition, n=4 DRGs per mouse. B, C Quantification of the area of (B) 
NF200 and (C) peripherin positive neurons. N=3 mice per condition, n=10 neurons per 
mouse. B Increase in the area of NF200 positive neurons. C Increase in the area of 
peripherin positive neurons. A-C Unpaired two-tailed Student’s t-test; ns – not significant, ** 
P ≤ 0.01, **** P ≤ 0.0001. 
 
In this section, I have shown that treatment with AAV9-UBA1 leads to a 
robust overexpression of UBA1 and a downregulation of GARS expression in DRGs 
from SMA mice. I then demonstrated that this results in a complete rescue of the 
disruption to sensory neuron fate seen in SMA mice as well as increasing the total 
neuron number per DRG. Finally, I showed that UBA1 overexpression in SMA mice 
rescued the reduction in area of NF200 and peripherin positive sensory neurons. 
Overall, this shows that the disruption to sensory neuron fate in SMA is both 
reversible and regulated by a UBA1 and GARS-dependent mechanism.  
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5.3 Discussion 
The studies described here were initiated to investigate the effect of UBA1-
dependent changes in tRNA synthetases on the pathogenesis of SMA. Initially I 
showed that the expression of the tRNA synthetases GARS and YARS was disrupted 
across a range of tissues from SMA mice. Importantly, all of the tissues investigated 
also showed a reduction in the expression of UBA1. I then characterised a novel 
phenotype in SMA whereby the fate of sensory neurons within the dorsal root 
ganglia was perturbed. Interestingly, the total number of sensory neurons and the 
area of the larger, NF200 positive neurons were both reduced in SMA mice 
compared to control littermates. I then showed that in the NF200 positive neurons the 
reduction in UBA1 NCR leads to an increase in the NCR of GARS and it is these 
expression changes that drive the sensory neuron phenotypes in SMA mice (Figure 
5-11). Finally, by treating SMA mice with AAV9-UBA1, I demonstrated that 
overexpression of UBA1 in SMA DRGs causes a reduction of GARS protein 
expression. This rescued not only the disruption to sensory neuron fate, but also the 
area of sensory neurons and the total number of sensory neurons per DRG (Figure 
5-11). Overall, here I have shown that the disruption to sensory neuron fate and 
sensory neuron area in SMA mice is reversible and dependent on a UBA1 and 
GARS-dependent pathway. 
 
Figure 5-11 Overview of sensory neuron phenotypes in SMA mice 
Reduced protein levels of UBA1 in dorsal root ganglia from SMA mice resulted in an 
increase in the expression of the tRNA synthetase GARS. This disruption to GARS 
expression distorted the proportions of sensory neuron subpopulations in the DRG, resulting 
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in a reduction of the medium to large area, NF200 positive neurons and an increase of the 
small area, peripherin positive sensory neurons. The NF200 positive neurons were also 
smaller in SMA and there is a reduction in the total number of sensory neurons per DRG. 
Treating SMA mice with AAV9-UBA1 increased UBA1 expression in the DRG which reduced 
GARS expression levels. This in turn rescued the disruption to sensory neuron fate, 
increased the area of NF200 positive neurons and increased the total cell number per DRG. 
 
A disruption to sensory neuron fate was recently described in mouse models 
of CMT2D, which are caused by mutations in Gars leading to increased expression 
of GARS (Achilli et al., 2009; Motley et al., 2010). Compared to other CMTs, 
CMT2D has relatively mild sensory involvement (Antonellis et al., 2003; El-Abassi 
et al., 2014; Liao et al., 2015) and in a severe mouse model of CMT2D there is 
approximately a 20% absolute shift in the proportions of the different sensory neuron 
subtypes (Sleigh et al., 2017a). In the milder mouse model of CMT there is a 10% 
shift in the proportions of NF200 and peripherin positive sensory neurons (Sleigh et 
al., 2017a). In the study performed here an absolute reduction of NF200 positive 
neurons by 5% and concomitant 5% increase in peripherin positive neurons in SMA 
was identified. Based on the changes in sensory neuron proportions in mouse models 
of CMT2D, the level of disruption to sensory neuron fate identified here is in line 
with the phenotypic involvement of the sensory system in SMA. 
To elaborate, several studies have investigated changes in the sensory system 
in various models of SMA. For example, one study identified that sensory neurons 
cultured from a severe mouse model of SMA do not develop properly due to defects 
in neurite outgrowth and growth cone morphology. The cultured neurons also 
showed a reduction of b-actin protein and mRNA in growth cones (Jablonka et al., 
2006) – a phenotype that is seen in SMN deficient motor neurons (Rossoll et al., 
2003). Interestingly, the study also found that there was no difference in the total 
number of sensory neurons per L5 DRG in SMA mice compared to control (Jablonka 
et al., 2006). This agrees with the results presented here as there was no significant 
difference in the number of sensory neurons per DRG from lumbar segments L3-L4, 
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but this difference was present in L1-L2 DRGs, thus indicating a consistent finding 
of no change in total cell number in lower lumbar DRGs. 
Two other studies also investigated sensory neurons within the DRG using 
antibodies against paravalbumin - a specific marker of proprioceptive neurons 
(Lallemend and Ernfors, 2012; Le Pichon and Chesler, 2014). One study showed no 
significant difference in the number of paravalbumin positive neurons in L1 DRGs 
from P13 (late-symptomatic) SMA delta 7 mice (Mentis et al., 2011), while the other 
study showed a significant reduction in the number of paravalbumin positive neurons 
in L4 DRGs from P14 SMA delta 7 mice (~13% reduction compared to control) 
(Ling et al., 2010). This suggests some variation in the presence of a sensory neuron 
phenotype in SMA mice. However, the quantification methods were strikingly 
different between the two studies indicating the relevance and reliability of a 
quantification method that relies on relative percentages, as used in this study, as 
opposed to quantification of total numbers of neurons and then in one case, 
multiplication to arrive at an estimated number of paravalbumin positive neurons per 
DRG (Ling et al., 2010; Mentis et al., 2011; Sleigh et al., 2017a). Importantly, the 
DRGs from SMA mice shown in both studies appear considerably smaller than their 
control counterparts, indicating a consistent reduction in size of dorsal root ganglia in 
SMA (Ling et al., 2010; Mentis et al., 2011).  
It has also been shown that there is a reduction in myelinated dorsal root 
axons (Ling et al., 2010) and a reduction in the number of synapses from 
proprioceptive sensory neurons onto motor neurons in SMA mice compared to 
control (Ling et al., 2010; Mentis et al., 2011). This suggests that the reduction in 
NF200 positive cells identified here may result in a reduction of processes of this 
sensory neuron subtype to the spinal column and thus a reduction of synapse number 
on motor neurons. Interestingly, the reduction in proprioceptive synapses onto motor 
neurons is differentially affected by the spinal cord level within the lumbar region. 
Synapses onto L1 motor neurons and medial L5 motor neurons are primarily lost, 
while synapses onto L5 lateral motor neurons are largely spared (Mentis et al., 2011). 
Importantly, the difference identified between these different pools of motor neurons 
are consistent with the differences seen in sensory neuron fate between L1-L2 DRGs 
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and L3-L4 DRGs. As previously mentioned the L1-L2 region receive inputs from 
and innervate trunk and proximal lower-limb body regions, while L3-L5 lumbar 
regions receive inputs from and innervate more distal lower limb regions, that is 
excluding the medial motor neurons in L5 which innervate trunk regions (Ladak et 
al., 2014; Mentis et al., 2011). This demonstrates that phenotypes affecting the 
sensory system in SMA consistently affect DRGs and motor neurons related to the 
body regions primarily affected in SMA. 
Furthermore, it has also been shown that the reduction of proprioceptive 
synapses onto motor neurons can be reversed by increasing SMN expression 
specifically in motor neurons (Gogliotti et al., 2012). Similarly, a study in maternal-
zygotic smn mutant zebrafish showed a reduction in the number of dorsal root 
ganglia neurons and that this could be rescued by overexpressing SMN in motor 
neurons (Hao le et al., 2015). However, another study showed that an increase in 
SMN expression in paravalbumin positive neurons was necessary, alongside SMN 
increase in motor neurons, to fully restore the number of proprioceptive synapses 
onto motor neurons in SMA mice (Fletcher et al., 2017). This study also showed that 
selective upregulation of SMN in proprioceptive neurons was required to normalise 
the hyperexcitability of motor neuron membranes seen in SMA and restore firing 
frequency of the motor neurons. It was also identified that blocking 
neurotransmission specifically in proprioceptive neurons caused severe motor 
defects, shortened lifespan of wild-type mice and rendered the motor neurons 
dysfunctional (Fletcher et al., 2017). This suggests that the reduction of NF200 
positive neurons in SMA mice may be causing additional defects to motor neurons, 
including hyperexcitability and reduced firing frequency. 
Moreover, there are several reports that identify sensory pathology in SMA 
patients. For example, an evaluation of electroneuromyographic studies in 15 SMA 
type 1 patients revealed that 26.7% of the patients had abnormal sensory conduction 
(Duman et al., 2013). In another study, sural nerve biopsies were performed on 19 
patients with infantile SMA. All 7 of the type 1 SMA patients showed axonal 
degeneration, 5 of which had abnormal sensory conduction; however, none of the 
patients with type 2 or 3 SMA showed signs of sensory involvement (Rudnik-
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Schoneborn et al., 2003). Furthermore, a recent case report described a 3-month-old 
boy who presented with hypotonia and weak muscles. Genetic diagnosis confirmed 
type 1 SMA however, the patient also had an absence of sensory responses on nerve 
conduction studies (Reid et al., 2016) further suggesting sensory involvement in 
some cases of SMA. Interestingly, several studies conducted on presumed SMA 
cases (patients diagnosed with SMA before genetic testing was available for the 
disease) also identified sensory pathology in SMA, finding not only degeneration of 
sensory nerves but also ballooned neurons and chromatolysis within the dorsal root 
ganglia (Carpenter et al., 1978; Marshall and Duchen, 1975; Murayama et al., 1991). 
Interestingly, a genetically-confirmed case of XL-SMA (caused by mutations in 
UBA1) showed nodules within the dorsal root ganglia, indicating a loss of sensory 
neurons (Dlamini et al., 2013). Together these studies demonstrate that not only are 
sensory phenotypes present in SMA patients as well as the models used to study the 
disease, but that the DRGs themselves may also be affected in SMA patients 
showing the relevance of the phenotypes identified here. The involvement of sensory 
phenotypes in SMA also starts to draw overlap between CMT and SMA at the 
patient level. 
One of the key features of this study was highlighting the overlap of SMA 
and CMT at both the phenotypic and molecular level. The identification of sensory 
phenotypes in SMA patients starts to shed some light on the phenotypic overlap of 
these diseases in patients. The identification of individuals with genetically 
confirmed cases of co-segregation of SMA and CMT further highlights phenotypic 
overlap of these diseases. For example, an 11-month-old patient presented with 
muscle weakness and genetic diagnosis confirmed SMA type 2, however, the patient 
also showed an absence of sensory nerve conduction and slow motor conduction 
velocities, symptoms typical of peripheral neuropathy (Fernandez et al., 2016). 
Through investigation of the patient’s family history, a paternal uncle with CMT1A 
was identified and genetic testing confirmed the patient had a duplication of PMP22 
and therefore, along with SMA type 2 received a diagnosis of CMT1A (Fernandez et 
al., 2016). Similarly, a second patient from a family with several members affected 
by CMT1A presented with muscle weakness and bilateral foot deformities. Genetic 
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analyse confirmed diagnosis of SMA type 3 and CMT1A (Jedrzejowska et al., 2008), 
indicating that the pathologies of these two diseases can occur simultaneously. 
Furthermore, and perhaps more interestingly, several genes have now been 
identified in which mutations can cause a range of phenotypes including both CMT 
and SMA-like diseases. As previously mentioned, mutations in GARS can cause 
classical infantile SMA, distal SMA type 5 and most commonly CMT2D (Antonellis 
et al., 2003; Eskuri et al., 2012; James et al., 2006). Similarly, mutations in MORC2, 
which encodes a nuclear protein involved in transcriptional regulation and DNA 
repair, can cause CMT type 2Z or SMA (Schottmann et al., 2016; Sevilla et al., 
2016). Patients with CMT2Z generally present in the second decade of life with 
distal weakness and sensory impairment, while the patients with an SMA-like 
disease present in infancy with an SMA-like phenotype that progresses with 
increasing sensory loss and weakness and atrophy of muscles (Schottmann et al., 
2016). Mutations in MORC2 have also been shown to cause an SMA-like disease 
with neuropathy, paralysis of the diaphragm and cerebellar atrophy but with an 
absence of sensory involvement (Sevilla et al., 2016). 
Likewise, mutations in IGHMBP2 have been shown to cause both CMT type 
2S and SMA with respiratory distress type 1 (SMARD1) (Cottenie et al., 2014; 
Jedrzejowska et al., 2014; Liu et al., 2017a; Pedurupillay et al., 2016). Patients with 
mutations in IGHMBP2 can present with sensorimotor axonal neuropathy, 
progressive weakness and wasting of muscles and are thus diagnosed with CMT2S; 
these patients do not generally have compromise of the respiratory system (Cottenie 
et al., 2014; Liu et al., 2017a). Conversely, mutations in IGHMBP2 also cause 
SMARD1 where patients present with infantile SMA and generally die within the 
first year of life due to respiratory failure (Jedrzejowska et al., 2014; Pedurupillay et 
al., 2016). It is predicted that the mutations in IGHMBP2 that cause SMARD1 are 
more severe and lead to lower protein expression of IGHMBP2 than mutations that 
cause CMT2S; thus, suggesting a spectrum of phenotypes distinguished by the 
specific mutations in IGHMBP2 (Cottenie et al., 2014; Pedurupillay et al., 2016). 
Together, not only does this highlight considerable overlap between the phenotypes 
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of CMT and SMA, but it also demonstrates overlap of genetic pathways and 
molecular causes of these diseases. 
Moreover, molecular overlap of CMT and SMA is further emphasised by a 
range of rare cases with mutations in genes in pathways known to be affected or 
involved in one of these diseases. For example, mutations in LRSAM1, an E3 
ubiquitin ligase, cause CMT type 2G (Peeters et al., 2016). Patients with CMT2G 
display mild lower-limb axonal sensorimotor neuropathy and fatty atrophy in 
musculature. Interestingly, it has been shown that mutations in LRSAM1 do not cause 
reduced levels of the protein or disrupt the enzymes ubiquitylation activity but they 
do lead to several transcriptional changes, including increased levels of NEDD4L (an 
E3 ligase) and TNFRSF21 a regulator of axonal degeneration (Peeters et al., 2016). 
This suggests that mechanisms of degeneration in CMT2G may be similar to UBA1-
mediated degeneration in SMA, as it is unlikely that alteration of canonical 
ubiquitylation activity is responsible for pathogenesis of either of these diseases. 
Finally, mutations in PIEZO2 can cause a neuromuscular disease 
characterised by muscle atrophy, mild sensory involvement, delayed motor 
milestones and scoliosis (Delle Vedove et al., 2016). PIEZO2 encodes a 
mechanosensitive ion channel responsible for mechanosensation of light touch and 
proprioception. Therefore, loss of PIEZO2 protein due to these mutations causes 
disturbed proprioception leading to aberrant muscle development and function (Delle 
Vedove et al., 2016), suggesting that defects within sensory neurons themselves can 
lead to muscle defects and delayed motor development. 
Together, these studies have demonstrated that tRNA synthetases are 
dysregulated within several tissues from a mouse model of spinal muscular atrophy 
and that UBA1-dependent dysregulation of the tRNA synthetase GARS is 
responsible for mediating a novel sensory neuron phenotype in SMA mice. Although 
disruption to sensory neurons has previously been identified in models of SMA, this 
is the first study to demonstrate disruption to sensory neuron fate and reduction in the 
size of sensory neurons within the dorsal root ganglia. Importantly, by targeting the 
molecular pathway responsible for these phenotypes it was possible to correct the 
disruption to sensory neuron fate and area, revealing a truly UBA1-dependent 
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phenotype in SMA mice and elucidating a mechanism of UBA1-mediated 
pathogenesis of SMA. The work here also suggests a reason for disruption to the 
sensory neurons identified in other studies on SMA models and draws closer the link 
between SMA and CMT from both a phenotypic and molecular perspective. 
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Chapter 6 General discussion 
6.1 Overview of results 
In this thesis, several questions were addressed to increase our understanding of the 
cellular and molecular mechanisms underlying UBA1-mediated pathogenesis of 
SMA.  
The first of these was to investigate whether UBA1 expression was disrupted 
at the single cell level in motor neurons (section 1.4, Aim 1). Following on from 
work previously reported in the literature I was able to show that UBA1 distribution 
varied between different cell types and for the first time characterise UBA1 
distribution in a healthy population of neurons. Interestingly, in these motor neurons 
a dramatic cellular redistribution of UBA1 was seen over-time in culture, a feature 
that was not present in long term cultures of dividing cells. I also showed that the 
NCR of UBA1 changed during neonatal development in lower motor neurons in 
healthy mice in vivo. Perhaps the most important finding of this section of work, was 
the identification of a significant reduction of UBA1 expression in spinal motor 
neurons from pre-symptomatic SMA mice compared to control littermates. This 
significantly builds upon and extends previous work, suggesting that UBA1 
reduction is likely to be a driving force of motor neuron degeneration in SMA. 
Furthermore, the identification that UBA1 is mislocalised in pre-symptomatic SMA 
spinal motor neurons and the different distribution patterns seen in different cell 
types suggests that disruption to UBA1 distribution may contribute to motor neuron 
susceptibility in SMA. 
Secondly, I sought to investigate what effect the pre-symptomatic reduction 
in UBA1 had on the proteome by identifying and validating novel downstream 
targets of UBA1 (section 1.4, Aim 2). Analysis of a label-free proteomic screen on 
HEK293 cells in which UBA1 expression levels had been modulated revealed three 
UBA1-dependent protein families: nuclear transport, translation elongation and 
tRNA synthetases. Individual proteins from each of these families were validated as 
being UBA1-dependent, both in vitro and in vivo. By performing a cross-comparison 
of the dataset generated here with SMA proteomic screens and related studies, I 
  Understanding the role of UBA1 in SMA 
General discussion 180 
identified that several different tRNA synthetases are disrupted across a range of 
studies suggesting that this protein family may be relevant for UBA1-mediated 
pathogenesis of SMA. Following this I demonstrated that, while changes to UBA1 
expression levels lead to alterations in overall ubiquitylation, one of the main UBA1-
dependent proteins identified in this screen, GARS, is not differentially ubiquitylated 
by UBA1. Therefore, this suggests that UBA1 influences the changes in expression 
of some of its downstream targets through non-canonical mechanisms.  
Finally, I investigated whether the novel downstream targets identified here 
were relevant for UBA1-mediated pathogenesis of SMA (section 1.4, Aim 3). To 
address this, Western blots were performed on SMA tissue which revealed that both 
YARS and GARS showed significant dysregulation across a range of tissues in SMA 
mice. To investigate whether this dysregulation was relevant for pathogenesis of 
SMA, the proportions of different sensory neuron subtypes were quantified in SMA 
mice as there is disruption to sensory neuron fate in CMT2D mice which have 
mutated GARS and elevated expression of GARS (Sleigh et al., 2017a). Not only did 
SMA mice show a disruption to sensory neuron fate in DRGs, but the sensory 
neurons themselves were smaller and there was reduction in the overall number of 
sensory neurons. Importantly, there was disruption to both UBA1 and GARS 
distribution in SMA sensory neurons. Following overexpression of UBA1 in SMA 
mice, the disruption to GARS expression seen in DRGs was reversed and all sensory 
neuron pathologies were rescued. Therefore, this work identified a novel SMA 
phenotype that is caused by UBA1-dependent disruption of GARS expression. 
Together the data presented in this thesis clearly implicates the pre-
symptomatic reduction of UBA1 in SMA pathogenesis, identifies downstream 
targets of UBA1 that are relevant for UBA1-mediated degeneration, and reveals a 
novel sensory neuron phenotype in SMA, dependent on one of the downstream 
targets of UBA1. This work has implications for a wider range of neurodegenerative 
and neuromuscular disorders than SMA, not least because disruption to ubiquitin 
homeostasis is a common feature of multiple neurodegenerative conditions but also 
because part of this study focused on characterising a phenotype shared by two 
neuromuscular diseases. 
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6.2 Ubiquitin pathways in disease 
In the first instance the studies performed here have clear relevance for XL-SMA as 
the causative mutations for this form of SMA reside within UBA1 (Dlamini et al., 
2013; Jedrzejowska et al., 2015; Ramser et al., 2008). Interestingly, the mutations for 
XL-SMA all cluster within exon 15 of UBA1 which forms part of the active 
adenylation domain (Figure 1-3) (Ramser et al., 2008). The active adenylation 
domain is responsible for binding both ATP and ubiquitin and so is essential for the 
catalytic activity of the enzyme (Lee and Schindelin, 2008). However, mutations 
identified in the active adenylation domain of UBA1 demonstrate only a partial loss 
of function (Tokgoz et al., 2006). Furthermore, mutations within UBA1 that do cause 
a reduction in adenylation activity do not completely eliminate the ability of UBA1 
to activate ubiquitin and transfer it to an E2 enzyme (Lao et al., 2012). Therefore, it 
is unlikely that mutations in UBA1 cause XL-SMA through alterations in the ability 
of the enzyme to perform its function in the ubiquitylation cascade. Interestingly, it 
has also been shown that mutations in UBA1 cause the enzyme to become less stable 
than wild-type UBA1 and thus lead to increased degradation (Lao et al., 2012). It is 
therefore conceivable that there may be reduced levels of UBA1 in XL-SMA and so 
while the mechanisms behind SMA pathogenesis in XL-SMA have yet to be 
elucidated, the work performed here may shed some light onto pathways disrupted 
downstream of UBA1 in XL-SMA. 
Similarly, as the proteomic screen was performed on HEK293 cells in which 
overexpression and knockdown of UBA1 had been performed, the data generated 
here may be relevant for a variety of diseases in which UBA1 expression is 
disrupted. However, different aspects of the screen may be more relevant for 
different diseases. For example, downstream targets of UBA1 changed following 
UBA1 overexpression may be relevant to understand cancers, such as leukemia and 
multiple myeloma, where UBA1 is over active and leads to increased protein 
ubiquitylation (Xu et al., 2010). Protein families identified as UBA1-dependent may 
be relevant for different neurodegenerative conditions. For example, as previously 
mentioned, it has recently been shown that nuclear transport is disrupted in ALS and 
that UBA1 binds to mutant FUS (one of the genetic causes of ALS) (Dormann et al., 
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2010; Wang et al., 2015; Woerner et al., 2016). Wild-type FUS protein primarily 
resides within neuronal nuclei but mutant FUS forms aggregates within the 
cytoplasm (Dormann et al., 2010; Wang et al., 2015). As UBA1 only binds to mutant 
FUS, sequestration of UBA1 into FUS aggregates may contribute to the defective 
nuclear transport seen in this disease and may also disrupt UBA1 localisation; a 
feature that could itself lead to detrimental effects on neuron health and function. 
Indeed, it has been shown that UBA1 is sequestered in Lewy bodies in models of PD 
(McNaught et al., 2002), demonstrating that UBA1 does get sequestered into disease-
associated protein aggregates. Moreover, it has also been shown that redistribution of 
SMN to mutant FUS aggregates leads to reduction in axonal SMN (Groen et al., 
2013), thus demonstrating that sequestration of proteins in disease-associated protein 
aggregates can lead to a redistribution of the protein. 
Furthermore, in this study I demonstrated that UBA1 does not regulate 
expression of its downstream target GARS through differential ubiquitylation. This 
raises the possibility of UBA1 influencing GARS, and perhaps other tRNA 
synthetases and downstream targets, through a non-canonical mechanism. A non-
canonical role of UBA1 has previously been identified in the regulation of autophagy 
(Chang et al., 2013). Moreover, the possible non-canonical function of UBA1 in 
mediating axon development (Watts et al., 2003), along with the work presented 
here, indicate that UBA1 may have multiple non-canonical functions. Not only does 
this expand our knowledge of the basic biology of UBA1 but it could also be crucial 
for a range of neurodegenerative conditions. Both UPS activity and autophagy are 
important for clearing damaged and misfolded proteins but both pathways are 
affected in several neurodegenerative conditions (Bedford et al., 2011; Kubben and 
Misteli, 2017; Shen and Mizushima, 2014), and UPS activity is known to decline 
with age (Tydlacka et al., 2008). Although activation of ubiquitin by UBA1 is not 
thought to be the rate limiting step in the UPS (Bedford et al., 2011), if UBA1 is 
redistributed, as occurs in AD and HD (Lopez Salon et al., 2000; Wade et al., 2014), 
or inhibited as in some cases of idiopathic PD (Chou et al., 2008; Viquez et al., 
2012), the requirement of UBA1 for both canonical and non-canonical functions 
(including autophagy) may not be met. Indeed, it has been shown for HD that UBA1 
function eventually declines below a critical threshold required to maintain protein 
  Understanding the role of UBA1 in SMA 
General discussion 183 
homeostasis (Wade et al., 2014). Therefore, these alterations in UBA1 localisation or 
expression may exasperate disruption to the UPS and autophagy in a range of 
neurodegenerative conditions characterised by accumulation of ubiquitylated 
proteins. 
6.3 tRNA synthetases in health and disease 
It is now well established that mutations in several different tRNA synthetases cause 
a variety of subtypes of Charcot-Marie-Tooth disease (Antonellis et al., 2003; 
Gonzalez et al., 2013; Jordanova et al., 2006; McLaughlin et al., 2012; McLaughlin 
et al., 2010; Vester et al., 2013). Here, two different tRNA synthetases were shown 
to be dysregulated in SMA tissue and the UBA1-dependent disruption to one of these 
tRNA synthetases was shown to cause a novel sensory neuron phenotype in SMA 
mice. Thus, extending the range of diseases in which tRNA synthetases, in particular 
GARS, are implicated in. Despite this, it is still unclear how mutations and 
dysregulation of tRNA synthetases lead to degeneration. 
6.3.1 Non-canonical functions of tRNA synthetases 
Of the tRNA synthetases that harbour mutations causative for CMT, GARS and 
YARS are the most studied. As previously mentioned (see 5.1), mutations in GARS 
cause CMT2D (Antonellis et al., 2003) and mutations in YARS cause DI-CMTC 
(Jordanova et al., 2006). In both of these diseases loss of aminoacylation activity is 
not a common feature of the different mutant GARS and YARS proteins (Motley et 
al., 2010; Niehues et al., 2015; Seburn et al., 2006). Recent work on CMT2D has 
identified that mutant GARS aberrantly binds to the transmembrane receptor protein 
neuropilin 1 (Nrp1) and disrupts the interactions of Nrp1 with its natural binding 
partners (He et al., 2015; Sleigh et al., 2017b). Therefore, the current understanding 
is that mutations most likely cause a toxic gain-of-function of GARS or lead to 
aberrant interaction with the wild-type GARS protein (He et al., 2015; Malissovas et 
al., 2016; Sleigh et al., 2017b). In contrast, the disruption to sensory neuron fate 
identified in SMA mice is unlikely to be due to either of these mechanisms as GARS 
expression is dysregulated in the absence of GARS mutations. 
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Interestingly, however, several non-canonical functions of tRNA synthetases 
have recently been identified where tRNA synthetases are adapted for dual roles that 
coexist with their aminoacylation activity (Pang et al., 2014). For example, GARS 
can be secreted from macrophages and exhibits cytokine-like properties by binding 
cadherin which leads to inhibition of growth of ERK-activated tumour cells (Park et 
al., 2012). It has also been demonstrated that GARS functions as a chaperone that 
critically supports neddylation by stabilising NEDD8 conjugated to E2 enzymes (Mo 
et al., 2016). This indicates a role of GARS in a related pathway to the UPS and 
suggests that dysregulation of GARS expression may indeed lead to disruption of 
sensory neuron fate through a mechanism not reliant on the aminoacylation activity 
of the enzyme. 
Similarly, YARS has been shown to have a non-canonical function in which 
it is cleaved into N- and C-terminal halves during apoptosis to generate two distinct 
cytokines with immunological activity (Wakasugi and Schimmel, 1999). Moreover, 
YARS has also been shown to become highly acetylated during oxidative stress 
which leads to a reduction in the aminoacylation activity of the enzyme and an 
increase in its nuclear translocation. Once in the nucleus, the acetylated YARS then 
protects against DNA damage caused by oxidative stress by activating DNA repair 
genes (Cao et al., 2017). Together this indicates that tRNA synthetases may have 
multiple non-canonical functions alongside their role in aminoacylation. Several 
other non-canonical functions of a range of tRNA synthetases have been identified 
including roles in mitochondrial functions, translation and transcriptional regulation 
and a wide range of immunological processes (Ibba and Soll, 2000; Pang et al., 
2014). Therefore, disruption of any one or any combination of these non-canonical 
functions of tRNA synthetases could contribute to neuronal degeneration in diseases 
such as CMT2D, DI-CMTC and SMA. 
6.3.2 tRNA synthetases in neurodegeneration 
Aside from their involvement in CMT and the dysregulation of tRNA synthetases in 
SMA, tRNA synthetases have also been implicated in other neuronal and 
neurodegenerative conditions (Park et al., 2008). For example, mutations in the 
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editing domain of the alanyl-tRNA synthetase gene (AARS) does not impair 
aminoacylation activity of AARS but reduces the accuracy of the enzyme leading to 
mistranslation (inclusion of the wrong amino acid at codons for alanine) (Nangle et 
al., 2006; Park et al., 2008). Mistranslation in turn leads to accumulation of 
misfolded proteins and a severe ataxia phenotype caused by Purkinje cell loss in the 
cerebellum in mice harbouring editing domain mutations in AARS (Lee et al., 2006; 
Nangle et al., 2006). Mutations in the editing domain of AARS have also been shown 
to cause cardioproteinopathy characterised by ubiquitylated protein aggregates and 
mitochondrial dysfunction in cardiomyocytes (Liu et al., 2014). This again suggests 
overlap of ubiquitin pathways and disruption to specific tRNA synthetases in disease 
pathogenesis. It has also been demonstrated that lysyl-tRNA synthetase interacts with 
mutant Cu/Zn superoxide dismutase 1 (SOD1) in ALS but not wild-type SOD1 
(Kunst et al., 1997), again suggesting a modifying effect on ALS disease 
pathogenesis by a disruption of a specific tRNA synthetase. 
Moreover, there is considerable evidence implicating disruption to 
aminoacyl-tRNA synthetase complex interacting multifunctional protein-2 (AIMP2) 
in Parkinson’s disease (Park et al., 2008). The multisynthetase complex is composed 
of nine tRNA synthetases and three non-synthetase proteins (AIMP1, AIMP2 and 
AIMP3). While it is thought that there may be cell-type specific differences in the 
tRNA synthetases that are part of this complex, it is known that the three AIMPs 
form the core of the multisynthetase complex (Ibba and Soll, 2000; Pang et al., 
2014). On release from the complex, the tRNA synthetases trigger specific signalling 
activities dependent on the non-canonical activities of the enzymes (Pang et al., 
2014). Therefore, it is understood that the multisynthetase complex acts as a 
‘functional depot’ for these tRNA synthetases (Ibba and Soll, 2000). 
It has been shown that AIMP2 is a substrate of the E3 ligase Parkin which, 
when mutated in PD, causes upregulation of AIMP2. This upregulation of AIMP2 
leads to apoptosis in neuronal cells (Ko et al., 2005; Park et al., 2008). Indeed, 
transgenic overexpression of AIMP2 in mice leads to an age-dependent loss of 
dopaminergic neurons and PD-like phenotypes (Lee et al., 2013). This is thought to 
occur via activation of poly(ADP-ribose) polymerase-1 (PARP1) which is also 
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known to be activated by YARS (Lee et al., 2013; Sajish and Schimmel, 2015). This 
clearly suggests a pathological connection of AIMP2 and tRNA synthetases to PD. 
Furthermore, this suggests that the involvement of UBA1 in idiopathic PD 
pathogenesis (Chou et al., 2008; Viquez et al., 2012) and the sequestration of UBA1 
to Lewy bodies (McNaught et al., 2002) may lead to UBA1-mediated degeneration 
through alterations in the functions of the UBA1-dependent tRNA synthetases 
identified in this thesis. 
6.4 The importance of investigating overlapping 
disease mechanisms 
One of the main strengths of this study was the ability to draw on recent findings 
concerning a related neuromuscular disorder and use this as a phenotypic readout for 
molecular involvement of specific proteins in SMA disease pathogenesis (Sleigh et 
al., 2017a). This highlights not only the feasibility, but also the importance, of 
investigating overlap between different diseases. In many neurodegenerative 
conditions, there is no clear picture of the mechanisms mediating selective 
degeneration of neuronal populations or how mutations lead to disease (Kubben and 
Misteli, 2017). Moreover, in most neurodegenerative conditions, a range of 
individual cellular defects have been implicated in disease pathogenesis (Ehrnhoefer 
et al., 2011). However, there are invariably extensive connections between the 
different cellular defects that contribute to neurodegeneration and so it is largely 
unclear where the molecular tipping point between health and disease lies within this 
complex network of interrelated cellular processes. While the sequence of events 
leading to degeneration may vary between different diseases, the interconnected 
nature of these processes may provide the opportunity to learn lessons from one 
disorder that have an impact for other disorders and may provide insight into 
therapeutic strategies beneficial for multiple neurodegenerative conditions by 
targeting specific cellular pathways disrupted across a range of these diseases 
(Ehrnhoefer et al., 2011; Kubben and Misteli, 2017). 
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6.5 Implications of novel phenotypes for treatment of 
SMA 
The work presented in this thesis also has implications for SMA from a therapeutic 
perspective. One of the issues that remains to be resolved in terms of SMN-
dependent therapy is whether restoration of SMN levels will be more important in 
the central nervous system (CNS), or in both the CNS and peripheral tissues, to 
successfully treat SMA (Hua et al., 2015; Hua et al., 2011; McGovern et al., 2015). 
Several studies in rodent models of the disease have shown that SMN restoration in 
extra-neural tissues and organ systems will likely be necessary for amelioration of 
the systemic SMA phenotype (Hua et al., 2015; Hua et al., 2011). The disruption to 
sensory neuron fate identified here further suggests the need to target tissues other 
than the motor neuron to fully rescue the SMA phenotype. Furthermore, this study 
has also shown that systemic administration of therapy is sufficient to rescue the 
disruption to sensory neuron fate in SMA mice (see Chapter 5); thus, highlighting the 
relevance of therapy delivery via systemic routes. 
One other major issue that is yet to be fully addressed concerns the presence 
of a ‘therapeutic time-window’ after which therapy delivery can only have a minimal 
effect. Several studies have indicated that for maximal benefit, SMN-replacement 
therapies will need to be delivered before the onset of overt symptoms (Kariya et al., 
2014; Robbins et al., 2014). It will therefore be essential to understand how this 
mouse work relates to the temporal development of SMA pathogenesis in human 
patients. In this thesis, I identified a pre-symptomatic disruption to a key downstream 
protein of SMN, occurring in the primary site of pathology, indicating that the 
consequences of SMN reduction are seen at the molecular level before the onset of 
symptoms (see Chapter 3). This suggests that molecular pathways not directly linked 
to SMN reduction may be involved in the early stages of disease pathogenesis and 
are likely to be less responsive to SMN-dependent therapies than the direct 
consequences of SMN reduction. Indeed, this work also highlights that targeted 
therapies to treat the molecular cause of specific phenotypes is a viable strategy. 
Therefore, raising the point that successful treatment of SMA by combinatorial 
approach may need to target the immediate molecular cause of phenotypes rather 
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than the result. Together this emphasizes the importance of pre-symptomatic 
diagnosis of SMA to enable early treatment for the best outcomes of SMN-targeted 
therapies. Moreover, this indicates that moving towards preventative rather than 
curative treatment may be necessary to have substantial effects on the disease course 
of SMA. 
6.6 Conclusion 
The work presented in this thesis demonstrates that SMA is a complex disease and is 
not solely characterised by motor neuron dysfunction due to defects in SMN specific 
pathways. I have shown that UBA1 is reduced pre-symptomatically in motor neurons 
from SMA mice and identified that disruption to UBA1 expression can cause 
dysregulation of multiple cellular pathways including translation elongation, nuclear 
transport and tRNA synthetases. I also identified that UBA1 leads to dysregulation of 
the tRNA synthetase GARS through a non-canonical mechanism. I then went on to 
characterise a novel SMA phenotype - a disruption to sensory neuron fate - caused 
by UBA1-dependent alterations in the expression of the tRNA synthetase GARS. 
Finally, I showed that by targeting the molecular cause, this phenotype could be fully 
rescued. This work has not only improved our understanding of the basic biology of 
UBA1 and the mechanisms of disease pathogenesis in SMA, but it also has wide 
reaching implications in terms of SMA therapeutics and UBA1-mediated 
degeneration in a range of neuronal diseases. 
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Appendix 1 UBA1 distribution varies between 
different cell types 
 
Appendix 1 UBA1 distribution in different cell types 
Percentage of UBA1 localised within the nucleus and cytoplasm of different cell types. 
HepG2 data is from (Schwartz et al., 1992); distribution analysis was performed on HEK293 
cells, glial cells (Glia) and motor neurons (MN) in Chapter 3. DIV: Days in vitro. Heat map 
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A0A024R1A3 UBA1 25 1992.7 2.47E608 7.5752 62.0289
B1AHA8 HMOX1 2 146.1 1.25E605 2.4372 61.2306
A0A087X2D8 SPAG9 3 141.86 4.34E606 1.6223 61.1416
J3KPF3 SLC3A2 4 288.19 2.76E605 1.5087 61.1112
C9J057 ASNS 6 418.07 2.33E604 1.4687 61.4855
A0A090N8G0 GARS 2 102.71 1.43E603 1.3665 61.2432
I4AY87 MIF 2 120.61 4.98E603 1.3432 1.0040
Q0VGA5 SARS 2 107.24 5.83E604 1.3004 61.1369
B3KSC3 PHGDH 3 198.13 6.55E604 1.2948 61.0058
P54577 YARS 2 101.88 2.88E603 1.2916 61.3236
Q6FHN3 NME2 2 117.64 8.48E603 1.2814 61.1113
F5GXH2 LDHA 2 91.25 7.61E603 1.2758 61.0760
Q8WTZ9 PFKP 2 144.13 1.31E602 1.2754 61.0276
D9IAI1 PEBP1 2 165.73 2.50E603 1.2753 1.0065
Q9NZL4 HSPBP1 3 136.31 3.83E603 1.2668 61.1535
H0YL92 IPO4 2 99.74 2.69E603 1.2586 61.2470
B3KRM8 TSN 2 124.82 1.97E602 1.2567 61.0626
A0A024R222 PSAT1 3 154.43 3.05E603 1.2530 61.3184
B7ZMD6 IRGQ 2 102.32 8.97E604 1.2471 61.2290
A0A024RD93 PAICS 4 198.65 2.98E603 1.2416 61.0830
Q0D2Q6 PGAM1 2 93.47 1.46E602 1.2389 61.0883
B9A041 MDH1 2 143.46 1.08E602 1.2374 61.0747
A0A024R4F1 ENO1 6 465.3 1.67E603 1.2349 61.1247
D3DUW5 DNM1L 2 169.82 9.51E603 1.2328 61.1404
A0A024R6K8 WARS 2 146.73 1.12E602 1.2327 61.1397
B3KTP2 NPEPPS 2 131.99 4.03E603 1.2321 61.0102
Q13885 TUBB2A 2 63.74 7.09E603 1.2265 61.0788
B2RCM3 CAPN2 2 82.93 3.96E603 1.2261 61.0921
A0A024RAM0 TNPO1 3 186.07 4.37E605 1.2257 61.0256
D3DX26 RANBP1 2 99.01 3.67E603 1.2236 61.1805
V9HWC7 PRDX6 2 124.05 2.46E603 1.2219 61.0766
B2RBR9 KPNB1 7 450.51 6.35E604 1.2191 61.0674
V9HWE9 GSTP1 3 154.67 6.22E603 1.2178 61.0854
Q5SRT3 CLIC1 3 173.11 2.32E603 1.2157 61.1414
V9HWC2 PARK7 2 160.44 1.11E603 1.2149 61.0993
A0A024R5Q7 ADSS 2 134.09 2.43E603 1.2139 61.1676
Q5JP53 TUBB 5 343.89 7.25E603 1.2122 61.1239
V9HW77 CKB 2 125.04 1.01E602 1.2106 1.0207
E7DVW5 FABP5 3 216.32 5.23E603 1.2105 61.2379
A0A0A6YY92 ADSL 2 143.23 4.15E603 1.2092 61.1857
B4DNK4 PKM 9 711.35 3.43E603 1.2073 61.1012
B2R7P8 ATIC 6 326.49 4.34E604 1.2059 61.1440
B5BU38 ANXA1 3 177.09 5.14E604 1.2052 61.0346
V9HWN7 ALDOA 4 248.49 6.60E604 1.2023 61.2127
A0A024R382 CNDP2 2 109.51 1.18E602 1.1942 61.1912
P23526 AHCY 2 114.16 4.26E603 1.1937 61.1566
B7Z1Y2 ALDOC 2 177.48 2.64E603 1.1936 61.1681
A8K5I0 HEL6S6103 15 1049.85 6.25E606 1.1922 61.2297
B4DN60 NARS 5 312.89 5.88E604 1.1918 61.0608
P07900 HSP90AA1 3 194.43 1.87E603 1.1884 61.1237
A0A024RDT4 LCP1 5 255.09 8.90E604 1.1876 61.1509
Q2Q9B7 G6PD 2 115.89 2.96E604 1.1848 61.2234
Q3B7A7 GART 3 153.2 4.51E603 1.1827 61.1826
V9HWB5 PPA1 2 118.96 3.49E604 1.1823 61.0866
A0A024RB85 PA2G4 2 105.89 2.37E603 1.1821 61.0591
Q9NSD9 FARSB 2 94.41 3.97E603 1.1808 61.0933
E7EUT5 GAPDH 4 252.14 1.70E603 1.1800 61.1347
Q8IWP6 TUBB4B 3 171.36 3.07E603 1.1795 61.1146
B4E1E0 CTPS1 2 84.36 4.39E603 1.1794 61.1064
A8K4W5 ACAT2 3 175.25 2.82E603 1.1784 61.1801
B2RD14 UCHL1 2 108.54 8.10E603 1.1772 61.1611
B4DHB3 PGK1 2 129.33 6.00E603 1.1752 61.0266
A0A0A0MSI0 PRDX1 3 145.93 1.14E602 1.1688 61.1767




A0A087WVQ9 EEF1A1 3 182.89 9.15E605 1.1657 61.2124
F5H5D3 TUBA1C 5 337.25 2.92E603 1.1649 61.1155
A0A024RBB7 NAP1L1 3 232.24 1.69E603 1.1632 61.1503
P07737 PFN1 3 195.51 3.22E603 1.1628 61.1342
B4DDD8 HARS 4 259.24 1.91E603 1.1558 61.1951
B7Z1G4 IMPDH2 2 133.44 2.40E603 1.1504 61.1485
I3L397 EIF5A 2 177.28 8.48E604 1.1493 61.2423
A0A087X1X7 EEF1D 2 114.81 1.29E603 1.1492 61.0758
A0A024R3W7 EEF1B2 2 167.21 4.26E604 1.1491 61.2699
Q53YD7 EEF1G 3 176.86 2.19E604 1.1463 61.2078
Q15645 TRIP13 2 119.77 8.50E603 1.1399 61.2405
B2RDR4 TES 2 106.58 5.18E603 1.1394 61.1778
B4DM31 CSE1L 2 127 1.14E602 1.1391 61.1006
P16152 CBR1 2 114.26 1.77E603 1.1383 61.1290
B2RD79 USP14 5 267.45 9.42E604 1.1374 61.1537
G9K388 YWHAE/FAM22A 2 137.1 4.77E603 1.1281 61.2118
A0A087WYC1 HSPA4 2 115.59 3.52E603 1.1275 61.1404
A8K690 STIP1 4 273.27 1.87E603 1.1274 61.1451
K7EQA1 PDCD5 3 191.73 6.88E603 1.1257 61.1960
J3QRS3 MYL12A 2 128.15 6.73E604 1.1245 61.1122
A0A024RAN2 CAST 3 172.27 2.44E603 1.1237 61.1010
A0A024R1U0 RANGAP1 2 147.36 2.21E604 1.1203 61.1820
A0A024RDY0 IPO5 5 338.22 6.32E604 1.1133 61.1463
B1ANR0 PABPC4 7 402.75 2.04E605 1.1131 61.1076
J3QLR1 RUVBL1 2 142.03 2.34E602 1.1061 61.0314
A0A024RDQ0 HSPH1 11 747.06 2.15E605 1.1034 61.1651
Q9NZZ3 CHMP5 2 115.3 2.87E603 1.1033 61.2016
P13639 EEF2 6 364.92 4.59E603 1.1029 61.2329
A0A024R1N1 MYH9 10 798.08 1.72E603 1.1024 61.1733
A0A024RD80 HSP90AB1 7 539.01 1.14E603 1.0958 61.1731
K7ESP1 DNAJC7 4 202.05 9.81E604 1.0943 61.2385
A8K8U1 CAND1 5 322.41 2.33E603 1.0935 61.1575
R4GNH3 PSMC3 3 191.39 1.07E603 1.0906 61.1080
Q06210 GFPT1 3 159.16 2.04E603 1.0871 61.2545
A0A087WUT6 EIF5B 2 84.07 1.63E603 1.0842 61.1764
B4DXP9 ACTR1A 2 133.58 1.90E603 1.0824 61.1334
H7C3P9 COPS3 3 184.04 2.16E606 1.0800 61.2699
A0A024R4K3 MDH2 3 172.94 3.62E603 1.0766 1.1721
A8K7F6 EIF4A1 8 589.74 3.53E604 1.0752 61.2544
A0A024R904 CACYBP 2 125.19 8.29E603 1.0737 61.1500
P0DME0 SETSIP 2 111.7 4.87E604 1.0666 61.1482
A0A024R201 PSMD13 3 159.52 2.64E603 1.0634 61.1469
Q6NVW7 KPNA2 9 590.84 3.87E603 1.0624 61.2470
F8VPD4 CAD 2 134.95 6.96E603 1.0597 61.2567
B4DJE7 ACADM 2 116 1.51E603 1.0584 1.2636
A0A024RCA7 RPLP2 2 146.34 5.81E604 1.0561 61.1062
S4R2X2 SFXN1 2 117.33 5.40E603 1.0523 1.2088
B4DHT9 HSP90B1 4 228.17 2.61E604 1.0491 1.1941
A0A024RBS1 GCN1L1 2 134.26 6.24E603 1.0455 61.1505
D3DP78 DARS 3 142.55 8.70E604 1.0411 61.1432
A0A024R7B7 CDC37 2 97 3.93E603 1.0402 61.2160
A0A024RA75 HIBADH 2 106.87 3.60E604 1.0358 1.3690
A2A274 ACO2 2 164.79 9.99E604 1.0293 1.2946
Q8N9M2 PSMD3 2 118.35 1.61E602 1.0290 61.1701
X5D299 ALDH5A1 2 96.22 4.72E605 1.0278 1.1590
A0A024R1T9 ACLY 10 658.57 5.45E604 1.0269 61.2902
P54886 ALDH18A1 2 91.62 3.27E603 1.0253 1.1438
H0YK49 ETFA 3 165.05 1.17E604 1.0253 1.1796
A8K4I8 NIPSNAP1 2 98.49 1.89E603 1.0213 1.2371
O9583163 AIFM1 3 179.26 4.60E603 1.0141 1.2093
A0A0A6YYK3 5 280.79 9.22E605 1.0138 61.4788
P07305 H1F0 4 251.17 1.15E603 1.0131 1.5511
H0YL11 IDH2 2 108.15 4.90E604 1.0121 1.4717
I3L1P8 SLC25A11 2 177.6 3.20E603 1.0105 1.2151
I1VE16 SEC22B 2 102.07 1.68E603 1.0093 1.1923




A8KAK1 UGGT1 4 207.7 3.24E603 1.0076 1.1845
Q13308 PTK7 2 96.05 5.20E603 61.0038 1.2386
Q5JR04 MOV10 2 116.7 9.76E604 61.0057 1.1794
Q7Z759 CCT8 4 259.85 4.72E603 61.0065 61.1438
A0A024R0C3 NNT 3 194.71 5.18E605 61.0073 1.2914
B7Z2F4 CCT4 4 254.59 8.30E604 61.0094 61.1948
Q6DC98 LMNB1 4 260.56 2.84E603 61.0146 1.1973
A0A0A0MSE2 HADH 2 85.21 5.36E604 61.0147 1.2656
A0A024QZ30 SDHA 3 147.97 1.46E603 61.0218 1.1608
A0A024QZJ8 CDK1 2 106.01 2.22E603 61.0219 61.2616
B2R984 HIST1H1E 4 331.09 1.63E603 61.0259 1.3035
J9JID7 LMNB2 2 140.42 1.05E602 61.0281 1.2447
E5KNY5 LRPPRC 3 156.12 1.64E603 61.0295 1.1213
Q5ST80 FLOT1 5 337.53 1.14E603 61.0298 1.2404
A0A087WWS1 THOC1 2 98.08 2.36E602 61.0329 1.2106
B4DMF5 GLUD1 3 173.76 1.21E604 61.0331 1.1182
P07814 EPRS 3 178.86 6.95E604 61.0344 61.1390
P80723 BASP1 5 230.47 3.87E603 61.0414 1.2690
E5RHW4 ERLIN2 2 119.01 2.91E603 61.0472 1.2673
A0A024QZ62 FLOT2 4 256.44 2.69E604 61.0496 1.1705
H7C333 GBAS 2 121.66 6.84E604 61.0576 1.1072
F5GWF6 CCT2 2 149.62 4.17E603 61.0610 61.2058
P78527 PRKDC 21 1376.42 1.42E603 61.0669 1.2558
P45954 ACADSB 3 205.48 2.41E604 61.0677 1.2521
Q53G72 BCAP31 2 110.36 1.46E602 61.0698 1.1047
H3BLZ8 DDX17 2 110.37 8.31E603 61.0699 1.1555
A0A024R5M9 NUMA1 3 199.24 9.24E603 61.0705 1.1953
B4DVE1 LGALS3BP 3 148.15 9.14E604 61.0753 1.3314
A0A024RCB7 CD81 2 129.05 4.29E603 61.0755 1.2742
Q92522 H1FX 3 192.5 1.92E603 61.0793 1.2606
Q5I6Y5 LMNA 6 345.73 5.07E603 61.0803 1.1932
A0A024RCR6 BAG6 2 96.3 4.90E604 61.0917 61.2532
A0A024R0Y2 ACACA 2 85.15 6.22E604 61.0945 61.2813
A0A090N8Y2 PDIA4 7 426.2 4.97E604 61.0978 1.1029
A0A024RD82 MUT 3 169.6 1.94E603 61.0998 1.1830
F5H6E2 MYO1C 2 113.26 1.86E602 61.1019 1.1678
Q6FHF5 PCNA 2 136.75 5.42E604 61.1033 61.2444
O14654 IRS4 6 348.58 6.30E604 61.1034 1.2411
A0A024RA27 HNRNPA2B1 3 200.66 4.53E603 61.1047 1.1195
Q6IB76 NDUFV2 2 96.58 5.08E603 61.1094 1.1029
O43491 EPB41L2 3 197.19 8.19E604 61.1134 1.1260
B3KSU9 ELAC2 3 147.53 1.15E603 61.1184 61.1766
A0A024R3T8 PARP1 3 216.74 4.21E603 61.1238 1.0820
G3V1C3 API5 2 115.39 6.75E604 61.1288 1.0092
A0A024R118 METTL7A 2 103.37 1.10E604 61.1354 1.3507
A8K6V3 SF3B3 2 99.4 7.45E604 61.1376 1.0009
Q02952 AKAP12 2 103.56 8.69E603 61.1430 61.2203
O14929 HAT1 3 219.42 7.92E605 61.1540 61.2930
B2R659 HSD17B4 2 111.14 8.40E604 61.1559 1.0492
P12270 TPR 2 113.55 1.41E603 61.1577 1.1511
P14854 COX6B1 2 100.16 1.16E603 61.1619 1.1569
P04181 OAT 6 302.84 2.30E604 61.1645 1.0273
A0A087WUZ3 SPTBN1 9 600.68 2.07E603 61.1691 1.0566
A0A024RB16 ESYT1 2 156.77 1.73E603 61.1719 1.0523
G3XAM7 CTNNA1 4 266.48 1.43E604 61.1814 1.0555
B4DL06 CTNNB1 3 143.91 2.81E604 61.1875 1.1775
Q9UG16 SPTAN1 6 355.1 3.67E603 61.1885 1.0986
Q6P2Q9 PRPF8 5 278.83 7.02E603 61.1911 1.0198
A0A024R7U6 MCM4 2 128.14 6.51E603 61.1945 61.1471
A6NEM2 HCFC1 2 128.76 6.18E606 61.2196 1.0424
Q1WWL2 PTGFRN 2 93.06 2.04E604 61.2263 1.4651
A0A024RBE7 TMPO 6 336.17 8.08E603 61.2288 1.0590
Q4TT76 ADD1 3 191.64 1.94E605 61.2289 1.0873
B0AZQ4 SMC3 3 161.5 8.04E604 61.2294 1.0714
Q99584 S100A13 2 87.7 6.86E603 61.2320 61.0186
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Appendix 2 Post-filtering proteomic dataset: proteins with expression change >10% 
following UBA1 overexpression or UBA1 knockdown 
Fold changes are presented as fold change compared to control. Unique peptides indicates 
the number of peptides detected that map only to that protein; p-value is from One-way 
ANOVA analysis performed in Mascot; score indicates the Mascot score for each protein. 
Proteins are ordered from greatest upregulation to greatest downregulation following UBA1 
overexpression.  
A0A024R7P2 FKBP8 4 258.66 8.80E605 61.2347 1.0931
P49792 RANBP2 2 122.72 8.85E604 61.2391 1.1613
P2322963 ITGA6 3 169.5 3.29E605 61.2405 1.2211
A4FU77 SNRNP200 3 192.72 1.02E602 61.2539 61.0172
H0Y394 HDLBP 2 147.89 5.78E604 61.2557 61.0243
A0A087WVV2 RRBP1 5 278.92 1.18E603 61.2749 1.1636
Q8IY81 FTSJ3 2 103.35 4.95E603 61.2770 1.0070
A0A024R0Q4 PLD3 3 144.25 4.21E605 61.2868 61.3192
P11717 IGF2R 2 103.71 6.30E603 61.3055 1.1088
P38432 COIL 2 110.25 4.13E603 61.3107 1.0493
A0A024R8H6 BRD3 2 123.26 5.00E603 61.3202 1.2752
A0A024R1X8 JUP 7 376.72 4.85E604 61.3226 1.1286
P49458 SRP9 2 123.7 3.34E604 61.3513 61.0306
P15924 DSP 10 588.73 1.84E603 61.3678 1.0061
Q9Y5J9 TIMM8B 2 130.09 2.04E604 61.3747 61.0012
A0A087WTW0 UHRF1 3 215.79 9.83E604 61.3827 61.0624
A0A024RC67 PRC1 2 98.1 3.27E603 61.4047 61.0930
B4DH46 DCAF7 3 236.57 5.19E606 61.4220 1.0050
Q6ZMF1 GLG1 2 177.7 1.08E604 61.4581 1.3975
A0A087WWE2 POLR2A 4 279.55 2.32E603 61.4849 1.0879
P11388 TOP2A 2 130.97 5.95E603 61.4923 61.1022
Q05DA4 P4HA2 3 173.92 3.48E603 61.4970 1.0883
Q5T1J5 CHCHD2P9 3 155.68 7.41E604 61.5524 61.0083
B2R6E2 PDCD4 3 156.83 1.41E604 61.5697 1.3253
Q6IAX1 FDFT1 3 183.07 1.01E604 61.6541 61.0790
A8K4B4 NUSAP1 2 123.68 5.42E604 61.6999 1.1715
D6RFI1 DBN1 6 369.19 5.53E606 61.8034 1.0158
P50402 EMD 5 290.89 2.49E604 61.9162 1.1069
P49454 CENPF 2 100.88 5.38E604 62.4006 1.0821
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Appendix 3 Proteins with fold change >1.2 or >-1.2 
following both UBA1 overexpression and UBA1 
knockdown 
 
Appendix 3 Proteins with fold change >1.2 or >-1.2 following both UBA1 
overexpression and UBA1 knockdown 
Fold changes are presented as fold change compared to control. Unique peptides indicates 
the number of peptides detected that map only to that protein; p-value is from One-way 
ANOVA analysis performed in Mascot; score indicates the Mascot score for each protein. 
Proteins are ordered from greatest upregulation to greatest downregulation following UBA1 
overexpression.  
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Appendix 4 Functional annotation changes in 
UBA1 proteomics dataset 
Appendix 4 Functional annotation changes for the UBA1 proteomics dataset identified 
in IPA 
Functional annotation changes identified in IPA for the UBA1 proteomics dataset. Number of 
proteins and the proteins that belong to each annotation are included. The p-value indicates 
the significance of the enrichment of that functional annotation within the dataset. Note the 
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